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Chapter 1 
Introduction 
 
1.1 Computer aided drug design  
Drug-discovery is important but extremely challenging. Between the years 1950-
2008 only 1,200 new biologically active small-molecules were approved by the FDA at 
the incredible cost of $50 billion.1-3 There has been an immense multidisciplinary effort 
to improve the attrition rates along the process, where approximately 35% discovery 
projects succeed in delivering dugs to the clinical development stage where chances are 
around 10% of reaching market.4-6 Failures at different phases of the clinical trials are 
fairly consistent in their reason. For example, the lack of sufficient efficacy leads to about 
two-thirds of Phase III failures, more than half for Phase II and about sixteen percent of 
Phase I failures.7-10 Discovery projects, however, fail for a variety of reasons, such as lack 
of leads and poor potency, or unexpected animal toxicity.11 As the understanding of the 
complexities and intricacies involved in successful drug design increased the value of a 
multidisciplinary approach became more apparent. Drugs today arise through discovery 
programs that begin with an identification of a target with extensive biological, 
biochemical and structural studies to assess the therapeutic value.2 Computational efforts 
are a large part of those programs.  
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In the infancy of computer-aided drug design the expectations for the new-
technology exceeded the capabilities at the time. Regardless of challenges, over the past 
few decades computational chemistry has become entrenched in the drug discovery 
process. Frequently applied methods include quantative-structure activity relationships 
(QSAR), ligand or structure-based drug design, and there is great value in the prolific 
nature of available databases.12-18 QSAR was one of the earliest contributions to the drug 
design process, with frontrunners such as Corwin Hansch and Yvonne Martin 
demonstrating a consistent relationship between a small-molecule’s in vivo biological 
activity and the log of the octanol/water partition coefficient (logP).19,20 Predicting in vivo 
activity is important, as the most potent drug in vitro is useless if it is never able to get to 
its target. Since the original logP relationship was outlined an incredible number of 
different QSAR equations have been reported in the literature. A wide variety of 
characteristics have been investigated such as molecular volume, surface area, and polar 
surface area.21-23 This method continues to be important in drug discovery process.2,11 
Predicting drug likeness using QSAR methods are a part of the drug discovery 
process but there is also a huge amount effort put into structure-based drug design 
(SBDD). The availability of structural data continues to increase at an incredibly rapid 
rate, as seen in the astonishing number of structures now available in the Protein Data 
Bank (PDB). SBDD methodology depends on the availability of high quality structural 
and biochemical data and efforts to collect such information in one place have been 
made. A plethora of databases have been procured such as the Ligand-Protein Databank 
(LPDB), the Protein-Protein Interaction Inhibitor (2P2I) database, and the Mother of All 
Databases (MOAD).12,13,16,17 Recently, there was an entire issue of Nucleic Acids 
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Research that was dedicated to the databases available online as of the beginning 2015.14 
With the advancements in structural information and computer hardware, advancements 
in computational software have attempted to keep pace. A variety of methodologies have 
been developed to predict possible high-affinity small-molecules for targets and their 
orientation within a binding pocket. Methods to enumerate possible modifications to a 
lead have become quite advanced, with abilities to predict relative affinities to a known 
compound within a few kcal/mol error or calculate free energies of binding with great 
accuracy.24-33   
  
 There has been much advancement in different areas of SBDD and the area of 
docking is no exception. Among first docking software to become available was called 
DOCK from the Kuntz research group in the 1980s, which still is at the forefront of 
docking software today with a recent release of DOCK6.34,35 Other software packages 
include, but are by no means limited to: Autodock, ICM, Glide, ROSETTALIGAND and 
CDOCKER.36-43 Structure-based docking uses available structural data for the protein 
Initialization Scoring Sampling 
Figure 1.1: Docking methodologies generally can be broken down into these three 
steps. Initialization describes the steps required to prepare the docking trials such as 
gather parameters and coordinates for the complex. The sampling step is the approach 
taken to explore the conformational space, and the scoring step ranks the resulting 
conformations from the sampling. 
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and attempts to identify compounds have high affinity for a target and, generally, how 
those small-molecules would orient themselves on the receptor surface. A schematic of 
the three basic components of docking methodology is illustrated in Figure 1. 
A frequently overlooked, but extremely important part of a docking trial is the 
initialization step. This first step is where the coordinates are prepared for the ligand and 
receptor, protonation states are declared, and parameters are gathered. The execution of 
this step can seriously impact the docking accuracy of any docking methodology being 
implemented where a small error can cause fluctuations of greater than 20% in the 
docking success rates.44-46 For assessing docking software limitations in this area and in 
general there is great need for high quality structural and biochemical data.47 Challenges 
arise in generating high quality data sets, due to the need for consistency in the 
experimental conditions across the set in addition to the need for high resolution 
structural data. There have been several docking and scoring challenges put out recently, 
including two by Nicholis and Jain in 2007 and 2011.48,49 It was a goal of the CSAR 
benchmarking exercises to provide the docking community with high-quality datasets 
that were also blind trials for the participants.50-53   
The Docking and Scoring Challenges and CSAR benchmarking exercises 
provided grounds to test different docking software sampling, and scoring 
methodologies.48-53 The sampling step is a challenging balance of search all the 
conformational space available to the small molecule while maintaining computational 
efficiency. There are many different approaches to achieve the efficiency; the primary 
method is to use some reduction on the degrees of freedom for the receptor. Traditionally, 
in docking protocols the receptor was maintained as a rigid entity. For example, 
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CDOCKER uses a series of nonbonded grids to represent the receptor. The grids are pre-
calculated for a single receptor prior to the docking trials, and while it is initially a time 
consuming calculation it only has to be performed once for each receptor. These grids 
then replace the computationally expensive calculations of van der Waals and 
electrostatic energies with essentially simple look-up tables. Autodock uses a very similar 
method where grids of various interaction energies are pre-calculated prior to the docking 
trials while the program DOCK uses affinity maps as their receptor representation.34-36,41  
This approximation of the receptor saves much on computational cost for the 
docking calculation, but there are still an enormous number of degrees of freedom 
available to a ligand that must in some way be sampled. The major classes of sampling 
methods fall into different flavors of Monte Carlo (MC), evolutionary or genetic 
algorithms (EA/GA), and molecular dynamics (MD). MC methods are popular in a wide 
variety of applications, from politics and economics to a wide array of scientific fields. 
MC methods have a long history, but much of the modern MC implementations have 
roots in the MC methods using Markov chains pioneered by the Los Alamos team of 
Fermi, Von Neumann, Ulam, Metropolis, Teller, and others. The most famous algorithm 
is that of Metropolis, A.W. Rosenbuth, M. N. Rosenbuth, A.H. Teller and E. Teller in 
1953.54,55 Modern MC methods efficiently generate conformational ensembles, and 
methods that incorporate a simulated annealing sampling protocol to heat up and cool the 
system assist in identifying low-energy regions. Autodock adopted a simulated annealing 
MC method very early on incorporated into docking programs like Autodock and 
ICM.36,37,56  
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 Genetic algorithms are another stochastic approach that was established around 
the 1970s and has become quite popular in docking methodologies.57-59 A GA approach 
for docking can be thought of as evolving a population of ligand conformations towards 
low energy as defined by a fitness function.60 Genes encode translational, rotational and 
internal degrees of freedom for the ligand. Each chromosome then represents a ligand 
conformation, which in practice is a string of numbers encoding for the degrees of 
freedom. A new population is generated from the previous generation through genetic 
operators: mutation, crossover exchanges and migration. A single mutation randomly 
changes a single gene, or degree of freedom. Crossover exchanges switch one or more 
genes between chromosomes, conformations, in the same population. Migration takes the 
least fit conformation from one population and switches it with the most fit individual 
from another population. These events are used at differing weights to obtain new ligand 
conformations, and have been implemented in the CHARMM docking methodology as 
well as Autodock.41,42      
The CHARMM docking methodology (CDOCKER) is the primary focus of the 
development portion, Chapter 2, of this dissertation. GA and MC have been implemented 
in previous versions of CDOCKER, but the primary sampling method currently is 
MD.40,42 MD has evolved from the study of simple hard spheres in the 1950s to massive 
biological systems with numerous advanced capablities.61,62 The CHARMM simulation 
package contains a wide variety of capabilities with many solvent approximations, 
methodology to perform alchemical transformations, and a plethora of advanced 
sampling techinques.40,63-70 MD is rooted in the fundamental laws of physics to shed light 
on structure, function and properties of complex systems. MD simulations take detailed 
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force field and integrates over Newton’s equations of motion to evolve the bio-
macromolecule system with time.70,71 The CDOCKER methodology utilizes simulated 
annealing MD protocol to sample the ligand on a grid representation of the 
receptor.40,42,43 The heating phase of the annealing protocol allows for the ligand to 
escape a minimum, and the cooling relaxes the system to, ideally, a new minimum. This 
sampling method and its analog in MC have shown reasonable success in various 
docking programs. Contained in Chapter 2 is more on CDOCKER docking methods and 
development.  
Once conformations of the small molecule are sampled they must be scored, both 
for selecting the “native” conformation and to predict the affinity of the molecule in a 
virtual screening application. Scoring functions for docking methodologies can generally 
be broken down into three classifications: force field/physics based, empirical, and 
knowledge based.72-74 Early on there was no scoring functions specifically developed for 
the purpose of ranking protein-ligand interactions and combinations of different 
components of the force field were used. In versions of DOCK and Autodock a hydrogen 
bonding term was added to the electrostatic interaction.34-36,41 There was addition of 
continuum and implicit solvent models for inclusion of solvation terms, where previously 
potential energies were calculated in gas phase.64,75-77 Methods were developed using a fit 
of force field energies with known binding energies of ligands to account for systematic 
error, like the unfortunately named Linear Interaction Energies (LIE).78,79   
The empirical scoring functions are frequently difficult to distinguish from a 
physics based scoring function, as both often decompose the components to protein-
ligand binding in some way. Popular empirical methods include PLP, ChemScore, X-
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Score, and Glide-Score.80-84 Most empirical scoring functions rely on a regression 
analysis to derive the weighted factors for various energy contributions or penalties. The 
major differences from a physics-based scoring method is the empirical scoring is 
composed of a functional form built up using different contributions, while physics based 
methods borrows the complete theoretical framework, including the parameters and 
energy function.73 Empirical scoring functions tend to include only common protein-
ligand interactions, as less common interactions are ignored because they are not 
significant in the regression analysis. These types of scoring functions tend to do well 
when the ligands of interest have frequently observed properties.  
The final major category is knowledge-based scoring functions. These scoring 
functions sum pairwise statistical potentials between protein and ligand and include 
scoring functions such as DrugScore, IT-Score, and KECSA. The distance dependent 
pairwise interaction is obtained through comparison to large data sets, if a particular 
pairwise interaction occurs with greater frequency than random it is scored as favorable; 
if it occurs less frequently that pair is scored as disfavorable. These scoring functions 
tend to be computationally inexpensive due to the pairwise distance nature of the 
calculation.  
 
1.2 Outline of chapters 
The CDOCKER methods in the future chapters use a physics-based scoring 
function, utilizing the CHARMM general force field (CGenFF) with the pre-calculated 
energies on the grid representation of the receptor.40,70,71,85-87 Outlined in Chapter 2 are 
developments to the CDOCKER sampling methodology to improve docking accuracy 
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and incorporate flexible receptor. The previous implementation of CDOCKER tried to 
accommodate for some receptor variability by using a soft grid representation, where 
steric clash penalties a severely reduced.40 However, with the increase in biophysical and 
structural data, it has become apparent that this soft grid representation is not sufficient 
for receptors that do not fit into the lock and key model of binding ligands.88-93 To 
accommodate local rearrangements of a receptor surface given various ligands we have 
implemented explicit side chain representation of select residues in the presence of the 
grid, and is termed Flexible CDOCKER. This methodology should account for local 
rearrangements and larger scale motions that may occur upon ligand binding must be 
addressed in some other manner.94-96 The Flexible CDOCKER implementation 
outperforms its rigid counterpart and is competitive with other docking software such as 
Glide and Autodock.36,38,41,81  
Contained in Chapters 3 and 4 are application projects of CDOCKER and other 
CHARMM MD methods in collaboration with experimental groups to investigate 
protein-ligand interactions. Chapter 3 outlines efforts to identify a putative ATP binding 
site on calreticulin (CRT), an important chaperone protein involved in MHC Class I 
assembly. This work was done in collaboration with the Raghavan research group at the 
University of Michigan. Initial docking trials narrowed down target regions on the 
surface of CRT and the experimental group took the docking predictions as a guide to 
perform point mutations. The mutations narrowed down the likely location for ATP 
binding, and more localized computational docking study followed by MD simulations 
identified other key residues for both binding and catalysis. These computational 
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predictions were confirmed by experiment, demonstrating for the first time that CRT both 
binds and catalyzes ATP.  
Collaborative efforts to target the GACKIX domain of CREB binding protein 
(CBP) with small molecules are described in Chapter 4. For these projects I worked with 
the Mapp research group at the University of Michigan.97,98 CBP is a coactivator in 
transcription regulation, a process integral to many cell processes. To better understand 
transcription regulation and towards developing biochemical tools we investigated two 
major different classes of small-molecules to target this domain of CBP. We identified 
natural product small-molecules that were the first to show the ability to inhibit 
transcriptional activator domain peptides at two separate binding sites on the GACKIX 
domain. The docking simulations of this ligand were challenging and MD simulations 
were undertaken to better understand possible binding interactions with GACKIX. These 
simulations demonstrated that the small-molecule, natural product sekikiac acid could 
interact with GACKIX as a helical mimetic. Additionally, through the innovative 
experimental technique of tethering the Mapp research group was able to crystalize this 
dynamic protein for the first time. The small molecule when tethered is covalently 
bonded to the receptor through a disulfide cross-link. Docking was undertaken of another 
tethered ligand identified as promising candidate followed by MD simulations. The 
closest to average structure of this ligand in complex with GACKIX showed it interacted 
with GACKIX in a different orientation than the crystalized ligand, and this could disrupt 
crystal contacts, suggesting a reason why they were unsuccessful in obtaining quality 
crystals from that complex.  
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Chapter 5 continues on the theme of the GACKIX domain of CBP, however 
instead of investigating ligand-protein interactions, we investigated protein-protein 
interactions.99 GACKIX is an interesting domain as it interacts with a large number of 
different transcriptional activator domains and has positive allostery between its two 
binding sites. We used Gō-like models tuned to the binary complexes of GACKIX to 
investigate the origin the allostery in the ternary complex. The results from these 
simulations showed that the binding of a ligand to one site results in a rigidifying of 
certain regions on the GACKIX domain. This yields a reduction in the states available to 
GACKIX causing a reduction in entropy of a binary complex, resulting in longer off rates 
in the ternary complex and an apparent increase in affinity of the second ligand. This 
work highlighted the importance of entropy, and a different view from the traditional 
structural/enthalpy based allostery. 
 Overall, these studies highlight the importance of receptor flexibility in binding 
ligands, both small-molecule and bio-macromolecule based. The development of the 
CDOCKER methodology to incorporate receptor flexibility was essential for targeting 
receptors such as the GACKIX domain.  SBDD is an important part of drug discovery 
process, and consideration of receptor flexibility has become more computationally 
affordable with hardware and software development. The drug discovery process also 
depends on investigations towards understanding fundamental biochemical questions 
such as the role of ATP in MHC Class I assembly and the immune response or allosteric 
signaling.  
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Chapter 2 
CHARMM Docking Method Development 
 
Text adapted from: J.K. Gagnon, S.M. Law, C.L. Brooks III. Flexible CDOCKER: Development 
and application of a pseudo-explicit structure-based docking method within CHARMM. 
Submitted. 
 
2.1 Introduction 
Structure-based protein-ligand docking is an important methodology in the repertoire of 
tools for drug discovery and design. This approach is often used to rapidly predict ligand 
orientation and affinity for virtual screening in lead identification or optimization applications.1,2 
A plethora of docking software has become available over the years, beginning with DOCK and 
including other programs such as Autodock, Glide and ICM.3-6 There have also been 
developments toward improving the ability to predict affinities of possible lead molecules 
through improved knowledge-based scoring functions such as Drugscore, IT-Score, and 
KECSA.7-10 
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Traditionally, structure-based docking uses a rigid approximation of the receptor to 
reduce the number of degrees of freedom needing to be sampled and thus maintain 
computational efficiency. Speed in these calculations is desirable for lead discovery through 
virtual screening to achieve feasibility in screening the immense chemical space of small 
molecules. For example, the ZINC Database contains approximately 34 million purchasable 
compounds.11 Additionally, this type of rigid receptor model represents a reasonable approach in 
the context of the lock and key type understanding of ligand binding as is important in many 
protein-ligand binding mechanisms.12 However, with ever increasing structural and biophysical 
data available, the importance of protein flexibility has become more apparent.13-17 Proteins exist 
as an inter-converting ensemble of states, and the highest populated state in the apo protein is 
often not the dominant state when a ligand is present. This has been captured experimentally, 
where throughout a series of crystallographic structures of the same protein side chain 
conformations can vary substantially.17-20 For example, in alpha-Momorcharin (alpha-MMC) 
(Figure 1) there are different rotameric states for many of the side chains depending on the ligand 
in complex. Predicting the ligand conformation consistent with the experimental holo structure 
would not be successful when docking to the experimental apo structure with a rigid receptor 
docking method due to steric clashes.  
Incorporation of protein flexibility has become more feasible due to advancements in 
computational resources as well as recent software development towards incorporating flexibility 
in docking.1,16,21,22 Existing methods try to balance computational cost and the enormous size of 
the configurational space that needs to be sampled through a variety of approaches. These 
approaches include docking to a soft receptor, sampling the ligand conformations relative to an 
ensemble of protein conformers, or representing the protein as a single averaged grid.23-25 Others 
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take advantage of rotamer libraries to optimize the receptor after sampling the ligand on a rigid 
representation of the receptor, or use a soft representation of the protein, where terms for steric 
clash penalties are reduced.6,26-29 Though advances have been made in these areas, incorporation 
of receptor flexibility into docking remains at the forefront of challenges in the field.1,23,24  
 
In this paper we present improvements to the sampling in the CHARMM based docking 
method to include receptor flexibility. Previously, CHARMM docking, or CDOCKER, achieved 
ligand sampling via simulated annealing on a rigid representation of the receptor, although 
genetic algorithm methods have also been explored in this context.29,30 In this setup, the protein 
Figure 2.1: The importance of receptor flexibility has become more obvious with the 
increase of structural data. For instance, pictured here is an overlay of an apo 
(PDBID: 1AHC in green) and holo (PDBID: 1AHB in blue and grey) structure of 
alpha-Momorcharin. There is a steric clash between the ligand and the apo structure 
that would prevent rigid docking methods from predicted the crystallographic 
conformation.    
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is represented as a series of non-bonded grids, where the non-bonded interactions are softened to 
accommodate small differences in protein structure when the ligand it bound to facilitate ligand 
sampling.29,31 This representation works well for rigid pockets but may not be sufficient for a 
case like that portrayed in Figure 1. Nevertheless, the CDOCKER approach has served as a 
standard in the field for a number of years.28-30,32  
 
To extend the capabilities and scope of CDOCKER to accommodate a wider variety of 
receptors, we have incorporated receptor flexibility by including explicit side-chains while 
maintaining the rest of the receptor interactions using a grid representation. This allows the 
protein and ligand to sample configurational space simultaneously while having a minimal 
impact on the computational cost (Figure 2), which scales linearly with the number of explicit 
receptor atoms included in the sampling (Figure 3).  In addition to incorporating receptor 
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Figure 2.2: The distribution of the fold increase of docking time compared to rigid 
receptor docking method.  
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flexibility we have implemented a docking protocol that employs enhanced sampling molecular 
dynamics followed by minimization (MD+Minimization) utilizing self-guided Langevin 
dynamics, which further improves CDOCKER docking accuracy.33,34 These improvements to the 
CHARMM docking methods lead to docking accuracy that is competitive with other highly 
successful docking programs, such as Glide and Autodock.5,6  
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Figure 2.3: The time for a single docking trial of Flexible CDOCKER related to the 
number of explicit receptor atoms.  
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2.2 Methods  
Setup of protein-ligand test set  
For the docking trials a subset of 161 protein-ligand complexes from the CCDC/ASTEX 
set was used.35 All structures were obtained directly from the Protein Data Bank (see Appendix 
A, Table 1 for PDBIDs).36 The set was selected for direct comparison against results presented 
recently in publications from the Gohlke research group.37 From the full set examined by Gohlke 
and co-workers, the entries in complex with heme or those for which parameters were not 
available within the CHARMM CGENFF36 parameter library were removed.38-40 Single 
complexes were extracted from the downloaded PDBs using the MMTSB Toolset and all 
crystallographic waters and small molecules not representing the target ligand were removed. 
Only ions found in the region of the binding site were retained as part of the receptor.41 The 
hydrogen atoms for the receptors and ligands were prepared independently of one another. The 
protonation states of the titratable residues in the protein were predicted using PROPKA version 
3.1.42 The hydrogen atoms were built using Babel version 2.3.2 for both the protein and ligand of 
each entry.43 Ligand parameters were obtained using MATCH, which assigns atom types, 
charges and force field parameters through a chemical pattern-matching engine.44 Symmetric 
models of the ligand, to assure uniquely named atoms that are of the same type do not contribute 
to higher RMSD, were generated using an in-house developed Perl script, mapPDB. This script 
is now in the MMTSB Toolset for use in root mean square deviation (RMSD) calculations.41  
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Docking protocol: Initialization of ligands and receptor grids 
Prior to docking the small molecule into the receptor the system must be initialized by 
generating parameters, building the grid and generating initial configurations of the ligand. We 
developed a Perl script as an automated tool to interface user input with CHARMM for docking 
initialization. During initialization the receptor representation may be set up as either rigid or 
flexible. The ligand parameters are generated using MATCH at the beginning of docking setup. 
The grid representation of the protein employs a set of van der Waals and electrostatic grid-based 
potentials that are used in the sampling and ranking steps of our docking protocol. The van der 
Waals grids are built from a set of test particles with 20 different van der Waals radii that are 
centered on the most highly populated radii found in the CHARMM general force-field 
(CGenFF).40 This grid is calculated with a mesh spacing of 1Å spanning 30Å centered at the 
specified center of mass for the target-binding pocket. In these trials the center of mass of the 
crystallographic conformation of the ligand was used. This grid size is sufficiently large to allow 
for a ligand to sample different rigid body rotations at the target binding site without a high 
energetic penalty. The “softness” of the grid can be varied for each non-bonded interaction: van 
der Waals, electrostatic attraction and repulsion, and follow the general form as given in equation 
1. 
!!" = !!"# − a r!"! !!!!!if! !!"∗ > !!"#!        (1) 
Where !!"∗ is the energy of the regular non-bonded potential at a given distance rij for either 
electrostatic or van der Waals.28 Outlined in Table 1 are three different CDOCKER sampling 
protocols, each utilizing alternative grid representations with differing !!"#!values. The a and b 
coefficients are extracted from equations that express the potential and forces at the switching 
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distance. Grids were generated with a distance dependent dielectric with the relative dielectric 
constant, ε, equal to 3 as previously outlined by Vieth et al.29 The grid soft-core potentials for the 
protocol with two grids, called here “SA- 2 Grids” for the simulated annealing protocol with two 
grids, were previously outlined in Wu, et. al.28 The other implementations of the grid use a single 
grid with simulated annealing, “SA – 1 Grid”, or our newly implemented molecular dynamics 
(MD) followed by minimization protocol, “MD+Minimization”, which is described later in this 
section.  
 
Protocol 
 !!"#!(!"#)  !!"#!(!""#!$"%&')  !!"#!(!"#$%&'(") 
SA- 1 Grid  15.0 -120.0 -2.0 
SA- 2 Grids 0.6 -0.4 8.0 
 3.0 -20.0 40.0 
MD+Minimization 15.0 -120.0 -2.0 
Table 2.1: The parameters that determine the softness of the grid potential, all !!"#!values are in 
units of kcal/mol. The methods outlined here use a either a single grid of different sampling 
methods, simulated annealing (SA- 1 Grid) or molecular dynamics followed by minimization 
(MD+Minimization), or a two grids with a simulated annealing protocol as outlined by Wu, et. 
al.28   
In previous versions of CDOCKER, the grid was generated with the entire protein held 
fixed, creating a rigid receptor, and will be referred to as rigid-docking (Figure 4A). To 
incorporate receptor flexibility, side-chains selected around the target binding-site are removed 
prior to grid generation. These residues are kept as explicit side chains during the sampling step 
and they are not present in the grid representation of the receptor (Figure 4B). The backbone 
atoms of these selected explicit residues are held fixed during all sampling. However, the side-
chains of the explicit residues are allowed to sample configuration space simultaneously with the 
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ligand, and both ligand and side chains interact with the grid representation of the receptor. The 
residues that remain flexible can be user specified or the residues may be selected to be within a 
specified cut-off distance from the reference small-molecule, 3Å in these docking trials. These 
residues allow for changes in the surface of the binding site to better accommodate the small 
molecule. Incorporating explicit side chains allows for receptor flexibility while adding a 
minimal number of degrees of freedom to the sampling calculations. Additionally, side chain 
conformational sampling should provide sufficient receptor flexibility to overcome the clashes 
between the apo receptor structure and the small molecule crystallographic conformation, as 
illustrated in Figure 1. The targeting of large-scale conformational changes involving the 
receptor backbone that occur upon ligand binding in some situations would need to be addressed 
in some other manner, such as ensemble docking, and is beyond the scope of this flexible 
receptor docking approach.22,25,45-47 
The initial configurations of the small molecule are generated through rigid body 
rotations and random rotations around the rotatable bonds. The energy for each configuration is 
calculated on the grid and all configurations below an energy cutoff of 1,000 kcal/mol are 
clustered. This removes the extremely high-energy conformations and also yields a structurally 
diverse set of starting conformations for docking. The clustering tool within the MMTSB toolset 
was used for the k-means based clustering of the configurations. The cutoff RMSD for the 
clustering was determined so that at least 50 clusters were generated. The lowest energy 
conformation from each of the lowest energy clusters was selected for the sampling steps. This 
protocol provides a diverse set of ligand conformations and also represents an ensemble of 
relatively low energy starting configurations from which to initialize sampling. Each docking 
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trial generates 50 ligand conformations starting from 50 unique, low energy conformations of the 
small molecule.     
 
Docking protocol: Sampling 
Flexible CDOCKER was implemented with two different sampling schemes; one uses a 
simulated annealing protocol while the other uses a series of short molecular dynamics 
simulations followed by minimization (MD+Minimization). Both implementations also utilize 
self-guided Langevin dynamics (SGLD) to accelerate the sampling.33,34 SGLD uses an average 
of local velocities to calculate a guiding force to accelerate dynamics of lower frequency 
motions. There are two key parameters that determine how aggressive the acceleration to the 
system is: the average time and the guiding factor. The larger the average time, 0.2ps in these 
simulations, the slower the motion that is enhanced. The guiding factor is related to the guiding 
force and governed by the target self-guiding temperature, 700K for these simulations. The 
larger the guiding factor the larger the energy barriers that can be overcome.  
For the re-docking trials using SA the protocol as previously outlined by Wu, et al was 
used.28 For details on the temperatures and lengths of phases for the SA protocols see Appendix 
A, Table 2. SGLD is implemented for use with this protocol but was not used in the simulated 
annealing protocol re-docking trials, as it tends to cause the ligand to move out of the pocket 
because the sampling becomes too aggressive. Each small-molecule starting configuration was 
subjected to five repetitions of this protocol, where the end result of one simulated annealing step 
provided the starting configuration for the next. This protocol allows the ligand, and in the case 
! 26!
of flexible receptor docking the side chains, to sample different conformations and rotameric 
states.  
The MD+Miniminization protocol was inspired by the successful ICM implementation of 
Monte Carlo steps followed by minimization, following the concept to guide the ligand down the 
energy landscape towards a low energy state corresponding to the crystallographic 
configuration.4 Each ligand configuration from the clustering results is subjected to 20 rounds of 
500 steps of molecular dynamics at 300K with SGLD, followed by 500 steps of Adopted Basis 
Newton-Raphson (ABNR) minimization. Before the start of each round an energy comparison 
between the current and the previous ligand configuration is made, and the lowest energy 
configuration is selected to continue the sampling, driving the system towards lower energy 
states.  Each MD step is 2fs of enhanced sampling on the grid representation of the receptor. We 
found that in order to prevent the ligand from being ejected from the binding site fewer than 
2,000 MD steps must be used. Additionally, to achieve high acceptance rates between rounds of 
sampling the number of MD steps fewer than 1,000 steps should be used.    
Each docking trial for the MD+Minimization and the simulated annealing protocol was 
limited to 2.6 x 106 energy evaluations to allow the fairest comparison with the benchmark 
studies by Gohlke and co-workers.37 The docking trials were repeated 10 times, with the same 
input structures for the protein and ligand. However, each trial generated a new set of random 
orientations and conformations of the small molecule followed by sampling on the grid 
representation of the receptor.    
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Docking protocol: Ranking and RMSD calculation 
As the focus of this work is to develop a new docking search strategy, the energy 
evaluation on the grid representation of the receptor is used for sorting the resulting 
configurations from the sampling step. The RMSD between the docked configurations and their 
respective crystallographic configurations was calculated with consideration for the symmetry of 
the small molecule. A configuration of the ligand is considered “docked” when it has an RMSD 
less than 2Å. This metric, as is the convention, will be used to assess docking accuracy.48   
 
Molecular dynamics simulations for investigating side-chain sampling 
To investigate the ability of side chains to sample alternative rotameric states we carried 
out explicit solvent simulations of a few selected receptors as well as performed sampling in the 
presence of the grid. Simulations of two structures from the MMC alpha protein (PDBIDs: 
1AHC and 1AHB) were run for comparison. The explicit solvent MD simulations were carried 
out using a GPU capable CHARMM version c39a2 with an OpenMM interface using OpenMM 
version 5.2.49-51 The simulations are 5ns in length using a 2fs time step and were run at constant 
pressure and temperature, 300K, with the CHARMM27 force field.38,39 Langevin dynamics was 
used to provide the thermal heat bath with a friction coefficient of 10 ps-1.  Particle mesh ewald 
with a non-bonded cutoff of 9Å was used with a FFT grid size of 72Å. SHAKE was applied to 
the hydrogen atoms and the parameters for the small molecules were obtained with MATCH 
using CGenFF.40,44 The simulations run on the grid were also 5ns in duration with flexible 
residues selected within a 3Å cutoff of the ligand. This is the same as the cutoff as used for the 
docking trials. The grid parameters used were identical to those described in the 
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MD+Minimization protocol outlined in Table 1, as this is the “hardest” grid and would be the 
most constraining. To investigate side-chain sampling, both the explicit solvent and grid-based 
simulations were run in the absence of the ligand. Analysis of the χ angles was performed using 
CHARMM.   
 
 
 
 
 
 
 
 
Figure 2.4: Rigid CDOCKER represents the receptor as a series of non-bonded grids 
(A). To include receptor flexibility, residues around a target binding site are kept as 
explicit side chains (B) allowing them to sample conformational space with the ligand 
simultaneously in the presence of the grids.  
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2.3 Results & discussion 
Grid-embedded explicit side chains sample well the side chain rotameric states 
To investigate the side chain sampling in the presence of the grid we compared the 
sampling of the side chains to that of an explicit solvent simulation. It was important to ensure 
that the side chains were able to sample alternate conformations and not be constrained by the 
surrounding grid. As has been noted in Figure 1, with the alpha MMC protein, a clash would 
occur between the tyrosine and the ligand in a cross-docking trial, and it is thus critical to ensure 
that both side-chain conformers are attainable during the course of a simulation on the grid-
embedded side chain representation of the receptor. In Figure 5, we illustrate the χ1 and χ2 
angles sampled in both explicit solvent and grid based simulations for the essential tyrosine 
residue noted in Figure 1. From the displayed configurational history maps we see more 
sampling on the grid than in the all-atom simulation. The triangles represent the angles observed 
in the starting structures. Indeed, independent of the starting conformation of the side chain, both 
conformations observed in the apo and holo-crystal structures are sampled. The grid-based 
simulations are able to sample the various conformations of the protein side chains without the 
enhanced sampling that is implemented in the docking protocol. As to be expected, even more 
sampling of alternate side-chain rotameric states occurs with the SGLD enhanced sampling. This 
sampling is important to consider because most applications of the docking methodology will be 
in cross-docking experiments one is trying to either improve the potency of a lead compound or 
identify a new lead compound.   
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Figure 2.5: Sampling of χ angles during molecular dynamics simulation of a single 
tyrosine of alpha-Momorcharin protein in the presence of explicit solvent (A) or the 
grid (B) with enhanced sampling (C).  The simulations started from the apo structure 
(PDBID: 1AHC) begin at the green triangle and sample the rotameric states shown in 
green circles. Alternatively, the blue triangle was the starting rotameric state for the 
holo structure (PDBID: 1AHB) and the states sampled are shown in blue circles.    
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Incorporation of SGLD MD and minimization in sampling protocol improves docking accuracy  
CDOCKER originally used a simulated annealing protocol, where the ligand was heated 
in the presence of the grid, allowed to sample at the higher temperature and then cooled. This 
would push the ligand out of minima and, ideally, into new ones, occasionally sampling the 
desired low-energy, docked conformation. While such an approach has worked well in many 
situations, for a single docking trial, a native-like pose (closer than 2Å) was sampled in less than 
60% of the complexes, and this is without scoring the conformations (see Table 2). To improve 
this step we implemented a MD and minimization approach, where a single starting ligand 
conformer is subjected to a short round of enhanced sampling SGLD molecular dynamics 
simulation and is followed up with a round of minimization. Each subsequent round of MD and 
minimization is started from either the conformation at the beginning or end of the previous 
round of sampling; whichever conformation is the lowest in energy. This protocol aims to reduce 
the time spent in high energy, irrelevant states that may be sampled during a simulated annealing 
procedure. This method improves docking accuracy for a single docking trial by about 16% 
when flexible side-chain sampling is employed (Table 2).  
Table 2.2: 
  
Rigid CDOCKER 
percent docked 
Flexible CDOCKER 
percent docked 
Simulated Annealing  54.50% 56.10% 
MD + Minimization 56.10% 72.40% 
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Docking to flexible receptor greatly improves re-docking accuracy  
Re-docking trials are commonly used to assess the quality of a docking method. Re-
docking takes a ligand and docks it into the same receptor structure with which it was originally 
crystallized. Presented here are re-docking trials of a subset of the CCDC/Astex set to compare 
various implementations of sampling and receptor flexibility within our novel extension of the 
CHARMM docking methodology. 
The docking accuracy results for the re-docking trials are presented in Figure 6, and 
include a percentage found and percentage scored. When a conformation that is “docked”, less 
than 2Å RMSD from the crystallographic conformation in the heavy atoms of the ligand, exists 
in the docking output it is considered “found”. If a docked conformation is chosen to be the 
lowest energy conformation it is considered “scored”, where the energy is that of the grid 
interacting with the ligand and, in the case of flexible docking, explicit receptor side-chains. 
Results are presented for 10 docking trials. To be included in the “found” percentage, at least one 
structure for a given complex in at least a single trial must be identified as docked. However, to 
be “scored” it must be the lowest predicted energy of all of the trials. For the rigid receptor 
docking, finding at least one docked conformation across all of the sampling methods occurred 
with high frequency, all greater than 81%. The docked conformation is selected out of the results 
at approximately half the frequency that the docked conformation is found. The MD and 
minimization (MD+Minimization) protocol improves docking accuracy in both finding and 
identifying a docked conformation with 41% scored with simulated annealing methods and 
53.4% when MD+Minimization is used. For the single grid, the incorporation of flexibility in 
both simulated annealing and the MD and minimization protocols improves the scoring step by 
8.7 and 9.3 percentage points respectively. This is likely due to some reorganization of the 
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protein side-chains to better accommodate the ligand and improve the overall energy. The two 
grid simulated annealing (SA – 2 Grids) protocol suffers greatly from the incorporation of the 
flexible side chains with a loss in the docked conformations found of 43.5 percentage points, 
which is also reflected in the scoring of 19.9%. Both of the grids in this SA – 2 Grids method are 
much softer than those used in the other protocols. While this allows for sampling of side chain 
and ligand conformations without large energetic penalties, it also causes loss of sensitivity in 
flexible receptor docking. It should be noted that this reduction of docking accuracy with the 
inclusion of flexible side chains is not unlikely for a re-docking trial, where additional receptor 
degrees of freedom added allow for sampling away from the crystallographic conformation 
predefined in the rigid docking case. However, the loss of docking accuracy seen in the SA – 2 
Grids case was not observed in the MD+Minimization or the SA – 1 Grid protocol, which have 
“harder” grids and larger penalties for high energy conformations. In general, the addition of the 
flexible receptor further improves the percent “scored” and does not diminish the percent 
“found” for the single grid sampling protocols. The MD+Minimization protocol improves re-
docking accuracy over the simulated annealing protocols, an improvement of 11.5 and 12.4 
percentage points for the rigid and flexible docking respectively. 
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Flexible CDOCKER performs comparably with current docking software 
Numerous docking methodologies have been developed in recent years and many useful 
comparisons of the re-docking ability of these software packages have been published.37,52-59 
Recently, the Gohlke research group published a comparative study of current docking programs 
for re-docking of ligand-receptor pairs in the CCDC/Astex dataset.35 Taking the results reported 
by Krueger, et al. for the subset of complexes from the CCDC/Astex set reported above, 
comparisons between the popular docking methods and CDOCKER can be made (Figure 7).37 In 
addition to reporting the Autodock results, these researchers reported Autodock results that were 
rescored using a knowledge based scoring function, DrugScore.37 Comparing the best 
performing CDOCKER, the flexible receptor with the MD+minimization sampling, and the other 
docking methods that were reported, CDOCKER is very competitive with the other methods. 
Rigid CDOCKER with the MD+Minimization protocol is competitive, with 53.4% of the 
complexes scored, which is on par with Autodock 3 and Autodock 4 rescored with DrugScore, 
which show 52.4%, docked. Only Autodock Vina and Flexible CDOCKER outperform Rigid 
CDOCKER with this subset of CCDC/Astex set. Flexible receptor CDOCKER outperforms the 
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Figure 2.6: Re-docking trial results by metrics of finding at least one conformation 
in the ten trials that is less than 2Å RMSD from crystallographic pose (found) and 
the lowest energy conformation is docked (scored). Rigid CDOCKER method results 
are shown in panel A and flexible CDOCKER results are in panel B.  
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other docking programs, selecting the docked conformation for 62.7% of the complexes, while 
the next most successful docking software reported, Autodock Vina, has a success rate of 57.7%.  
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Figure 2.7: 
Docking accuracy comparison of widely used docking programs and Flexible 
CDOCKER and CDOCKER for a subset of the CCDC/Astex. Docked is defined as 
the lowest predicted energy conformation is within 2Å RMSD of the 
crystallographic conformation. Results for the non-CDOCKER based methods are 
taken from the published results of Krueger et al, and are marked with an asterix.37 
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Flexible CDOCKER improves cross-docking accuracy: a case study  
The primary motivation for incorporating receptor flexibility into docking was to target a 
receptor structure that requires side chain conformational flexibility to accommodate its ligand 
(Figure 1). As a case study, we performed re-docking and cross-docking experiments using the 
structures from Figure 1, utilizing the MD+Minimization implementation of CDOCKER. For 
proper comparison identical starting conformations of the small molecule were used for the 
sampling step of the docking trial with either rigid or flexible receptor representations and for 
both re-docking and cross-docking trials. Using the same small molecule conformations allows 
for investigation of the benefits of the sampling without concern for the variability in initial 
conditions. The re-docking trial docked the small-molecule to the receptor conformation from 
which it was derived (PDBID: 1AHB). The cross-docking trial docked the small-molecule to the 
experimentally determined apo receptor conformation (PDBID: 1AHC).   
The results for these trials are presented in Table 3, and show the percentage of the 
resulting conformations, from the ten docking trials, that have a RMSD of less than or equal to 
2Å, as well as the RMSD of the lowest predicted free energy conformation. The percentages 
docked shown in Table 3 are different from the percentages shown in Figure 7, which shows the 
percent of complexes that the lowest predicted energy conformation is docked. Consistent with 
the results observed for the CCDC/Astex set, rigid and flexible CDOCKER sample docked 
conformations with similar frequency, 10.6% and 10.2% of the resulting conformations (500 
total) docked for rigid and flexible CDOCKER respectively for the re-docking trial. Flexible 
CDOCKER is superior in identifying the docked conformation; selecting a conformation with a 
1.69Å RMSD while the rigid version’s low energy conformation had an RMSD of 6.99Å. As 
expected, there is a drop in the frequency of sampling native-like poses for the cross-docking 
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trial. We observed docked conformations with a frequency of 5.6% for rigid CDOCKER and 
7.2% for flexible CDOCKER of 500 total conformations. Interestingly, in the cross-docking trial 
rigid CDOCKER was able to sample a docked conformation of the small-molecule 5.6% of the 
time. This suggests the softness of the grid mimics some aspects of receptor flexibility and 
enables the sampling of docked conformations. However, for scoring flexible CDOCKER was 
superior, identifying a docked conformation of 1.42Å RMSD compared to 5.0Å RMSD for the 
rigid implementation. Flexible CDOCKER, in this test case, has no loss in sampling for the re-
docking trial despite an increase in the number of degrees of freedom. It also shows improved 
sampling compared to the rigid implementation for the cross-docking trial. Flexible CDOCKER 
is superior to the rigid implementation in ranking docked conformations, leading to improved 
docking accuracy.  
Table 2.3: 
 
Flexible CDOCKER cross-docking HIV Reverse Transcriptase  
Flexible CDOCKER is capable sampling and scoring a docked conformation in a cross-
docking test case of a single receptor. Cross-docking trials are more challenging than re-docking 
trials, as the receptor is not in the optimal configuration to interact with the small molecule. 
Results from the CSAR Benchmark Exercise 2011-2012, hosted by the Carlson research group, 
demonstrated a wide range of docking accuracy for different targets.53 The overall docking 
accuracy for the different receptors found that 33% of the top scoring results were docked, 
Docking Method Percent of all conformations docked Low Energy RMSD(Å)
Re-docking Rigid CDOCKER 10.6 6.99
Flexible CDOCKER 10.2 1.69
Cross-docking Rigid CDOCKER 5.6 5.00
Flexible CDOCKER 7.2 1.42
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however some complexes were as low as 5.4% scored.53 As a challenge for the newly 
implemented CDOCKER methodology we performed a cross-docking trial of 131 unique 
complexes of HIV reverse transcriptase (Appendix A, Table 3). Consistent with previous results, 
the flexible and rigid receptor implementations had similar ability to sample docked 
conformations with 47.3% and 48.1% of the complexes docked respectively. Again, Flexible 
CDOCKER outperformed the rigid implementation in its ability to score the docked 
conformation as lowest in energy, with 19.1% docked compared to 10.7% for rigid. These 
docking percentages are low compared to redocking trials, which is to be expected, as the 
receptor structure is not in an optimal conformation for ligand binding. Histograms of the low 
energy conformations demonstrate the improvement of docking success with Flexible 
CDOCKER over rigid CDOCKER, as illustrated in Figure 8 left-side y-axis. It is especially 
apparent that the inclusion of flexible side-chains improves the sampling of docked 
conformations when considering the total structures docked, which is plotted in dashed lines 
along the right-side y-axis of Figure 8. For Flexible CDOCKER, 26.2% of all the conformations 
sampled were docked while the rigid implementation only achieved 14.2% docked.  
While adding the receptor flexibility improves the docking accuracy, it is still fairly low. 
Recent results published for this crossdocking set using DOCK 6 show 66.7% of the 61 
overlapping complexes were scored (Appendix A, Table 4).6 The initial placement of the small 
molecule for CDOCKER is somewhat naïve, generating many random ligand conformations 
targeting a specific binding site, neglecting much information concerning the receptor surface, 
and perhaps improvements to the initial placement would lead to increased docking accuracy. 
DOCK 6 for example, uses pre-computed site points for excluded volume and chemical 
matching for initial ligand placement. There was an overlap of 61 complexes, while the 
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remaining 70 complexes were considered non-viable pairings by Rizzo et al. A non-viable 
pairing was defined as a ligand minimized in a receptor structure that had an RMSD of greater 
than 2Å.6 For the complexes not attempted by Rizzo et al, Flexible CDOCKER had about twice 
the docking accuracy as the rigid implementation with 14.3% and 7.1%, respectively, scored and 
32.9% of the complexes were found by both methods (Appendix A, Table 4). CDOCKER was 
able to find docked conformations of these more challenging complexes. However, many of the 
docked conformations that are being found by the docking protocol are not being scored as low 
energy conformations. This suggests a need for improved methods of ranking ligand 
conformations.  
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the HIV reverse transcriptase for both rigid (blue) and flexible (green) CDOCKER. 
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2.4 Conclusions 
Incorporating receptor flexibility into docking methods is an essential step in more 
accurately modeling protein-ligand interactions, however, maintaining efficiency requires this to 
be done in a limited manner. Flexible CDOCKER represents the majority of the receptor as a 
rigid entity, representing side chains around a target binding pocket explicitly to minimize 
computational costs (Figure 1). When integrated with a grid representation of the remaining 
receptor that is softened with respect to its interactions one finds that the sampling of flexible 
side chains is maintained similarly to what is observed with conventional solvated molecular 
dynamics. Compared to the previously reported rigid receptor CDOCKER method, the inclusion 
of flexibility with a new MD+Minimization sampling protocol leads to improvements in docking 
accuracy, particularly in the scoring step of the docking process.28 This approach to 
incorporating receptor flexibility does not lead to loss of docking accuracy in re-docking trials 
over the rigid implementation, as may occur when including additional degrees of freedom. The 
computational cost of includiing the receptor flexibility increases linearly with the number of 
atoms (Appendix A, Figure 2). In a test case of cross-docking, the flexible receptor version of 
CDOCKER was superior to the rigid implementation in both sampling and scoring of docked 
conformations of the receptor’s paired small-molecule. Finally, comparing our new docking 
protocols to results reported by the Gohlke research group shows that Flexible CDOCKER 
outperforms other widely used docking methodologies in re-docking trials of the CCDC/Astex 
clean set.37 
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2.5 Development of automated covalent ligand docking method 
 Covalent, irreversable drugs have become increasingly popular category. In fact a 
surprising number of approved drugs can covalently inhibit enzymes.60-64 Asprin, developed and 
manufactured in the 1800s by Bayer acts by a covalent and irreversable inhibition. Though the 
mode of action was not identified until the 1970s.65 Antibiotics also act as covalent inhibitiors, 
such as penicillins and cephalasporins.66 There are at least 39 approved drugs that are covalent 
inhibitors, many targeting GPCRs.62,67 Three of the top ten best selling drugs in the United States 
in 2009 were covalent inhibitors to their respective targets: clopidogrel, lansoprazole and 
esomeprazole.67 There are two major classes of colvalent ligands, those that have prexisting 
reactive electrophilic functionality (penicilin) and compounds that undergo a transformation in 
viio creating reactive metabolites (acetaminophen).68 The second class has great safety concerns 
due to possibility of highly reactive intermediates that may react non-specifically. For this 
reason, a drug discovery project does not generally set out to develop a covalent drug.67,69 
Though the theraputic value of these compounds is still great, much study of the possible off 
target interactions must be undertaken.  
 In addition to being used as drugs, covalent ligands have become a powerful biochemical 
and biophysical tool. Development by the Wells research group of tethering methodology for 
screening a library of small-molecule fragments for a targeting a specific binding pocket with a 
cysteine mutation has yeilded impressive results.70,71 This tethering technique is a rapid and 
reliable screening method of small-molecule fragments to be used for rational design benifiting 
from the use of a covalent disulfide bond. A non-covalent fragment screen often suffers from 
non-specific binding of the small molecule fragments at many sites on the receptor, while the 
tethering techinque assures localization to the target binding site.70-72 This method was employed 
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by the Mapp research group to target KIX domain of CBP, a transcriptional coactivator 
domain.72,73 The resulting small molecule hits stabilized the KIX domain sufficently to obtain the 
first ever crystal structure of this receptor (see Chapter 4).72,73 The tethering method has been 
used to target other protein-protein interfaces including the identification of an IL-2 inhibitor.74 
Furthermore, tethering was used as a basis for rational design by the Mann research group, who 
developed a non-covalent inhibitor based on the fragment hits in the tethering screen.75  
 Targeting challegning surfaces with covalent ligands is becoming increasingly popular, 
with a recent review demonstrating an increase in the percentage of colvalent inhibitors 
compared to non-covalent inhibitors. However, functionality to investigate covalent ligands with 
docking methodology remains fairly limited. CovalentDock is available as an interface with 
AutoDock creating molecular geometry based restraints to keep the ligand in the desired region 
on the receptor.76 Also available is the CovDock suite within Schrodinger, which also mimics 
covalent docking through restraining the ligand to the target vicinity on the receptor.77 We 
developed a docking methodology that creates a physcial bond between the ligand and receptor 
in an automated fashion, named CHARMM Docker with crosslink, or CDOCKER with XLink. 
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2.6 XLink: A tethering docking method 
 The tethering methodology that is currently implemented within CDOCKER is based off 
of the disulfide linkers utilized in the fragment screening method developed by the Wells 
research group. However, CHARMM is a very versitile software package, and tethers other than 
disulfide bonds could be implemented.49,50 The XLink functionality is structured as a MMTSB 
tool, as is CDOCKER, using a set of Perl scripts to interface user input with CHARMM.41 These 
scripts generate ligand parameters in an automated fashion using MATCH and the CHARMM 
CGENFF36 parameter library.38-40,44 Additonally, there is functionality to generate a cystiene 
point mutation on a receptor, allowing for screening of various target regions on the receptor. 
The framework of the XLink functionality is incorporated into CDOCKER, so that the sampling 
methodologies already implemented within CDOCKER including receptor flexibility are 
available with XLink functionality.  
 A cysteine on the receptor and a small molecule structure are required for the crosslink 
parameters to be generated (Figure 9). XLink uses MATCH to generate the parameters of just the 
small molecule and of the small molecule bound to the cystiene.44 The ligand-cystiene tethered 
structure is generated in the absence of the rest of the receptor and as such the orientation has no 
relation to, for example, the lowest energy conformation in the prescence of the receptor. 
MATCH utilizes a chemical pattern-matching engine to assign atom types, charges and force 
field parameters through comparision to a list of chemical fragments, and as such the initial 
orientation need not be optimized in the context of the rest of the receptor. XLink takes the 
differences between the ligand and ligand-cystiene MATCH generated parameters to create a 
CHARMM readable patch.49,50 This patch accounts for the changes in partial charges of the 
ligand and cystiene when they are tethered, as well as adding angles, dihidrals etc.  
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 In addition to having an extra initialization step, XLink also must sample the ligand 
conformational space differently than non-covalent CDOCKER. Instead of performing rigid 
body rotations of the ligand about a center of mass, we rotate the ligand around the disulfide 
bond. Like non-covalent CDOCKER, we also randomly rotate the rotatable bonds contained 
within the ligand. The resulting low energy conformations are clustered and the low energy 
member of the low energy clusters is subjected to simulated annealling sampling as outlined 
Figure 2.9: Illustrated here is an example of a small-molecule fragment being tethered 
to a cysteine residue. XLink generates parameters using MATCH for small-molecule 
when it is free (upper) and when it is tethered (lower).   
4I9O%
~%
~%
~%
~%
Small-Molecule Fragment Cysteine  
Disulfide bond: after patch is applied 
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above. Additionally, the flexible receptor and MD+Minimization sampling can be employed 
with XLink in a fairly straightforward fashion.  
 This CDOCKER with XLink was utilized to investigate tethered fragments binding to 
KIX domain of CBP (See Chapter 4.3). Flexible CDOCKER with XLink was able to predict a 
small-molecule conformation that is similar to the crystallographic conformation in a cross-
docking trial. Additionally, the resulting CHARMM parameters can be used in straigthforward 
MD simulations for further investigation of the dynamics of the receptor-ligand complex. This 
implementation of tethering in docking is, to my knowledge, the first that generates a physical 
bond as opposed to using constraints to keep the ligand within a certain region of the receptor.     
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Chapter 3 
Application of CDOCKER: Identification of a putative ATP binding site on calreticulin 
 
Text adapted from: S.J. Wijeyesakere, J.K. Gagnon, K.A. Arora, C.L. Brooks III, M. 
Raghavan. Regulation of calreticulin-major histocompatibility complex (MHC) class I 
interactions by ATP. Submitted. 
 
3.1 Introduction 
In the protein-dense environment of the ER, macromolecular chaperones help 
maintain protein homeostasis.1,2 These specialized proteins support the folding of nascent 
or mis-folded proteins by interacting with exposed hydrophobic regions on these proteins, 
thereby preventing their aggregation and stabilizing folding intermediates.3 Protein 
chaperone cycles are often regulated by conformational changes that occur upon 
nucleotide binding and hydrolysis.2,4-8 Most well characterized chaperones such as 
GroEL, HSP70, and HSP90, employ nucleotide-associated conformational changes to 
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regulate and guide their interactions with client proteins.3,6,8-10 Calreticulin (CRT) is a 
multi-domain lectin-binding chaperone that is believed to play an important role in the 
assembly of the peptide loading complex and proper folding of proteins in endoplasmic 
reticulum (ER).7,11-13  
CRT is a soluble dual function ER protein. It behaves as a lectin, binding 
monoglucosylated glycans present on nascent glycopeptides and as a chaperone, 
preventing aggregation of proteins through glycan-independent interactions.14-16 CRT is 
recruited into the peptide-loading complex within the ER, where, with other proteins,! 
MHC Class-I molecules that mediate immune surveillance by CD8+T-cells and natural  
killer (NK) cells are folded.13,17 Structurally, CRT consists of three domains (Figure 1). 
One domain is a lectin fold globular domain containing interaction sites for glycans and 
peptides.15,18,19 Another consists of a proline-rich domain termed the P-domain where 
Figure 3.1: CRT globular domain, containing the glycan binding site, is shown in teal. 
The acidic domain has low affinity calcium binding sites (red), and ERp57 binds the 
with p-loop (green). (PDBID:3o0v with p-loop modeled in)  
 52 
interactions with co-chaperones like ERp57 and cyclophillin-B occur.12,20,21 The final 
domain is a C-terminal acidic region that acts as a calcium buffer due to numerous low 
affinity calcium binding-sites.7,16  
While it has been shown in vitro that ATP can induce conformational changes in 
CRT and enhance its chaperone activity towards both glycosylated and non-glycosylated 
substrates the nature and location of the nucleotide-binding site of CRT remains 
unknown.15,19 Contained in this chapter is a collaborative effort with the Raghavan 
research group at the University of Michigan Medical School towards identifying a 
putative binding site for ATP on CRT and the role of ATP on the CRT chaperone cycle. 
All wet-lab experimental work reported in this chapter was carried out by the Raghavan 
group. I would also like to acknowledge Karunesh Arora, from the Brooks research 
group, for his assistance and guidance in this project.  
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3.2 Results and Discussion  
Towards characterizing the nucleotide dependence of CRT we employed 
fluorescence quenching to determine the steady-state affinity of both ATP and ADP with 
murine calreticulin (mCRT(WT)). The affinity for binding ATP to mCRT(WT) is 480 ± 
69 µM and 1.26 ± 0.28 µM for ADP. These affinities are similar to those reported for 
other nucleotide binding chaperones such as HSP90.6,8 Using differential scanning 
calorimetry (DSC) we find that there is significant decrease in thermostability of 
mCRT(WT) in the presence of 4mM ATP (ΔTtrans = 2.5 ± 0.2 °C; p > 0.001) which is 
consistent with previous findings from the Raghavan research group.11 Furthermore, 
removal of the P-domain (mCRT(ΔP)) or C-terminal region (mCRT(ΔC)) leads to similar 
loss of thermostability ( ΔTtrans = 5.9 ± 0.7 °C; p > 0.001 and ΔTtrans = 4.6 ± 0.5 °C; p > 
0.001 respectively) indicating the ATP binding site is located on the globular domain 
(Figure 1, teal). Using this information from the DSC experiments we employed a blind, 
global docking trial of ATP and the crystal structure of CRT globular domain (PDBID: 
3o0v) to predict the location of the nucleotide binding site. This initial trial was 
undertaken using a consensus approach, utilizing both Autodock Vina and CDOCKER in 
CHARMM simulation packages.22-25 The version of CDOCKER applied to this trial did 
not include the flexible receptor options, and both the Autodock Vina and CDOCKER 
trials were rigid receptor structure-based docking trials. The initial docked ligand poses 
obtained from the Autodock suite were rescored using an all-atom protein and ligand 
representation with Generalized Born Molecular Volume (GBMV) implicit solvent in 
CHARMM and compared to the docked poses identified by CDOCKER.22,23,26-30 These 
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results yielded 4 distinct clusters of ATP binding site locations with similar predicted 
energies ranging from 1.8 to -1.1 kcal/mol (Figure 2).  
 
Guided by these docking results we undertook site-directed mutagenesis, mutating 
residues that were in contact with the predicted ATP pose. Using DSC we identified 
residues inhibiting ATP binding based on the lack of significant loss of thermostability of 
mCRT(WT) in the presence of ATP as seen in the initial DSC scans (Figure 3). All initial 
Figure 3.2: Structure-based docking results showed 4 major clusters, shown in sticks. 
The predicted lowest energy conformation is shown in blue, which corresponds to a 
binding site near Lys7.  
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mutants tested displayed 
the loss in 
thermostability as shown 
with mCRT(WT) upon 
interacting with ATP 
with the exception of the 
K7A and E8A mutants, 
indicating that this 
residue is key in ATP 
binding (Figure 3).  
These data informed a 
more focused docking 
trial centered on Lys7. 
The resulting predicted 
low energy ATP 
conformation from this 
docking trial was 
subjected to a 20 ns all-atom explicit solvent molecular dynamic (MD) simulation. The 
structure-based docking performed held the protein fixed while ligand conformations 
were sampled, this allows for rapid and computationally inexpensive sampling. The 
advantage of the MD simulations is that the receptor conformation is allowed to relax 
around the ligand and adapt side-chain orientations to optimally interact with the 
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Figure 3.3: Wild-type CRT experiences a thermostability 
loss upon binding ATP as measured with DSC. Residues 
that were near predicted binding sites by docking that 
disrupted this thermostability loss, K7A and E8A, are 
likely residues important for ATP binding.     
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nucleotide. The resulting average structure from the MD simulations allowed us to 
identify additional residues important for ligand binding and catalysis (Figure 4).  
 
The structure shows Lys7 interacting with the alpha-phosphate of ATP and 
another lysine, Lys63, interacts with the base of ATP. Additional residues interacted with 
the γ-phosphate moiety of ATP, Asp12 and Arg19, suggesting these to be putative 
catalytic residues that hydrolyze ATP, forming ADP and Pi. Interestingly during the 
Figure 3.4: Closest to average structure from explicit solvent 
simulation started from predicted lowest energy conformation of ATP 
(blue) bound to CRT at the Lys7 (green) binding surface.   
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course of the MD simulations, sodium ions from the bulk solvent come in and interact 
with the γ-phosphate of ATP and orient this moiety with the Asp12 and Arg19 residues. 
It should be noted that while CRT lacks the consensus sequences for common ATP-
binding and hydrolysis motifs, such as the Walker A and Walker B motifs, but Asp12 is 
contained in a DxD motif that has been suggested as an alternative to the Walker B 
motif.31 Additionally, we mutated the residue 7 from a lysine to alanine in silico and 
simulated the mutant (mCRT(K7A)) with ATP started in its predicted conformation from 
the structure-based docking. While the simulation of mCRT(WT) remained stable 
throughout the simulation the ATP dissociated from mCRT(K7A) within 10ns of the 
simulation further supporting Lys7 is essential for ATP binding. 
Lead by the computational predictions we used fluorescence quenching to assess 
the ATP binding ability of CRT containing single point alanine mutations at Lys7, Glu8, 
Asp12, or Arg19 positions. mCRT(K7A) and mCRT(E8A) showed a decrease in their 
steady state affinities for ATP (KD = 8.1 ± 0.2 mM and KD = 5.1 ± 1.8 mM respectively, 
Figure 4). Conversely, the steady state affinities for mCRT(D12A) and mCRT(R19A) 
towards ATP are similar to that observed for the wild-type protein ( KD = 1.3 ± 0.3 mM 
and KD = 1.0 ± 0.3 mM respectively, Figure 4). The loss of affinity for ATP with 
mutations at the Lys7 or Glu8 positions was encouraging. The small change in affinity 
with alanine mutations at Asp12 and Arg19 suggest these residues do not play a large 
role in ATP binding to CRT, however as shown in Figure 3, the simulation results predict 
these residues interact with ATP.    
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In well-defined chaperones such as HSP90, ATP hydrolysis is a key factor in 
driving the chaperone cycle. Previous studies have shown recombinant CRT to have a 
weak ATPase activity but the lack of a CRT mutant deficient in ATP binding has made it 
difficult to rule out contamination with endogenous ATPases. To this end, we measured 
the ATPase activity of mCRT(WT) and the identified ATP-binding site mutants: 
mCRT(K7A), mCRT(E8A), mCRT(D12A), mCRT(R19A). We find the Michaelis–
Menten constant (Km) of ATP hydrolysis for mCRT(WT) was 424.5 ± 9.3 µM (Figure 5), 
a value similar to the calculated steady-state affinity, KD, of CRT for ATP (480 ± 69 
µM). Furthermore, significantly higher Km values are observed for mCRT(K7A) and 
mCRT(E8A) relative to mCRT(WT) (Figure 5), findings consistent with the reduced 
ability of these mutants to interact with nucleotides. Similarly, significantly higher Km 
values is observed for mCRT(D12A) and mCRT(R19A) relative to mCRT(WT), 
suggesting that these constructs are deficient in their ability to hydrolyze ATP. These data 
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Figure 3.5: Dissociation (A) and Michaelis–Menten (B) constants for ATP binding to 
wild-type CRT and mutants. Residues Lys7 and Glu8 are important for ATP binding 
while Asp12 and Arg19 are key for catalysis.   
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with data presented in Figure 4, showing no loss of affinity upon mutating residues D12A 
or R19A, support that the residues Asp12 and Arg19 are key to the hydrolysis of ATP.  
In chaperone systems such as HSP70, both nucleotide binding and hydrolysis play 
an allosteric role in the chaperone’s interactions with various substrates.5,12,32 It is known 
that ATP increases the chaperone activity of CRT towards glycosylated and non-
glycosylated substrates as measured via its ability to prevent the thermal aggregation of 
proteins containing and lacking monoglucosylated glycans.15,19 However, the effect of 
nucleotide binding on the ability of CRT to interact with the glycan moiety of a 
glycoprotein is currently unknown. To investigate these interactions we chose a synthetic 
monoglucosylated glycan Glcα1–3Manα1–2Manα1–2Man (G1M3) that has been used 
previously as a model substrate to investigate CRT+glycan interactions.19,33-35 We 
performed MD simulations of CRT in complex with G1M3, as well as a ternary complex 
of CRT with G1M3 and either ATP or ADP. From these simulations we calculated a free 
energy of binding using MM/GBMV method with quasiharmonics to predict entropy.22,27 
The calculated ΔGbinding for G1M3 in the absence of nucleotides is -55.12 kcal/mol. 
Interestingly, there is a 2.8 fold reduction in affinity predicted when ATP is bound 
(ΔGbinding = -19.4 kcal/mol) while the reduction in affinity is only 1.8 fold in the presence 
of ADP (ΔGbinding = -35.4 kcal/mol).  
To better understand the basis for ATP-mediated reduction in the glycan-binding 
affinity of calreticulin, we performed covariance analyses on MD trajectories of mCRT-
G1M3 complexes in the presence or absence of nucleotides (ATP or ADP). Covariance 
analysis reports on the coupled motions between distant regions of proteins.36 Results of 
the covariance analyses show that the distant residues located at the ATP and glycan 
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binding sites are coupled, exhibiting correlated motions (Figure 6). Relative to the ATP-
bound state, the correlated motions are reduced in the ADP bound state and in the 
absence of nucleotide (Figure 6A and 6C vs. 6B). These findings suggest that dynamic 
coupling between the remote glycan and nucleotide-binding sites of calreticulin following 
ATP binding could cause a reduction in glycan-binding affinity.  
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Figure 3.6: Covariance matrices for 
highly correlated residues ( |r| > 0.5) 
from simulations of CRT bound to 
G1M3 (A) and the ternary complexes 
with ATP(B) or ADP(C). Note that the 
residue numbering is discontinuous 
from residue 228 onward to match the 
numbering in the experimental 
structure (PDBID: 3rg0).  
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In conclusion, these biochemical experiments guided with molecular modeling 
identify a putative ATP binding site on the globular domain of CRT defined by the 
residues Lys7, Glu8, Asp12, and Arg19. The residues Lys7 and Glu8 are essential for 
ATP binding (Figure 5A) while Asp12 and Arg19 (Figure 5B) are shown to be key for 
ATP hydrolysis. The MD simulations demonstrate that there is allosteric communication 
between the identified ATP binding site and the glycan binding site, suggesting ATP may 
trigger release of glycosylated ligands. The computationally identified residues lead to 
the ATP hydrolysis deficient mutants, allowing experimental conformation that CRT has 
ATPase activity, ruling out endogenous ATPase contamination.   
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3.3 Methods Initial!docking!runs!were!performed!in!AutoDock!Vina!1.1.1!using!the!crystal!structure! of! the! globular! domain! of! murine! calreticulin! (PDB! ID! 3o0v)! as! the!receptor.24,25! The! AutoDock! results! were! scored! in! GBMV! implicit! solvent! using!CHARMM! and! compared! to! results! from! the! CHARMM! docking! protocol,!CDOCKER.22,23,26,27!Subsequent!docking!trials!were!constrained!within!a!simulation!cell! (a! =! b! =! c! =! 15! Å)! centered! on! the! CWatom! of! Lys7.! The! lowest! scoring!configuration!of!ATP!was!subjected!to!molecular!dynamics!(MD)!simulations!using!the!CHARMM!force!field!within!NAMD.37W41!Six!different!conditions!were!simulated:!calreticulin! bound! to!ATP,! ATP!+!G1M3,!ADP,!ADP!+!G1M3,! G1M3,! and!no! ligand.!G1M3!was!docked! to! the! glycanWbinding! site!based!on! the! crystal! structure!of! the!calreticulinWG1M3! complex! (PDB! ID! 3o0w).! Each! simulation! lasted! 20ns! and! was!run! in! triplicate! with! a! Ca2+! ion! in! the! high! affinity! calcium! binding! site! of!calreticulin.!The!simulations!were!run!in!triplicate!using!constant!volume!Langevin!dynamics!with!a!2fs!timeWstep!at!310K!and!a!total!of!50ns!of!production!simulation!was!analyzed.!Systems!were!solvated!in!an!octahedral!water!box!with!0.15M!NaCl!to!neutralize!charges.! 
Additional simulations were run using Mg2+ as a counter ion for ATP-bound 
calreticulin. MM/GBMV calculations were performed in CHARMM to estimate free 
energies of binding for G1M3 in the presence and absence of ATP or ADP. MM/GBMV 
free energy calculations take the energies from the molecular dynamics simulation, an 
estimate of solvation energies in implicit  solvent (GBMV), and a quasi-harmonic 
entropy calculation to estimate free energies of binding. Ion lifetimes were also 
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calculated using CHARMM.  
For covariance analysis of MD trajectories, the normalized covariance (Cij) 
between two atoms i and j of a protein is defined as:  
!!" = ! !! − ! !! ∙ !! − ! !!!!! − ! !!! ! ∙ ! !! − ! !! !  
ri and rj represents the instantaneous fluctuations of the position of the atoms i and j with 
respect to their mean positions. When two atoms i and j move concertedly in the same 
direction, Cij=1, and, when the atoms move in opposite directions, Cij=-1.  
In this study, covariance analyses of Cα atoms were performed on 60 ns MD 
trajectories obtained by combining three individual 20ns MD trajectories for each system 
(calreticulin + G1M3, calreticulin + G1M3 + ATP and calreticulin + G1M3 + ADP) 
using the crystal structure of murine calreticulin (PDB ID 3RG0) docked to G1M3 and 
nucleotides. For the covariance analyses, each individual structure in the MD trajectory 
was superimposed onto the globular domain of calreticulin in the starting structure. This 
procedure removes rotational and translational motions of the proteins that occur over the 
course of the MD trajectories.  
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Chapter 4 
Targeting KIX domain of CBP with small molecules 
 
4.1: Introduction  
 
Figure 4.1: Schematic of transcription activation, where a DNA binding domain 
(DBD) and a transcriptional activation domain (TAD) recruit the transcription 
machinery to up-regulate a gene. (Adapted from Lee LW, et. al., 2010) 
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Transcription is an intricate and 
highly regulated process that is essential 
for a myriad of cellular processes 
including cell proliferation and 
apoptosis.1-4 A vast assortment of 
protein-protein interactions compose the 
complex machinery that oversees the 
regulation of transcription.5 The 
schematic in Figure 1 is a brief overview 
of some of the components required for 
transcription to be up regulated. A DNA 
binding domain  (DBD) interacts with 
transcriptional activator domains 
(TAD).5,6 The TADs recruit the 
transcription machinery, and bring it into proximity to the DNA upstream of the gene 
because of the DBD interaction with the DNA, up-regulating transcription of that gene.  
One protein involved in transcription regulation is the co-activator CREB binding 
protein (CBP) and its paralog p300. The GACKIX domain of CBP interacts with greater 
than ten distinct sequences at two unique binding sites (Figure 2).7-10 The ability of this 
domain to interact with such a variety of peptide sequences makes it difficult to target 
with small molecules due to the necessary plasticity of these molecules to recognize so 
many unique binding partners.11,12 Additionally, specificity is can be encouraged through 
allosteric regulation, where the binding of one peptide will effect the affinity of the 
Figure 4.2: GACKIX domain of CREB 
binding protein (CBP in blue with 
activation domains from the c-Myb (in 
purple) and mixed lineage leukemia 
(MLL in green) transcription factors 
bound to the two distinct binding sites of 
this CBP. (PDBID: 2agh)    
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second, adding further complexity to inhibiting these interactions.13-16 While there have 
been some here have been successes in targeting protein-protein interactions with small 
molecules targeting interactions that demonstrate such high promiscuity continue to be 
fairly illusive.17-21   
This challenging system was an interesting application for collaborative efforts 
that I undertook with the Mapp research group at University of Michigan. Contained in 
this chapter are efforts towards identifying possible small molecule inhibitors for the 
GACKIX domain of CBP.  
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4.2 Natural products inhibitors as possible helical mimetic  
 The GACKIX domain of CBP is a plastic surface, and has the ability to interact 
with a variety of different peptide sequences. This domain has further complexity with 
the ability have an allosteric response between its two binding pockets. To overcome this 
challenging system my experimental collaborators developed a high throughput screen to 
capture possible inhibitors of this domain. The high throughput screen utilized a high-
throughput fluorescence polarization assay with a fluorescein-labeled version of the MLL 
transcriptional activation domain. Two different compound sets were screened 
experimentally. One was a drug-like set of 50,000 commercially available compounds, 
which yielded no hits. A set of approximately 15,000 natural product extracts was also 
screened. This set consisted of extracts isolated from cyanobacteria, sponges and 
sediments, and yielded 64 hits that inhibited the MLL interaction with the GACKIX 
domain. The active ingredients were identified using NMR and mass spectrometry and 
included sekikaic acid (Figure 3). Sekikaic acid is a depside which was first identified by 
Emil Fischer as polypeptide-like small molecules consisting of a series of phenol 
carboxylic acids units.22 Depsides have been reported to have antibiotic, anti-oxidant, and 
anti-HIV activity and have recently been shown to affect protein-protein interactions. 23-26  
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Sekikaic acid inhibits the MLL-GACKIX complex in a dose dependent fashion 
with an IC50 of 34 mM based on fluoresce polarization based inhibition assays. As shown 
in Figure 2 in section 4.1, GACKIX has two unique binding sites, and to investigate the 
second binding site a FP-based inhibition experiment was performed with KID. Sekikaic 
acid also inhibited the KID-GACKIX interaction with an IC50 of 64 µM. These 
experiments demonstrate that the small-molecule sekikaic acid is capable of blocking 
activator peptides at both binding sites on the GACKIX domain, and is the first reported 
small molecule that can effectively perform this function. 
Due to this unique property of sekikaic acid it was important to investigate the 
structural details of the small-molecule’s interaction with the GACKIX domain. Circular 
dichroism and 1D- 1H-NMR experiments demonstrated that sekikaic acid binding is 
reversible and not inducing protein misfolding or aggregation. Additionally, 1H,15N-
HSQC NMR experiments with 15N-labeled GACKIX in the presence and absence of 
sekikaic acid revealed significant chemical shift perturbations in several regions of the 
Lecanoric acid  Lobaric acid  Sekikaic acid  
Figure 4.3: Sekikaic acid is a small molecule natural product and was identified by 
high-throughput screening as an inhibitor for peptide interactions with GACKIX 
domain of CBP. The success of sekikaic acid lead to investigated the structurally 
relevant small molecules lecanoric and lobaric acids.   
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receptor (Figure 4). The most significant shifts were around the flexible loop region 
 
where MLL interacts with GACKIX and defined by residues: Val 608, Leu 620, Lys 621, 
Arg 624, Met 625, and Glu 626.27 Residues near the binding region for CREB also 
experienced significant shifts upon sekikaic acid binding: Leu 664 and Lys 662, which is 
a key residue in binding CREB to GACKIX.28 These shifts suggest a model where 
sekikaic acid binds to the MLL binding site and disrupts the interaction of the 
allosterically connected KID-binding site. This experimental data was used to inform the 
computational protein-ligand docking experiments with aims to obtain an atomistic-
structural model of the sekikaic-GACKIX interaction.  The highly shifted residues, 
shown in green in Figure 4, were used as centers for the grid generation of the different 
docking trials. Sekikaic acid conformations were randomly generated and placed at 
centers of mass selected near each target binding site. However, the generated ligand 
Rotate 180° 
Figure 4.4: Residues (green) measured to be highly shifted upon binding of sekikaic 
acid via HSQC-NMR. (PDBID:2agh) Regions containing these residues were 
targeted as possible binding surfaces during docking trials.  
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conformations had near identical energies, making it difficult to distinguish small-
molecule binding modes from misdocked conformations.  
While unable to identify in atomistic detail the binding orientation of sekikaic 
acid to the GACKIX domain other structural questions could be addressed. TAD-binding 
motifs like those on the GACKIX domain tend to be hydrophobic and conformationally 
dynamic so they can interact with many distinct amphipathic TADs.27,29-32 Sekikaic acid 
has unique ability to interact with two unique sites that bind these helical, amphipathic 
TADs and it was hypothesized that this small-molecule could interact with GACKIX in a 
helical mimetic manner. To investigate this we performed molecular dynamics (MD) 
simulations of sekikaic acid and two structurally similar compounds lecanoric and lobaric 
acids (Figure 3).  
  The MD simulations were run in implicit solvent and begun from geometry-
optimized coordinates of the small molecules. All three small molecules have a 
convenient property of containing two substituted phenyl rings with an ester linker. This 
allows for an equivalent metric to inspect the conformational rigidity across these small 
molecules (Figure 5). The trajectories of the small-molecules were aligned to one phenyl 
ring and the angle between the two planes defined by the phenyl rings was followed 
throughout the trajectory (Left panel of Figure 5) and the probability density of the angles 
sampled was calculated (Right panel Figure 5). Lecanoric acid has the largest variation in 
angles sampled, as seen by its broad probability distribution, which spans approximately 
160 degrees. Sekikaic acid has a more narrow distribution, peaking at about 95 degrees, 
indicating it is not as free to rotate around its ester bond, and is likely hindered by its 
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larger functional groups. Lobaric acid is limited to sampling angles distributed about 50 
degrees as it is restrained by the bonds between the phenyl rings.  
 
  While sekikaic and lobaric acids are not as free to rotate about the ester bond as 
lecanoric acid, it does not show the positioning of the functional groups off the phenyl 
rings. For a helical mimetic, looking down the z-axis of the small molecule there should 
be functional groups occupying space in regular intervals. In Figure 6 (A-C), the small-
molecule phenyl rings were aligned to the first frame and the position of the last heavy 
atom for a given functional group was plotted. Interestingly, sekikaic acid has functional 
groups that stay in a fairly constrained area, in a circular pattern around the z-axis when 
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Figure 4.5: Angles between the phenyl rings during MD simulation in implicit 
solvent for three natural products that are structurally similar. Lobaric acid (cyan) 
rings are constrained by bonds between them and has very narrow angles that may 
be sampled. Sekikiac acid (black) has larger functional groups that limit the angles 
sampled unlike the unhindered lecanoric acid (blue). 
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compared to the other two small-molecules. Lecanoric acid, consistent with the relative 
angle analysis in Figure 5, had the largest spread of positions of its functional groups. 
Lobaric acid was similar to sekikaic acid. However, due to the functional groups 
containing longer chains the spread of possible positions is greater than that of sekikaic 
acid. Sekikaic acid demonstrates a relative structural rigidity to the other two small 
molecules, and has functional group able to occupy space as would side chains of peptide 
helix.  
 
Lecanoric acid Sekikaic acid 
Lobaric acid Sekikaic acid fit into MLL density 
Figure 4.6: Panels A-C show position of functional groups of various small 
molecules over the course of an implicit solvent simulation given alignment of the 
core of the molecule. Sekikaic acid functional groups are restrained to a limited 
region of space due to steric hindrance. Shown in panel D is a low energy 
conformation of sekikaic acid from the simulation fit it into the computed density of 
MLL. The functional groups of sekikaic acid orient in similar position of the 
amphipathic helix.  
A B 
C D 
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  To visualize sekikaic acid as a possible helical mimetic, low energy members of 
highly populated clusters of conformations from the implicit solvent trajectories were fit 
into a computed pseudo-density map of MLL (Figure 6D). The density map was 
generated with a 5Å resolution using the Situs tool and the clustered conformations were 
rigidly fit using Chimera.33,34 The low energy, highly sampled conformations of sekikaic 
acid fits well into the pseudo-density map, with functional groups oriented in similar 
positions as the side-chains of MLL supporting that this small molecule would interact 
with GACKIX as helical mimetic.      
  To investigate the acids that are structurally similar to sekikaic acid were 
subjected to competitive binding assays. Interestingly, the highly flexible lecanoric acid 
was unable to inhibit binding of both peptides, MLL and KID, which bind to separate 
binding sites on GACKIX.  However, the more constrained lobaric acid was able to 
inhibit both activators, as did sekikaic acid, with IC50s of 17 µM for MLL and 25 µM for 
KID. These data suggest that identification of possible helical mimetic could be used as a 
tool towards targeting challenging, dynamic surfaces like those on GACKIX.   
  These natural product GACKIX inhibitors were the first shown to modulate two 
distinct binding sites of such a dynamic receptor surface. Sekikaic acid shows 
conformational rigid and functional group orientations in solvent to suggest a helical 
mimetic. These properties can be used as a basis for the development of future small-
molecule inhibitors to target dynamic surfaces. Targeting transcription co-activator 
domains with small-molecule transcriptional modulators could be an invaluable 
biochemical probe and, potentially, have powerful therapeutic implications.  
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4.3: Methods 
Molecular dynamics simulations of the natural products in implicit solvent were 
performed using CHARMM.35,36 Simulations were run at 300K for 1 nanosecond after an 
equilibration of 500 picoseconds using the Leapfrog Verlet integrator and a 1 
femtosecond timestep.37 The CHARMM27 all-atom force field was used while the 
parameters for the small molecules were produced using the atom typing toolset MATCH 
and the CHARMM Generalized Force Field (CGenFF).38-40 The implicit solvent model 
used was GBMV, with a constant dielectric and a 16 angstrom nonbonded cutoff.41,42 The 
simulations were started from geometry optimized ligand coordinates using Hartree-Fock 
with the 6-31G* basis set in Guassian03.43-45 Clustering was performed using the 
MMTSB Tool Set with a 2 angstrom heavy atom RMSD radius.46  
The simulations revealed that these small molecules prefer to adopt a helical-like 
conformation in solution. Specifically, it was observed that the two phenyl rings of the 
small-molecules had a tendency to orient themselves out of register with respect to the 
other.  To quantify this observation we measured the angle between the two planes that 
pass through the carbons on each of the phenyl rings. A time series of these angles is 
plotted in the right panel of Figure 4, while the probability density is plotted on the left 
panel of the same figure. The simulations were then aligned to the core of the small 
molecule such that the core was along the z-axis. For Figure 5(A-C), the x and y 
coordinates of the last heavy atom of a given function group (see Figure 1) was plotted at 
each simulation snapshot.  
To visually demonstrate that sekikaic acid takes on a helical mimetic-like 
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conformation in solution, the small molecule conformations generated from the 
simulations were clustered and a low energy member from each of the five largest 
clusters was rigidly fit using Chimera into a pseudo-density map of the MLL peptide 
generated using the Situs tool with an approximate resolution of 5 angstroms. As shown 
in Figure 5D, a preferred conformation of sekikaic acid fits well into the pseudo-density 
map, and supports the idea that it behaves as a helical mimic.  
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4.4 Tethered small-molecule fragments and further docking methodology development 
Text adapted from: N. Wang, C.Y. Majmudar, W.C. Pomerantz, JK Gagnon, JD 
Sadowsky, JL Meagher, TK Johnson, JA Stuckey, CL Brooks III, JA Wells and AK 
Mapp. Ordering a dynamic protein via a small-molecule stabilizer. J Am Chem 
Soc, 2013, 135:3363-6. 
The GACKIX domain of co-activator CBP/p300 recognizes a diverse set of 
transcriptional activators at two separate binding sites. This ability to reorganize to 
accommodate so many different binding partners makes it especially challenging for 
structural characterization. Here we use a covalently tethered small-molecule to capture 
an angstrom-resolution snapshot of the conformationally dynamic GACKIX domain. 
This is the first time a crystal structure of this coactivator was obtained, suggesting that 
the ligand discovery strategy of tethering to stabilize a dynamic protein could be a 
general approach for structural characterization of these challenging targets.47-50 
We screened small molecule fragments using the tethering approach to identify 
small-molecule fragments that interact with the GACKIX domain.50 GACKIX has two 
unique binding sites, and the site that binds the Mixed Lineage Leukemia (MLL) 
activator consists of a deeper more distinct binding pocket than the other site that binds 
KID activator.51,52 A residue was selected near the edge of the MLL binding surface, Leu 
664, and was mutated to a cysteine. Small molecule fragments were screened in the 
presence of a competitor, β-mercaptoethanol, where molecules with some affinity for the 
receptor would remain through the experiment to be characterized. Two fragments 
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(fragment 1-10 and 2-64) were identified in this screen to have high tethering efficiency 
to GACKIX L664C by DR50 (dose response) values of 2-8µM (Figure 7). 
  Given the promising tethering 
efficiency we investigated the 
fragments’ ability to inhibit binding of 
activators at the two binding surfaces of 
GACKIX. Employing fluorescent 
polarization binding assays the affect the 
fragments had on GACKIX L664C 
binding MLL or pKID. Fragment 1-10 
and 2-64 both decreased the binding of 
MLL by approximately 7-16 fold. 
Fragment 2-64 has no affect on the ability of GACKIX L664C to bind pKID, which is the 
distal site from the MLL site targeted by the initial high throughput screen.53 However, 
pKID affinity is reduced by approximately 2-fold when GACKIX is bound to the 
fragment 1-10. This suggests that 1-10 is disrupting the allosteric communication 
between the two binding surfaces on GACKIX.9,54,55 
The tethered fragments significantly altered the stability of the GACKIX domain. 
This was assessed for each of the fragment-protein pairs by measuring changes in CD-
monitored thermal melting temperature, the extent of amide hydrogen-deuterium (H-D) 
exchange and the extent of proteolysis. The protein-small molecule complexes 
demonstrate a 15-18°C (≥20%) increase in melting temperature. Improved protection in 
Frag 1-10 
Frag 2-64 
Figure 4.7: Small-molecule fragments 
identified with a high throughput screen 
that utilizes a disulfide tethering technique. 
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hydrogen-deuterium exchange showing that 40-55% of the amides were protected 
compared to the apo protein.47 The proteolytic stability (half life) of the tethered complex 
increased 5-37 fold compared to a T½ range of 0.7-2.1 min of the untethered protein.15,56 
These data encouraged the pursuit of crystallization of fragment—GACKIX L664C 
complexes.  
 High quality crystals were obtained of the fragment 1-10/GACKIX L664C 
complex when dissolved 
in 1.8 M ammonium 
sulfate and 0.1 M Tris, pH 
7.0 at 25° C. However, 
only microcrystals of 2-64 
tethered to GACKIX 
L664C were obtained and 
were of too poor quality to 
solve. Initial attempts at 
molecular replacement 
strategies were undertaken 
using the NMR structures 
of GACKIX bound to native transcriptional activation domains but were 
unsuccessful.53,57 Therefore, a selenomethionine mutant of GACKIX tethered to 1-10 was 
prepared and the X-ray structure solved. Using these data, the structure of 1-10—
GACKIX L664C was determined to 2.0 Å resolution (Figure 8). The tethered fragment 
sits in the MLL binding surface of GACKIX and is oriented towards the core of the 
Figure 4.8: The first crystal structure of the GACKIX 
domain of CBP was obtained with the stability gained 
from binding tethered small-molecule fragment 1-10. 
(PDBID:4i9o) 
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protein. Interestingly, the aromatic ring of 1-10 is positioned relatively deep in a 
hydrophobic pocket that is created by a rotameric shift of Tyr631 which has previously 
been shown to be involved in GACKIX interacting with MLL.55,57  
     The prevailing structural model of amphipathic activator/coactivator complexes is that 
the activator forms an amphipathic helix upon binding to the surface of the coactivator.58-
60 While only a few different surfaces have been characterized to date, the available 
structures suggest that 
the binding surfaces are 
often shallow and broad 
making them 
particularly challenging 
to target with small 
molecules that have far 
less volume and surface 
area than the typical 
helix of a 
transcriptional activator.61-63 Considering an overlay of the 1-10/GACKIX L664C 
structure with the averages of the previously reported NMR structures of GACKIX 
demonstrates a high similarity of backbone structure with a RMSD of the backbone 
ranging between 1.07-1.81Å.57,64,65 These structures vary in the loop region between 
helices α1 and α2 that has a backbone RMSD range of 2.73-3.11Å. These variations in 
the loop region are consistent with literature suggesting the conformational loop being 
Figure 4.9: Cα RMSF for untethered GACKIX L664C 
(blue), fragment 1-10 tethered (yellow), and fragment 
2-64 tethered (green). 
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integral in the ability of GACKIX to accommodate such a variety of binding partners. 
53,64,66,67  
 To dissect in more detail how the GACKIX surface remodels itself to recognize  
fragment 1-10 we carried out 40 ns MD simulations of the GACKIX solid-state structure 
in the presence and absence of ligand. A gross comparison of the amide backbone reveals 
that a change in the loop 
confirmation is the most 
significant, as shown in 
the root mean square 
fluctuations (Figure 9) 
and in the average 
structure overlay (Figure 
10). These changes are 
often difficult to 
visualize by solution 
methods because the 
loop region contains 
several proline residues, 
but mutagenesis and 
NMR methods have 
suggested that conformational plasticity in this region underlies the ability of GACKIX to 
recognize diverse amphipathic sequences.54,57,67 It is this movement of the loop and a 
rotation of helix α1 that enable the formation of a narrower binding surface to 
Figure 4.10: Overlay of the structures closest to the 
calculated average from the simulations with untethered 
GACKIX L664C shown in blue, fragment 1-10 tethered 
in yellow, and fragment 2-64 tethered in green. 
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accommodate a molecule that is considerably smaller than a peptidic helix (~77% smaller 
volume). The binding surface that is targeted by 1-10 is also significantly different, both 
as a result of loop conformational changes and because of side chain motions as 
demonstrated by the change in solvent accessible surface area of the residues when the 
fragment is tethered (Figure 11). For example, the liganded GACKIX shows a population 
shift in the Tyr 631 side chain chi angles relative to the untethered protein, leading to a 
deeper hydrophobic binding surface for the small molecule. 
 
  
Figure 4.11: Difference in the average solvent-accessible surface area (SASA, in 
Å2) calculated by residue between simulations of untethered and 1-10-tethered 
GACKIX L664C. A residue colored red is less solvent-exposed in the 1-10-tethered 
structure, with the color intensity indicating the extent of the change; blue residues 
are more solvent-exposed in the 1-10-tethered structure.  
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While the larger fragment 2-64 demonstrated greater stabilization to the GACKIX 
domain in thermal melt, and greater protection in the H/D exchange the crystals produced 
for the 2-64 tethered to GACKIX complex were of poor quality. To identify a 
conformation of fragment 2-64 when tethered to GACKIX we developed methodology 
within the CHARMM docking package, CDOCKER.68-70 The methodology is in the style 
of MMTSB tool and consists of a set of Perl scripts to interface user input with 
CHARMM.35,36,46 The scripts generate a disulfide bond between the fragment and protein 
receptor allowing for sampling of physical dihedral angle around that bond. Docking 
trials of fragment 2-64 onto GACKIX L664C were performed in triplicate, and the 
resulting conformations clustered. The lowest energy member of the lowest energy 
cluster was simulated 
using a GPU capable 
version of CHARMM. The 
resulting simulations of 2-
64 tethered to GACKIX 
L664C predict the binding 
mode of this ligand to be 
similar to that of 1-10 and 
further demonstrates the 
ability of this protein to 
adapt to different binding 
partners  (Figure 12).  The 
α3 and α2 helices must open to accommodate this larger ligand and correspond to 
Figure 4.12: Predicted low energy docking result of 
Fragment 2-64 into L664C KIX domain of CBP 
suggests that binding of this fragment disrupts the 
crystal packing through rearrangement of key residues. 
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changes in the NMR chemical shifts of residues involved in this opening. Additionally, 
many side chains shift to accommodate the larger fragment 2-64 including Tyr 631 which 
makes important crystal contacts (Figure 12). This ligand binding orientation offers a 
hypothesis to the lack of high-quality crystals for the fragment 2-64/GACKIX complex.   
Having a crystal structure of such a dynamic receptor as GACKIX domain of 
CBP was a very interesting trial for Flexible CDOCKER. As previously mentioned we 
developed the docking methodology to have flexible side-chains to sample with the 
ligand conformations during docking simultaneously. In addition to the flexible receptor 
docking, we developed a docking methodology that includes physical disulfide bond 
between the small molecule fragment and GACKIX. A cross-docking trial of docking 
fragment 1-10 into a structure of GACKIX solved in the presence of another ligand 
 
would be a challenging test for this new docking methodology. Towards this end, we 
Figure 4.13: Cross-docking of fragment 1-10 to the NMR structure of KIX domain of 
CBP. (PDBID:1kdx) During docking the tyrosine is able to move out of the way to 
accomidate the small molecule (A). For comparison the same ligand conformation 
overlay with the starting NMR structure (B).   
A B 
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docked to the first set of coordinates from the NMR structure of GACKIX (PDBID:  
1kdx), which was experimentally determined in the presence of phosphorylated kinase-
inducible domain (pKID). The resulting low energy conformation is shown in Figure 13 
(left panel), which has a RMSD from the crystallographic ligand pose of about 3Å. While 
the RMSD is greater than that of the docking convention of a RMSD of < 2Å to be 
considered docked it should be noted that the Tyr631 (shown in green) shifts rotameric 
orientation to reveal the deeper hydrophobic pocket (Figure 13 right panel). Also notable 
are the energies for the lower RMSD to the crystallographic orientation of fragment 1-10 
tend to be lower than those conformations far from the native state (Figure 14). The 
results from this test are encouraging test and suggest Flexible CDOCKER with tethered 
ligands can be a powerful tool for investigating fragments binding at alternate locations 
or possibly other receptors.  
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In conclusion, we have obtained an angstrom-resolution snapshot of the 
conformationally dynamic co-activator GACKIX domain complexed with a small 
molecule. Development in the CDOCKER docking protocol to include a physical 
disulfide bond and a flexible receptor were used to investigate the conformation of the 
larger fragment 2-64 and a cross-docking trial of fragment 1-10. In the cross-docking 
trial, the receptor conformation shifted in a way that allowed the fragment to sit in a 
deeper hydrophobic pocket seen in the crystal structure (Figure 13). Additionally, the 
docking results followed by simulation suggest that the fragment 2-64/GACKIX complex 
may not have crystalized due to the binding mode of fragment 2-64 disrupting key crystal 
contacts formed in the fragment 1-10/GACKIX complex.  
From a broader perspective, these results suggest that tethering may be an 
exceptionally enabling approach to obtain long-sought solid state data of 
conformationally dynamic proteins. This includes transcriptional coactivators such as 
CBP/p300 targeted here, but also members of other cellular machineries that rely upon 
conformationally dynamic interfaces to recognize binding partners.71-72,73 
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4.4 Tethering methods 
The MD simulations were carried out using a GPU capable CHARMM version 
c37b1 with an OpenMM interface and run on two nVidia Tesla C2050 GPUs using 
OpenMM version 4.0.35,36,38,74 The simulations are 40 ns in length, and were run at 
constant pressure and temperature (298K) with the CHARMM27 forcefield, using 
Langevin dynamics to provide the thermal heat bath with a friction coefficient of 10 ps-
1.38,75 A variable time step was implemented, where the time step was minimally bound 
to 2 fs, but could increase to a time step that satisfied the error tolerance of 0.002. Particle 
mesh ewald and a non-bonded cutoff of 9Å were used with an FFT grid size of 72. 
SHAKE was applied to the hydrogen atoms and the parameters for the small molecule 
fragments were obtained using MATCH.39,40 For the fragment 1-10 simulation, the 
starting structure was the crystal structure reported in this manuscript. Similarly, the 
untethered GACKIX L664C simulation began from the crystal structure. However, the 
small molecule fragment was deleted, leaving only GACKIX L664C. 
CDOCKER was used to determine the pose for fragment 2-64 and the predicted 
lowest energy pose was simulated for a total of 80 ns under the same conditions as above 
to confirm the ligand was stable in that configuration. The fragment was docked into the 
crystal structure, as the fragment was a similar small molecule as fragment 1-10. Starting 
configurations for fragment 2-64 were generated using random rotations around torsions 
that were then subjected to 100 rounds of simulated annealing, where the ligand and 
select residues were flexible while the rest of the system was represented as a grid. Each 
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docking trial generated a total of 2,500 structures and three docking trials were run for 
this study, yielding a total of 7,500 ligand poses. These poses were clustered using K-
means clustering within the MMTSB toolset with a heavy atom cutoff of 3Å.46 The 
energy was calculated for each cluster, using the member closest to the cluster centroid. 
The resulting lowest energy pose was used in the all-atom simulation. 
The solvent accessible surface area (SASA), root mean square fluctuations 
(RMSF), and average structures were calculated using CHARMM.35,36 The SASA was 
calculated per residue and averaged over each frame of the trajectory. The average 
structures were calculated for the heavy atoms, also using the entire trajectory. The 
calculated average structure was then compared to each simulation frame and the frame 
with the smallest root mean square deviation (RMSD) from the calculated average was 
chosen for figures 9 & 10. Images were generated using PyMol and VMD.76,77  
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Chapter 5 
Applying Go-Like models to investigate allosteric signalling in KIX 
 
Text adapted from: S.M. Law, J.K. Gagnon, A.K. Mapp, C.L. Brooks III. Pre-Paying the 
Entropic Cost for Allosteric Regulation in KIX. Proc. Natl. Acad. Sci. U.S.A. 2014.  
!
5.1 Introduction 
The term “allosteric” describes the effects of one ligand (or effector) on the 
catalysis or binding of another ligand at a non-overlapping site.1,2 This classical view can 
be characterized by three main attributes: (i) only two states exist (e.g. active or inactive); 
(ii) the allosteric signal is relayed through a single well-defined pathway; and (iii) a 
conformational change occurs in the non-overlapping site. A modern interpretation treats 
the native state as a conformational ensemble (rather than only two conformational states) 
whose pre-existing population of conformations can be redistributed as a result of some 
allosteric perturbation that can be transmitted through multiple signaling pathways.3-6 
This new “unified view” defines allostery in purely structural and thermodynamic terms 
(i.e. allostery can be controlled by entropy and/or enthalpy) and provides a quantitative 
framework for classifying allosteric mechanisms.  
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Allostery is a central pillar in the regulation of gene transcription. The 
transcriptional coactivator CREB binding protein (CBP), which serves as a keystone in 
the assembly of the transcriptional machinery, is responsible for regulating transcriptional 
processes relating to hematopoiesis 7,8, cell differentiation 9,10, etc. Contained within CBP 
is an 87 residue-long domain called KIX that is critical for regulating transcriptional 
activity and can be cooperatively 
targeted by a diverse set of 
transcription factors 11-16 and 
small molecules.17-22,23 The 
structure of KIX (Figure 1) can be 
summarized as a three-helix 
bundle (α1, residues 597-611; α2, 
residues 623-640; α3, residues 
646-669) containing a mobile L12-G2 loop (residues 614-621) and an N-terminal 310 helix 
(residues 591-594). More importantly, KIX consists of at least two binding sites that are 
located on opposite surfaces of the protein, which can simultaneously bind, for example, 
the activation domain of the mixed lineage leukemia (MLL) protein and the activation 
domain of the proto-oncogene protein c-Myb (Figure 1), both of which are expressed 
concurrently during hematopoietic precursor cell development and therefore play an 
important role in blood cell proliferation.24-27  
The binding of either MLL or c-Myb to one of these promiscuous sites can 
stabilize the C-terminus of the α3 helix of KIX and/or decrease the mobility of the L12-G2 
loop but the functional role of these changes remains to be delineated.4,19,28-32 
Figure 5.1: Different representations of the 
MLL-KIX-c-Myb ternary complex (PDB ID code 
2AGH).  picture that connects the microscopic changes in structural dy-
namics to the macroscopic shift in binding affinities and kinetics,
we performed multiple simulations for each of KIX-free, MLL-
KIX, KIX-c-Myb, and MLL-KIX-c-Myb, and carried out a com-
parative analysis of the potential allosteric communication path-
ways. Through this approach, we detected similarities in protein
folding/unfolding, observed multiple c-Myb/MLL binding events,
and estimated thermodynamic and kinetic parameters for these
processes. Our results show that the binding of either peptide
stabilizes the L12-G2 loop as well a increas s the h licity of the α3
helix, both of which play a role in controlling the size of the hy-
drophobic core. Most notably, we find that this reduction in
structural dynamics results in an increase in the population of KIX
structures that resemble KIX in the ternary complex and the en-
tropic cost for binding a peptide at the allosteric site is lowered
when an effector is already bound to KIX. Collectively, our data
demonstrate that these observations are sufficient to explain the
increased binding affinity for c-Myb and MLL when the other
complementary peptide is bound to KIX and can direct the design
of small molecules to target important regions of conformationally
dynamic proteins.
Results
Binding Affinities an Configurational Entropies. Using a renormal-
ized G!o-like model that was adjusted to capture experimentally
reported helical content and binding affinities (Fig. S1), exten-
sive MD simulations of the free KIX, KIX-c-Myb, MLL-KIX,
and MLL-KIX-c-Myb systems were performed. It is important to
emphasize that no additional calibration of the intermolecular
interactions was used to simulate the MLL-KIX-c-Myb ternary
complex. That is, aside from the native contacts, the interaction
energies were not explicitly biased toward ternary complex for-
mation (SI Text). The resulting thermodynamic parameters and
kinetic rate constants for each simulation system are presented in
Table 1 and show that MLL and c-Myb bind cooperatively to
KIX rather than compete for KIX binding. The simulations
revealed that c-Myb and MLL bind to KIX with a Kd = 30 ±
8 μM and a Kd = 0.8 ± 0.3 μM, respectively. In the presence of
MLL, the affinity of KIX for c-Myb is enhanced by ∼10-fold and
is accompanied by a ∼4.4-fold decrease in koff and ∼2.4-fold
increase in kon. Similarly, the affinity of KIX-c-Myb for MLL is
enhanced by ∼8-fold and is accompanied by a ∼3.3-fold decrease
in koff and ∼1.9-fold increase in kon. Relative to free KIX,
the difference in configurational entropy (−TΔS) at 300 K for
forming KIX-c-Myb, MLL-KIX, and MLL-KIX-c-Myb was
∼0.8, ∼1.2, and ∼1.4 kcal/mol, respectively (Table 1).
Intrinsically Disordered Protein Binding Mechanism. We examined
the relationship between c-Myb binding and c-Myb folding by
constructing free-energy profiles along the fraction of intra-
molecular (Qintra) and intermolecular (Qinter) native contacts
(Fig. 2). In both the presence and absence of MLL, the free-
energy minimum shows c-Myb as being ∼40–80% folded and
bound to KIX with ∼70–95% of its intermolecular native
contacts intact. However, when c-Myb loses all of its in-
termolecular native contacts, it is ∼10–50% helical. Free c-Myb
was not found to exist in a preformed helical state and, instead,
followed a folding-and-binding mechanism that appears to be
independent of MLL. Similar results that support a folding-
and-binding mechanism were also observed for MLL binding to
free KIX (Fig. S2).
To further probe the effects of MLL on c-Myb binding, we
compared the rder of contact formation between KIX and
c-Myb by monitoring the contact appearance order. Leu302 of
c-Myb is predominantly first to form its intermolecular native
contacts (Fig. S3). Then, other intermolecular native contacts are
formed sequentially outward toward both termini of c-Myb. The
order in which the intermolecular native contacts were formed
between KIX-c-Myb was also found to be independent of MLL
binding. Similarly, the order of contact formation between MLL
and KIX was also found to be independent of c-Myb binding
(Fig. S4).
KIX Dynamics. Fig. 3 shows the root-mean-square fluctuation of
the highest ranked mode computed from principal component
analysis (PCA) and projected onto the average simulation
structure for each system. In free KIX, the C terminus of the α3
helix and the L12-G2 loop were the most mobile. In fact, the
average structure shows a completely unfolded α3 C terminus
beginning at around resid e 657. Upon binding c-Myb, the mo-
bility of the α3 helix is slightly reduced, whereas the L12-G2 loop
remains as flexible as in free KIX. Aside from the C terminus of
the α3 helix, the average structures of KIX-free and KIX-c-Myb
are very similar. In contrast, MLL binding stabilizes the C-ter-
minal residues of α3 and regains the secondary structure of this
helix. Also, the L12-G2 loop appears to be less mobile than in free
KIX or KIX-c-Myb. Finally, the ternary complex shows a rigid α3
helix and only some flexibility in the L12-G2 loop, similar to the
MLL-KIX binary system. Consistent with these findings, Fig. S5
shows that the binding of MLL and/or c-Myb results in a signif-
icant increase in α3 helicity.
Representative free-energy surfaces along the L12-G2 loop
root-mean-square deviation (rmsd) (with respect to the NMR
structure) and the hydrophobic core size, which effectively
NMR Structure Cα Atoms
KIX MLL c-Myb
G1
α1
L12
α2
α3
G2
Fig. 1. Different representations of the MLL-KIX-c-Myb ternary complex
(PDB ID code 2AGH).
Table 1. Thermodynamic parameters and kinetic rate constants
Ligand Binding to Expt. Kd*, μM Simulated Kd† , μM Simulated koff† , s−1 Simulated kon† , M−1·s−1 −TΔS‡, kcal/mol
c-Myb KIX 10 ± 2 30 ± 8 5.92E+06 ± 0.94E+06 0.20E+12 ± 0.02E+12 0.8
c-Myb KIX-MLL 4 ± 1 3 ± 1 1.36E+06 ± 0.24E+06 0.48E+12 ± 0.17E+12 1.4
MLL KIX 2.8 ± 0.4 0.8 ± 0.3 2.46E+06 ± 0.54E+06 3.19E+12 ± 0.60E+12 1.2
MLL KIX-c-Myb 1.7 ± 0.1 0.1 ± 0.1 0.75E+06 ± 0.10E+06 6.02E+12 ± 0.57E+12 1.4
*Experimental Kd published in ref. 13.
†Averaged over three groups of 20 simulations.
‡Calculated at 300 K relative to KIX-free.
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Furthermore, in vitro, KIX alone demonstrates a ~2 fold lower affinity for c-Myb and 
~1.6 fold lower affinity for MLL when compared to KIX bound to MLL or c-Myb, 
respectively.12 Although numerous efforts have been put forth to clarify the molecular 
mechanism for cooperative binding in KIX, the current allosteric picture detailing the 
thermodynamic and structural effects of MLL and/or c-Myb binding remains incomplete. 
While all-atom MD simulations complement experiment and have provided valuable 
insight into the allosteric process, they are computationally too expensive to explore 
timescales where multiple binding events or protein folding/unfolding are necessary to 
understand the underlying mechanism of action.19,30,33 To address these limitations, we 
utilize a topology-based Gō-like model 34,35 that has shown success in examining coupled 
protein folding and binding 36-44 as well as modeling ligand-induced structural transitions, 
and allosteric communication.45-47 We extend its application to the quantitative study of 
allostery and cooperative binding for the first time here in the context of the MLL-KIX-c-
Myb ternary system. To develop a quantitative picture that connects the microscopic 
changes in structural dynamics to the macroscopic shift in binding affinities and kinetics, 
we performed multiple simulations for each of KIX-free, MLL-KIX, KIX-c-Myb, and 
MLL-KIX-c-Myb and carried out a comparative analysis of the potential allosteric 
communication pathways. Through this approach, we detected similarities in protein 
folding/unfolding, observed multiple c-Myb/MLL binding events, and estimated 
thermodynamic and kinetic parameters for these processes. Our results show that the 
binding of either peptide stabilizes the L12-G2 loop as well as increases the helicity of the 
α3 helix, both of which play a role in controlling the size of the hydrophobic core. Most 
notably, we find that this reduction in structural dynamics results in an increase in the 
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population of KIX structures that resemble KIX in the ternary complex and the entropic 
cost for binding a peptide at the allosteric site is lowered when an effector is already 
bound to KIX. Collectively, our data demonstrate that these observations are sufficient to 
explain the increased binding affinity for c-Myb and MLL when the other complementary 
peptide is bound to KIX and can direct the design of small molecules to target important 
regions of conformationally dynamic proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
picture that connects the microscopic changes in structural dy-
namics to the macroscopic shift in binding affinities and kinetics,
we performed multiple simulations for each of KIX-free, MLL-
KIX, KIX-c-Myb, and MLL-KIX-c-Myb, and carried out a com-
parative analysis of the potential allosteric communication path-
ways. Through this approach, we detected similarities in protein
folding/unfolding, observed multiple c-Myb/MLL binding events,
and estimated thermodynamic and kinetic parameters for these
processes. Our results show that the binding of either peptide
stabilizes the L12-G2 loop as well as increases the helicity of the α3
helix, both of which play a role in controlling the size of the hy-
drophobic core. Most notably, we find that this reduction in
structural dynamics results in an increase in the population of KIX
structures that resemble KIX in the ternary complex and the en-
tropic cost for binding a peptide at the allosteric site is lowered
when an effector is already bound to KIX. Collectively, our data
demonstrate that these observations are sufficient to explain the
increased binding affinity for c-Myb and MLL when the other
complementary peptide is bound to KIX and can direct the design
of small molecules to target important regions of conformationally
dynamic proteins.
Results
Binding Affinities and Configurational Entropies. Using a renormal-
ized G!o-like model that was adjusted to capture experimentally
reported helical content and binding affinities (Fig. S1), exten-
sive MD simulations of the free KIX, KIX-c-Myb, MLL-KIX,
and MLL-KIX-c-Myb systems were performed. It is important to
emphasize that no additional calibration of the intermolecular
interactions was used to simulate the MLL-KIX-c-Myb ternary
complex. That is, aside from the native contacts, the interaction
energies were not explicitly biased toward ternary complex for-
mation (SI Text). The resulting thermodynamic parameters and
kinetic rate constants for each simulation system are presented in
Table 1 and show that MLL and c-Myb bind cooperatively to
KIX rather than compete for KIX binding. The simulations
revealed that c-Myb and MLL bind to KIX with a Kd = 30 ±
8 μM and a Kd = 0.8 ± 0.3 μM, respectively. In the presence of
MLL, the affinity of KIX for c-Myb is enhanced by ∼10-fold and
is accompanied by a ∼4.4-fold decrease in koff and ∼2.4-fold
increase in kon. Similarly, the affinity of KIX-c-Myb for MLL is
enhanced by ∼8-fold and is accompanied by a ∼3.3-fold decrease
in koff and ∼1.9-fold increase in kon. Relative to free KIX,
the difference in configurational entropy (−TΔS) at 300 K for
forming KIX-c-Myb, MLL-KIX, and MLL-KIX-c-Myb was
∼0.8, ∼1.2, and ∼1.4 kcal/mol, respectively (Table 1).
Intrinsically Disordered Protein Binding Mechanism. We examined
the relationship between c-Myb binding and c-Myb folding by
constructing free-energy profiles along the fraction of intra-
molecular (Qintra) and intermolecular (Qinter) native contacts
(Fig. 2). In both the presence and absence of MLL, the free-
energy minimum shows c-Myb as being ∼40–80% folded and
bound to KIX with ∼70–95% of its intermolecular native
contacts intact. However, when c-Myb loses all of its in-
termolecular native contacts, it is ∼10–50% helical. Free c-Myb
was not found to exist in a preformed helical state and, instead,
followed a folding-and-binding mechanism that appears to be
independent of MLL. Similar results that support a folding-
and-binding mechanism were also observed for MLL binding to
free KIX (Fig. S2).
To further probe the effects of MLL on c-Myb binding, we
compared the order of contact formation between KIX and
c-Myb by monitoring the contact appearance order. Leu302 of
c-Myb is predominantly first to form its intermolecular native
contacts (Fig. S3). Then, other intermolecular native contacts are
formed sequentially outward toward both termini of c-Myb. The
order in which the intermolecular native contacts were formed
between KIX-c-Myb was also found to be independent of MLL
binding. Similarly, the order of contact formation between MLL
and KIX was also found to be independent of c-Myb binding
(Fig. S4).
KIX Dynamics. Fig. 3 shows the root-mean-square fluctuation of
the highest ranked mode computed from principal component
analysis (PCA) and projected onto the average simulation
structure for each system. In free KIX, the C terminus of the α3
helix and the L12-G2 loop were the most mobile. In fact, the
average structure shows a completely unfolded α3 C terminus
beginning at around residue 657. Upon binding c-Myb, the mo-
bility of the α3 helix is slightly reduced, whereas the L12-G2 loop
r mains as flexible as in free KIX. Aside from the C terminus of
the α3 helix, the average structures of KIX-free and KIX-c-Myb
are very similar. In contrast, MLL binding stabilizes the C-ter-
minal residues of α3 and regains the s condary structure of this
helix. Also, the L12-G2 loop appears to be less mobile than in free
KIX or KIX-c-Myb. Finally, the ternary complex shows a rigid α3
helix and only some flexibility in the L12-G2 loop, similar to the
MLL-KIX binary system. Consistent with these findings, Fig. S5
shows that the binding of MLL and/or c-Myb results in a signif-
icant increase in α3 helicity.
Representative free-energy surfaces along the L12-G2 loop
root-mean-square deviation (rmsd) (with respect to the NMR
structure) and the hydrophobic core size, which effectively
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Fig. 1. Different representations of the MLL-KIX-c-Myb ternary complex
(PDB ID code 2AGH).
Table 1. Thermodynamic parameters and kinetic rate constants
Ligand Binding to Expt. Kd*, μM Simulated Kd† , μM Simulated koff† , s−1 Simulated kon† , M−1·s−1 −TΔS‡, kcal/mol
c-Myb KIX 10 ± 2 30 ± 8 5.92E+06 ± 0.94E+06 0.20E+12 ± 0.02E+12 0.8
c-Myb KIX-MLL 4 ± 1 3 ± 1 1.36E+06 ± 0.24E+06 0.48E+12 ± 0.17E+12 1.4
MLL KIX 2.8 ± 0.4 0.8 ± 0.3 2.46E+06 ± 0.54E+06 3.19E+12 ± 0.60E+12 1.2
MLL KIX-c-Myb 1.7 ± 0.1 0.1 ± 0.1 0.75E+06 ± 0.10E+06 6.02E+12 ± 0.57E+12 1.4
*Experimental Kd published in ref. 13.
†Averaged over three groups of 20 simulations.
‡Calculated at 300 K relative to KIX-free.
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5.2 Results 
Binding affinities and configurational entropies 
Using a renormalized Gō-like model that was adjusted to capture experimentally 
reported helical content and binding affinities, extensive MD simulations of the free KIX, 
KIX-c-Myb, MLL-KIX, and MLL-KIX-c-Myb systems were performed. It is important 
to emphasize that no additional calibration of the intermolecular interactions was used to 
simulate the MLL-KIX-c-Myb ternary complex. That is, aside from the native contacts, 
the interaction energies were not explicitly biased towards ternary complex formation 
(see Supporting Information). The resulting thermodynamic parameters and kinetic rate 
constants for each simulation system are presented in Table 1 and show that MLL and c-
Myb bind cooperatively to KIX rather than competing for KIX binding. The simulations 
revealed that c-Myb and MLL bind to KIX with a Kd = 30 ± 8 µM and a Kd = 0.8 ± 0.3 
µM, respectively. In the presence of MLL, the affinity of KIX for c-Myb is enhanced by 
~10 fold and is accompanied by a ~4.4 fold decrease in koff and ~2.4 fold increase in kon. 
Similarly, the affinity of KIX-c-Myb for MLL is enhanced by ~8 fold and is 
accompanied by a ~3.3 fold decrease in koff and ~1.9 fold increase in kon. Relative to free 
KIX, the difference in configurational entropy ( ) at 300 K for forming KIX-c-Myb, 
MLL-KIX, and MLL-KIX-c-Myb was ~0.8 kcal/mol, ~1.2 kcal/mol, and ~1.4 kcal/mol, 
respectively (see Table 1, Figure 4 and Figure 8).  
−TΔS
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IDP binding mechanism 
We examined the relationship between c-Myb binding and c-Myb folding by 
constructing free energy profiles along the fraction of intramolecular (Qintra) and 
intermolecular (Qinter) native contacts (Figure 2). In both the presence and absence of 
MLL, the free energy minimum shows c-Myb as being ~40-80% folded and bound to 
KIX with ~70-95% of its intermolecular native contacts intact. However, when c-Myb 
loses all of its intermolecular native contacts it is ~10-50% helical. Free c-Myb was not 
found to exist in a preformed helical state and, instead, followed a folding-and-binding 
mechanism that appears to be independent of MLL. Similar results that support a folding-
and-binding mechanism were also observed for MLL binding to free KIX (Figure 3*). 
 
Figure 5.2: Two$dimensional-free$energy-surfaces-as-a-func4on-of-c$Myb-folding-and-
binding-in-(A)-the-absence-of-MLL-and-(B)-the-presence-of-MLL.-Qintra-is-the-frac4on-
of-na4ve- intramolecular-contacts- in-c$Myb,-whereas-Qinter- is- the- frac4on-of-na4ve-
intermolecular-contacts-formed-between-KIX$c$Myb.--
 
describes the distance between helices α1 and α3, were computed
and are displayed in Fig. 4. Overall, the conformational sampling
f KIX along the two collective vari bles is the ost restricted
when both peptides are bound. Relative to KIX-free, the binding
of MLL and/or c-Myb decreases the extent of sampling of the
loop with the ternary complex being affected the most. The
maximum opening of the hydrophobic core is also reduced from
∼5.5 to ∼4 Å when the loop deviates signific ntly from the ref-
erence NMR structure. Again, this trend is most pronounced in
the ternary complex. In all cases, the lowest free-energy mini-
mum has a hydrophobic core that is open by ∼3.5–4 Å, but the
loop rmsd within each minimum is restricted to ∼4–7 Å when
MLL is present, and expands to a wider range (∼4–10 Å) when
MLL is absent. Additional free-energy profiles calculated with
respect to the α3 helix rmsd, which is believed to contribute to
the allosteric binding of c-Myb, are reported in Fig. S6 and show
similar results to Fig. 4. Overall, all of the free-energy surfaces
show a reduction in the conformational space being sampled
when one or both peptides are bound to KIX (i.e., the colored
area became smaller upon binding MLL and/or c-Myb and
narrowed toward a ternary-like KIX).
Discussion
It has been hypothesized that protein intrinsic disorder offers
numerous benefits such as fast protein turnover (48), high
specificity for a diverse set of targets (48–52), and high specificity
with low affinity binding (49, 50). In addition, it has been pre-
dicted that allosteric coupling between independent sites is
maximized in the presence of intrinsic disorder (53). In in-
trinsically disordered protein systems, like those in the present
study, there is an intricate relationship between binding and
folding (36–39, 54–60). We observed that both c-Myb and MLL
first bind to KIX before forming a folded peptide, and the free-
energy surfaces between binary and ternary KIX complexes were
virtually indistinguishable for both MLL and c-Myb (Fig. 2 and
Fig. S2). Additionally, MLL and c-Myb, which were tuned to
have a peak helicity of ∼5% and ∼25%, respectively, to match
experiment (Fig. S1), achieved over 80% helicity upon binding to
KIX. This binding-induced-folding mechanism is consistent with
kinetic experiments of KIX-c-Myb (i.e., rapid mixing of KIX with
c-Myb) (55, 61, 62), and our results suggest that effector binding
allosterically regulates peptide binding at the second site without
altering the binding mechanism.
We explored this further by examining the intermolecular
contact appearance order for KIX and c-Myb to see whether
MLL binding alters the sequence in which contacts between
c-Myb and KIX are formed with a low probability of breaking.
Fig. S3A shows that Leu302, which is positioned in the middle of
the helix and inserts its side chain deep into the hydrophobic
core in the native NMR structure (28), is first to form most of
its interactions with the α1 and α3 helices of KIX. According to
Fig. 2, c-Myb is mostly unstructured at this stage, with only
∼20–40% helicity. Then, binding proceeds outward toward both
termini of c-Myb and is concomitant with c-Myb folding
(Fig. S3A). The N terminus of c-Myb, which interacts exclusively
with the C terminus of the α3 helix, has a slightly higher proba-
bility than the C terminus for forming last, which may imply
a potential role for α3 in regulating c-Myb binding. These results
were similar for c-Myb binding to the binary complex (Fig. S3B)
and demonstrate that MLL binding does not have a significant
impact on the order in which c-Myb residues contact KIX.
Previous studies have observed changes in the KIX structure
resulting from transcription factor binding, and both MLL and
c-Myb have been shown to allosterically affect the affinity of KIX
for the complementary peptide (4, 20, 28–32). However, a con-
nection between the changes in structural dynamics in KIX and
how this directly leads to shifts in transcription factor binding
affinities remain tenuous. To bridge this gap, we used a coarse-
grained simulation model that is capable of capturing both the
microscopic structural changes and macroscopic ligand binding
events. Consistent with cooperative binding, we found that the
binding affinity for c-Myb is increased by an order of magni-
tude in the presence of MLL while the affinity for MLL is also
increased by a factor of 8 when c-Myb is present (Table 1).
These observations are in agreement with experiment, albeit
with an approximately fivefold difference in both cases (13),
but given the simplicity of our simulation model, it is remark-
able that we are able to capture the same allosteric trends as
seen in experiment. We also observed relative decreases in koff
(∼4.4-fold and ∼3.3-fold for c-Myb and MLL, respectively) and
small increases in kon (∼2.4-fold and ∼1.9-fold for c-Myb and
MLL, respectively) when an effector was bound first (Table 1).
These changes in kinetics combined with our observations of an
effector-independent binding-induced-folding mechanism sug-
gest that prebinding of the first peptide likely stabilizes the
flexible/unfolded parts of the KIX structure so that the second
peptide can (i) form a native intermolecular contact more
quickly (i.e., small increase in kon) and (ii) stay bound for much
longer (i.e., decrease koff).
To further understand the allosteric mechanism, we in-
vestigated how MLL and/or c-Myb binding can affect the dy-
namics of KIX (Figs. 3 and 4, and Fig. S6). Overall, we found
that binding of MLL and/or c-Myb resulted in an increase in
stability (or a reduction in dynamics) of the α3 C terminus and
the L12-G2 loop. This is consistent with observations made in
previous NMR and computational studies, which have led to the
suggestion that the increased structural stability of KIX may play
a role in allosteric signaling (4, 20, 28–32). For example, NMR
backbone order parameter measurements of KIX have demon-
strated that the L12-G2 loop and the C-terminal residues of the
α3 helix are more rigid when MLL is bound to KIX (29). Thus,
our findings are not only supported by experiment but they also
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Fig. 2. Two-dimensional free-energy surfaces as a function of c-Myb folding
and binding in (A) the absence of MLL and (B) the presence of MLL. Qintra is
the fraction of native intramolecular contacts in c-Myb, whereas Qinter is the
fraction of native intermolecular contacts formed between KIX-c-Myb.
Fig. 3. Root-mean-square fluctuations from PCA. The average KIX structure
from each simulation is shown in white, and the ligands were omitted for
clarity. The red arrows point along the direction of the lowest frequency
mode (highest ranked eigenvector), and the amplitude is directly pro-
portional to the length of the arrow. Only fluctuations greater than 1.0 Å
are displayed.
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To further probe the effects of 
MLL on c-Myb binding, we 
compared the order of contact 
formation between KIX and c-
Myb by monitoring the contact 
appearance order. Leu302 of c-
Myb is predominantly first to form 
its intermolecular native contacts 
(Figure 4*). Then, other 
intermolecular native contacts are 
formed sequentially outward 
towards both termini of c-Myb. 
The order in which the 
intermolecular native contacts 
were formed between KIX-c-Myb 
was also found to be independent of MLL binding. Similarly, the order of contact 
formation between MLL and KIX was also found to be independent of c-Myb binding 
(Figure 5). 
 
 
 
 
Figure 5.3: 2-D free energy surfaces as a 
function of MLL folding and binding in (A) the 
absence of c-Myb and (B) the presence of c-
Myb. Qintra i s the f ract ion of nat ive 
intramolecular contacts in MLL while Qinter is the 
fraction of native intermolecular contacts formed 
between MLL-KIX. 
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Figure 5.4: Contact appearance order (CAO) 
for c-Myb binding in (A) the absence of MLL 
and (B) the presence of MLL. The horizontal 
axis corresponds to native intermolecular 
contacts made between KIX-c-Myb and low, 
medium, and high contact numbers 
correspond to contacts made by the N-
terminus, middle, and C-terminus of c-Myb, 
respectively. The order in which contacts are 
formed between KIX-c-Myb is shown along 
the vertical axis and can be thought of as a 
time axis. White squares have a zero 
probability and dark red squares have the 
highest probability of being the nth contact 
formed. The colored bar above the figure 
shows where c-Myb contacts KIX with 
orange and yellow squares corresponding to 
helices α1 and α3, respectively. The C-
terminus of α3 is denoted by solid black 
boxes. Intermolecular native contacts made 
by Leu302 are enclosed by a dashed box 
(contact numbers 9-15).  
Figure 5.5: Contact'appearance'order' (CAO)'
for'MLL'binding' in' (A)' the'absence'of' c8Myb'
and'(B)'the'presence'of'c8Myb.'The'horizontal'
axis' corresponds' to' na@ve' intermolecular'
contacts' made' between' MLL8KIX' and' low,'
medium,' and' high' contact' numbers'
correspond' to' contacts' made' by' the' N8
terminus,' middle,' and' C8terminus' of' MLL,'
respec@vely.'The'order' in'which'contacts'are'
formed'between'MLL8KIX' is'shown'along'the'
ver@cal'axis'and'can'be'thought'of'as'a'@me'
axis.' White' squares' have' a' zero' probability'
and' dark' red' squares' have' the' highest'
probability'of'being'the'nth'contact'formed.' 
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KIX dynamics 
Figure 6 shows the root-mean-square fluctuation of the highest ranked mode 
computed from principal component analysis (PCA) and projected onto the average 
simulation structure for each system. In free KIX, the C-terminus of the α3 helix and the 
L12-G2 loop were the most mobile. In fact, the average structure shows a completely 
unfolded α3 C-terminus beginning at around residue 657. Upon binding c-Myb, the 
mobility of the α3 helix is slightly reduced while the L12-G2 loop remains as flexible as in 
free KIX. Aside from the C-terminus of the α3 helix, the average structures of KIX-free 
and KIX-c-Myb are very similar. In contrast, MLL binding stabilizes the C-terminal 
residues of α3 and regains the secondary structure of this helix. Also, the L12-G2 loop 
appears to be less mobile than in free KIX or KIX-c-Myb. Finally, the ternary complex 
shows a rigid α3 helix and only some flexibility in the L12-G2 loop, similar to the MLL-
KIX binary system. Consistent with these findings, Figure 9 shows that the binding of 
MLL and/or c-Myb results in a significant increase in α3 helicity. 
 
 
Figure 5.6: Root$mean$square-fluctua0ons-from-PCA.-The-average-KIX-structure-from-
each-simula0on-is-shown-in-white,-and-the-ligands-were-omiBed-for-clarity.-The-red-
arrows- point- along- the- direc0on- of- the- lowest- frequency- mode- (highest- ranked-
eigenvector),-and-the-amplitude-is-directly-pro$-por0onal-to-the-length-of-the-arrow.-
Only-fluctua0ons-greater-than-1.0-Å-are-displayed.--
describes the distance between helices α1 and α3, were computed
and are displayed in Fig. 4. Overall, the conformational sampling
of KIX along the two collective variables is the most restricted
when both peptides are bound. Relative to KIX-free, the binding
of MLL and/or c-Myb decreases the extent of sampling of the
loop with the ternary complex being affected the most. The
maximum opening of the hydrophobic core is also reduced from
∼5.5 to ∼4 Å when the loop deviates significantly from the ref-
erence NMR structure. Again, this trend is most pronounced in
the ternary complex. In all cases, the lowest free-energy mini-
mum has a hydrophobic core that is open by ∼3.5–4 Å, but the
loop rmsd within each minimum is restricted to ∼4–7 Å when
MLL is present, and expands to a wider range (∼4–10 Å) when
MLL is absent. Additional free-energy profiles calculated with
respect to the α3 helix rmsd, which is believed to contribute to
the allosteric binding of c-Myb, are reported in Fig. S6 and show
similar results to Fig. 4. Overall, all of the free-energy surfaces
show a reduction in the conformational space being sampled
when one or both peptides are bound to KIX (i.e., the colored
area became smaller upon binding MLL and/or c-Myb and
narrowed toward a ternary-like KIX).
Discussion
It has been hypothesized that protein intrinsic disorder offers
numerous benefits such as fast protein turnover (48), high
specificity for a diverse set of targets (48–52), and high specificity
with low affinity binding (49, 50). In addition, it has been pre-
dicted that allosteric coupling between independent sites is
maximized in the presence of intrinsic disorder (53). In in-
trinsically disordered protein systems, like those in the present
study, there is an intricate relationship between binding and
folding (36–39, 54–60). We observed that both c-Myb and MLL
first bind to KIX before forming a folded peptide, and the free-
energy surfaces between binary and ternary KIX complexes were
virtually indistinguishable for both MLL and c-Myb (Fig. 2 and
Fig. S2). Additionally, MLL and c-Myb, which were tuned to
have a peak helicity of ∼5% and ∼25%, respectively, to match
experiment (Fig. S1), achieved over 80% helicity upon binding to
KIX. This binding-induced-folding mechanism is consistent with
kinetic experiments of KIX-c-Myb (i.e., rapid mixing of KIX with
c-Myb) (55, 61, 62), and our results suggest that effector binding
allosterically regulates peptide binding at the second site without
altering the binding mechanism.
We explored this further by examining the intermolecular
contact appearance order for KIX and c-Myb to see whether
MLL binding alters the sequence in which contacts between
c-Myb and KIX are formed with a low probability of breaking.
Fig. S3A shows that Leu302, which is positioned in the middle of
the helix and inserts its side chain deep into the hydrophobic
core in the native NMR structure (28), is first to form most of
its interactions with the α1 and α3 helices of KIX. According to
Fig. 2, c-Myb is mostly unstructured at this stage, with only
∼20–40% helicity. Then, binding proceeds outward toward both
termini of c-Myb and is concomitant with c-Myb folding
(Fig. S3A). The N terminus of c-Myb, which interacts exclusively
with the C terminus of the α3 helix, has a slightly higher proba-
bility than the C terminus for forming last, which may imply
a potential role for α3 in regulating c-Myb binding. These results
were similar for c-Myb binding to the binary complex (Fig. S3B)
and demonstrate that MLL binding does not have a significant
impact on the order in which c-Myb residues contact KIX.
Previous studies have observed changes in the KIX structure
resulting from transcription factor binding, and both MLL and
c-Myb have been shown to allosterically affect the affinity of KIX
for the complementary peptide (4, 20, 28–32). However, a con-
nection between the changes in structural dynamics in KIX and
how this directly leads to shifts in transcription factor binding
affinities remain tenuous. To bridge this gap, we used a coarse-
grained simulation model that is capable of capturing both the
microscopic structural changes and macroscopic ligand binding
events. Consistent with cooperative binding, we found that the
binding affinity for c-Myb is increased by an order of magni-
tude in the presence of MLL while the affinity for MLL is also
increased by a factor of 8 when c-Myb is present (Table 1).
These observations are in agreement with experiment, albeit
with an approximately fivefold difference in both cases (13),
but given the simplicity of our simulation model, it is remark-
able that we are able to capture the same allosteric trends as
seen in experiment. We also observed relative decreases in koff
(∼4.4-fold and ∼3.3-fold for c-Myb and MLL, respectively) and
small increases in kon (∼2.4-fold and ∼1.9-fold for c-Myb and
MLL, respectively) when an effector was bound first (Table 1).
These changes in kinetics combined with our observations of an
effector-independent binding-induced-folding mechanism sug-
gest that prebinding of the first peptide likely stabilizes the
flexible/unfolded parts of the KIX structure so that the second
peptide can (i) form a native intermolecular contact more
quickly (i. ., small increase in kon) and (ii) stay bound for much
longer (i.e., decrease koff).
To further understand the allosteric mechanism, we in-
vestigated how MLL and/or c-Myb binding can affect the dy-
namics of KIX (Figs. 3 and 4, and Fig. S6). Overall, we found
that binding of MLL a d/ r c-Myb resulted in an increase in
stability (or a reduction in dynamics) of the α3 C terminus and
the L12-G2 loop. This is consistent with observations made in
previous NMR and computational studies, which have led to the
suggestion that the increased structural stability of KIX may play
a role in allosteric signaling (4, 20, 28–32). or example, NMR
backbone order parameter measurements of KIX have demon-
strated that the L12-G2 loop and the C-terminal residues of the
α3 helix ar more rigid w en MLL is bound to KIX (29). Thus,
our findings are not only supported by experiment but they also
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Fig. 2. Two-dimensional free-energy surfaces as a function of c-Myb folding
and binding in (A) the absence of MLL and (B) the presence of MLL. Qintra is
the fraction of native intramolecular contacts in c-Myb, whereas Qinter is the
fraction of native intermolecular contacts formed between KIX-c-Myb.
Fig. 3. Root-mean-square fluctuations from PCA. The average KIX structure
from each simulation is shown in white, and the ligands were omitted for
clarity. The red arrows point along the direction of the lowest frequency
mode (highest ranked eigenvector), and the amplitude is directly pro-
portional to the length of the arrow. Only fluctuations greater than 1.0 Å
are displayed.
Law et al. PNAS | August 19, 2014 | vol. 111 | no. 33 | 12069
BI
O
PH
YS
IC
S
A
N
D
CO
M
PU
TA
TI
O
N
A
L
BI
O
LO
G
Y
! 103!
Representative free energy surfaces along the L12-G2 loop RMSD (with respect to 
the NMR structure) and the hydrophobic core size, which effectively describes the 
distance between helices α1 and α3, were computed and are displayed in Figure 7.  
 
Overall, the conformational sampling of KIX along the two collective variables is the 
most restricted when both peptides are bound. Relative to KIX-free, the binding of MLL 
and/or c-Myb decreases the extent of sampling of the loop with the ternary complex 
being affected the most. The maximum opening of the hydrophobic core is also reduced 
from ~5.5 Å to ~4 Å when the loop deviates significantly from the reference NMR 
structure. Again, this trend is most pronounced in the ternary complex. In all cases, the 
provide a direct causative link between changes in the local
structural dynamics and its effects on the global binding affini-
ties. From the observations made in Fig. 4 and Fig. S6, we cal-
culated the configurational entropy for each system (Table 1 an
Eq. 1) by examining the distribution of configurations along all
three collective variables (i.e., L12-G2 loop rmsd, α3 rmsd, and
hydrophobic core size). The energetic cost for binding either
MLL or c-Myb to KIX-free was –TΔΔS = 0.6 kcal/mol higher
than when binding to its complementary binary complex (Table 1,
Fig. 4, and Fig. S6). Thus, our analyses show that effector-
bound KIX lowers the entropic cost for binding the comple-
mentary peptide at the second site, and this is achieved by
stabilizing the KIX structure. The observed reduction in en-
tropy due to effector binding explains the decrease in koff and
the small increase in kon and this notion of “prepaying the
entropic cost” in allostery has been found to play a role in the
tryptophan RNA binding attenuation protein (TRAP) (63, 64)
and the catabolite activator protein (CAP) (5, 65, 66). Describing
allostery within a thermodynamic framework (3–6) allows us to
organize the information in a quantitative manner, and it enables
comparisons between entropically driven and/or enthalpically
driven allosteric mechanisms.
Previous NMR studies have shown that a minor excited state
of KIX, which is believed to be a higher affinity conformer for
c-Myb and pKID, becomes 7% populated when bound by MLL
and has been characterized by a rearrangement of the KIX hy-
drophobic core (29, 32). In a recent metadynamics-based MD
simulation study (31) of the MLL-KIX binary structure (29), it
was demonstrated that when the L12-G2 loop was in the “up”
state then this resulted in opening of the KIX hydrophobic core,
which was said to allow KIX to spontaneously interconvert be-
tween a major lower energy state and a minor higher energy
state. Essentially, the authors proffered that KIX mediates
cooperativity between transcription factors through conforma-
tional selection of a higher affinity conformer. This means that, if
conformational selection for a 7% binding-competent state were
at play, we should expect to see an observable population in-
crease of a minor state in our free-energy surfaces. However, we
find no evidence to support this. Instead, upon binding an ef-
fector, we observe a narrowing of the preexisting KIX ensemble
toward the highly populated minimum, which corresponds to
a ternary-like KIX structure (Fig. 4 and Fig. S6). We also point
out that, although the enhanced sampling MD simulations of the
MLL-KIX complex were informative, simulations of the binary
complex alone are insufficient to show, unequivocally, that the
observed changes in structural dynamics due to the presence of
an effector would have any direct effect on binding affinities of a
second transactivation domain. However, our simulations of the
free KIX, MLL-KIX, KIX-c-Myb, and MLL-KIX-c-Myb systems
provide a clear and systematic way to directly relate the mi-
croscopic allosteric effects and the macroscopic changes in the
binding affinity that result from MLL and/or c-Myb binding
to KIX.
In the accompanying paper, Shammas and coworkers (67)
have performed fluorescence stopped-flow measurements to
investigate the binding kinetics of peptides from five different
transcription factors that can all bind to KIX (c-Myb and pKID
bind at the c-Myb site, whereas MLL, HBZ, and E2A bind at
the MLL site). Consistent with a coupled folding-and-binding
mechanism, they found that the helicity for c-Myb (as well as all
of the other peptides) increased upon mixing with KIX, which is
consistent with our results. They also observed a positive allo-
steric effect and identified relative decreases in koff of 3.9 ± 0.1
and 4.1 ± 0.1 for c-Myb and MLL, respectively, that are similar
to those reported above. They also demonstrated that the re-
duction in the dissociation rate constant was generally true for
four different pairs of KIX binding partners, and, based upon
their data, they proposed a common allosteric mechanism where
the entropic cost of binding the second ligand is paid on binding
the first ligand rather than involving the formation of a binding-
competent low-populated conformer of KIX (29, 31, 32). Our
simulation results show good agreement with their kinetics
experiments and confirm the hypothesis that MLL binding to
KIX lowers the entropic cost for c-Myb binding, and vice versa,
by stabilizing the L12-G2 loop and α3 helix. However, they found
a relative decrease, rather than a small relative increase, in kon of
2.9 ± 0.1 and 2.8 ± 0.1 for c-Myb and MLL, respectively, and,
when the favorable long-range electrostatics was screened with
salt, only negligible differences in kon were observed. This can be
attributed to differences in temperature or in how a bound state
is detected in experiment versus computation. Overall, both
bodies of work are in good complementary agreement and
support an allosteric mechanism whereby the binding of an ef-
fector prepays the entropic cost for binding a complementary
peptide in the secondary site.
If a change in the structural stability (or dynamics) is what
drives the allosteric mechanism, one could explore alternative
ways to modulate the stability of KIX to affect binding affinity.
It was previously proposed that stabilizing the C terminus of
α3 through MLL binding would result in favorable side-chain
electrostatic interactions between residues Glu665 and Glu666
of α3 and Arg294 and Lys291 of c-Myb, (28). Not surprisingly,
these electrostatically complementary residues are essentially
conserved in all known c-Myb and CBP/p300 sequences (28).
Table S1 reports the top six point mutant candidates that were
predicted from AGADIR (68–72) to increase the helical pro-
pensity of the α3 helix and therefore can potentially affect co-
operative binding (SI Text). Out of all of the C-terminal residues
located in the α3 helix that make no intermolecular native con-
tacts with either c-Myb or MLL, only six point mutations at ei-
ther Lys667 or Ser670 caused a significant increase in the
predicted helicity of α3 (∼3.5–12.7%) relative to the wild-type
sequence. Thus, we predict that, even in the absence of MLL,
one or more of these strategically selected point mutations could
mimic the effects of MLL binding to KIX and result in an in-
creased c-Myb binding affinity. These predictions can be verified
experimentally and could inform the design of small molecules
that could stabilize KIX and allow for further structural
Fig. 4. Representative 2D free-energy surfaces as a function of the hydro-
phobic core size and the L12-G2 loop rmsd. All rmsd values were calculated
relative to the NMR structure, which had a hydrophobic core size of ∼3.6 Å.
All ΔS were calculated with respect to KIX-free at 300 K (Methods and
Table 1).
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Figure 5.7: Representative 2D free-energy surfaces as a function of the hydro- phobic 
core size and the L12-G2 loop RMSD. All RMSD values were calculated relative to 
the NMR structure, which had a hydrophobic core size of 3.6 Å. All ΔS were 
calculated with respect to KIX-free at 300 K.  
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lowest free energy minimum has a hydrophobic core that is open by ~3.5-4 Å but the 
loop RMSD within each minimum is restricted to ~4-7 Å when MLL is present, and 
expands to a wider range (~4-10 Å) when MLL is absent. Additional free energy profiles 
calculated with respect to the α3 helix RMSD, which is believed to contribute to the 
allosteric binding of c-Myb, are reported in Figure S6 and show similar results to Figure 
4. Overall, all of the free energy surfaces show a reduction in the conformational space 
being sampled when one or both peptides are bound to KIX (i.e. the colored area became 
smaller upon binding MLL and/or c-Myb and narrowed towards a ternary-like KIX).  
! 105!
 
 
 
 
 
Figure 5.8:  2-D free energy surfaces as a function of the α3 RMSD and (A-D) the 
hydrophobic core size or (E-H) the L12-G2 loop RMSD. All RMSDs were calculated 
relative to the NMR structure, which had a hydrophobic core size of ~3.6 Å. All ΔS 
were calculated with respect to KIX-free at 300 K. 
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5.3 Discussion 
It has been hypothesized that protein intrinsic disorder offers numerous benefits 
such as fast protein turnover 48, high specificity for a diverse set of targets 48-52, and high 
specificity with low affinity binding 49,50. In addition, it has been predicted that allosteric 
coupling between independent sites is maximized in the presence of intrinsic disorder 53. 
In IDP systems, like those in the present study, there is an intricate relationship between 
binding and folding.36-39,54-60 We observed that both c-Myb and MLL first bind to KIX 
before forming a folded peptide and the free energy surfaces between binary and ternary 
KIX complexes were virtually indistinguishable for both MLL and c-Myb (Figure 2 and 
Figure 3). Additionally, MLL and c-Myb, 
which were tuned to have a peak helicity of 
~5% and ~25%, respectively, to match 
experiment (Figure 9), achieved over 80% 
helicity upon binding to KIX. This binding-
induced-folding mechanism is consistent 
with kinetic experiments of KIX-c-Myb (i.e. 
rapid mixing of KIX with c-Myb) 55,61,62 and 
our results suggest that effector binding 
allosterically regulates peptide binding at the second site without altering the binding 
mechanism.  
 We explored this further by examining the intermolecular contact appearance 
order for KIX and c-Myb to see whether MLL binding alters the sequence in which 
contacts between c-Myb and KIX are formed with a low probability of breaking. Figure 
Figure 5.9: Helicity of the α3 helix. 
The RMSD is calculated with respect 
to the fully helical α3 in the NMR 
structure and RMSDs > ~5 Å 
correspond to a significant loss of 
secondary structure. 
! 107!
4A shows that Leu302, which is positioned in the middle of the helix and inserts its side 
chain deep into the hydrophobic core in the native NMR structure 28, is first to form most 
of its interactions with the α1 and α3 helices of KIX. According to Figure 2, c-Myb is 
mostly unstructured at this stage, with only ~20-40% helicity. Then, binding proceeds 
outward towards both termini of c-Myb and is concomitant with c-Myb folding (Figure 
4A). The N-terminus of c-Myb, which interacts exclusively with the C-terminus of the α3 
helix, has a slightly higher probability than the C-terminus for forming last, which may 
imply a potential role for α3 in regulating c-Myb binding. These results were similar for 
c-Myb binding to the binary complex (Figure 4B) and demonstrate that MLL binding 
does not have a significant impact on the order in which c-Myb residues contact KIX.  
Previous studies have observed changes in the KIX structure resulting from 
transcription factor binding and both MLL and c-Myb have been shown to allosterically 
affect the affinity of KIX for the complementary peptide.4,19,28-32 However, a connection 
between the changes in structural dynamics in KIX and how this directly leads to shifts in 
transcription factor binding affinities remain tenuous. To bridge this gap, we employed a 
coarse-grained simulation model that is capable of capturing both the microscopic 
structural changes and macroscopic ligand binding events. Consistent with cooperative 
binding, we found that the binding affinity for c-Myb is increased by an order of 
magnitude in the presence of MLL while the affinity for MLL is also increased by a 
factor of 8 when c-Myb is present (Table 1). These observations are in agreement with 
experiment, albeit with a ~5-fold difference in both cases 12, but given the simplicity of 
our simulation model, it is remarkable that we are able to capture the same allosteric 
trends as seen in experiment. We also observed relative decreases in koff (~4.4 fold and 
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~3.3 fold for c-Myb and MLL, respectively) and small increases in kon (~2.4 fold and 
~1.9 fold for c-Myb and MLL, respectively) when an effector was bound first (Table 1). 
These changes in kinetics combined with our observations of an effector-independent 
binding-induced-folding mechanism suggest that pre-binding of the first peptide likely 
stabilizes the flexible/unfolded parts of the KIX structure so that the second peptide can 
(i) form a native intermolecular contact more quickly (i.e. small increase in kon) and (ii) 
stay bound for much longer (i.e. decrease koff). 
To further understand the allosteric mechanism, we investigated how MLL and/or 
c-Myb binding can affect the dynamics of KIX (Figure 3, Figure 4, and Figure 8). Overall, 
we found that binding of MLL and/or c-Myb resulted in an increase in stability (or a 
reduction in dynamics) of the α3 C-terminus and the L12-G2 loop. This is consistent with 
observations made in previous NMR and computational studies, which have led to the 
suggestion that the increased structural stability of KIX may play a role in allosteric 
signaling.4,19,28-32 For example, NMR backbone order parameter measurements of KIX 
have demonstrated that the L12-G2 loop and the C-terminal residues of the α3 helix are 
more rigid when MLL is bound to KIX.29 Thus, our findings are not only supported by 
experiment but they also provide a direct causative link between changes in the local 
structural dynamics and its effects on the global binding affinities. From the observations 
made in Figure 4 and Figure 8, we calculated the configurational entropy for each system 
(Table 1 and Eq. Error! Reference source not found.) by examining the distribution of 
configurations along all three collective variables (i.e. L12-G2 loop RMSD, α3 RMSD, and 
hydrophobic core size). The energetic cost for binding either MLL or c-Myb to KIX-free 
was –TΔΔS = 0.6 kcal/mol higher than when binding to its complementary binary 
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complex (Table 1, Figure 4, and Figure 8). Thus, our analyses show that effector-bound 
KIX lowers the entropic cost for binding the complementary peptide at the second site 
and this is achieved by stabilizing the KIX structure. The observed reduction in entropy 
due to effector binding explains the decrease in koff and the small increase in kon and this 
notion of “prepaying the entropic cost” in allostery has been found to play a role in the 
tryptophan RNA binding attenuation protein (TRAP) 63,64 and the catabolite activator 
protein (CAP).5,65,66 Describing allostery within a thermodynamic framework 3-6 allows 
us to organize the information in a quantitative manner and it enables comparisons 
between entropically-driven and/or enthalpically-driven allosteric mechanisms. 
Previous NMR studies have shown that a minor excited state of KIX, which is 
believed to be a higher affinity conformer for c-Myb and pKID, becomes 7% populated 
when bound by MLL and has been characterized by a rearrangement of the KIX 
hydrophobic core.29,32 In a recent metadynamics-based MD simulation study 31 of the 
MLL-KIX binary structure 29, it was demonstrated that when the L12-G2 loop was in the 
“up” state then this resulted in opening of the KIX hydrophobic core which was said to 
allow KIX to spontaneously interconvert between a major lower energy state and a minor 
higher energy state. Essentially, the authors proffered that KIX mediates cooperativity 
between transcription factors through conformational selection of a higher affinity 
conformer. This means that if conformational selection for a 7% binding-competent state 
were at play we should expect to see an observable population increase of a minor state in 
our free energy surfaces. However, we find no evidence to support this. Instead, upon 
binding an effector, we observe a narrowing of the pre-existing KIX ensemble towards 
the highly populated minimum, which corresponds to a ternary-like KIX structure (Figure 
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4 and Figure 8). We also point out that while the enhanced sampling MD simulations of 
the MLL-KIX complex were informative, simulations of the binary complex alone are 
insufficient to show, unequivocally, that the observed changes in structural dynamics due 
to the presence of an effector would have any direct effect on binding affinities of a 
second transactivation domain. On the other hand, our simulations of the free KIX, MLL-
KIX, KIX-c-Myb, and MLL-KIX-c-Myb systems provide a clear and systematic way to 
directly relate the microscopic allosteric effects and the macroscopic changes in the 
binding affinity that result from MLL and/or c-Myb binding to KIX. 
In the accompanying paper, Shammas and coworkers have performed 
fluorescence stopped-flow measurements to investigate the binding kinetics of peptides 
from five different transcription factors that can all bind to KIX (c-Myb and pKID bind at 
the c-Myb site while MLL, HBZ, and E2A bind at the MLL site). Consistent with a 
coupled folding-and-binding mechanism, they found that the helicity for c-Myb (as well 
as all of the other peptides) increased upon mixing with KIX, which is consistent with our 
results. They also observed a positive allosteric effect and identified relative decreases in 
koff of 3.9 ± 0.1 and 4.1 ± 0.1 for c-Myb and MLL, respectively, that are similar to those 
reported above. They also demonstrated that the reduction in the dissociation rate 
constant was generally true for four different pairs of KIX binding partners and, based 
upon their data, they proposed a common allosteric mechanism where the entropic cost of 
binding the second ligand is paid on binding the first ligand rather than involving the 
formation of a binding-competent low-populated conformer of KIX.29,31,32 Our simulation 
results show good agreement with their kinetics experiments and confirm the hypothesis 
that MLL binding to KIX lowers the entropic cost for c-Myb binding, and vice versa, by 
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stabilizing the L12-G2 loop and α3 helix. However, they found a relative decrease, rather 
than a small relative increase, in kon of 2.9 ± 0.1 and 2.8 ± 0.1 for c-Myb and MLL, 
respectively, and, when the favorable long-range electrostatics was screened with salt, 
only negligible differences in kon were observed. This can be attributed to differences in 
temperature or in how a bound state is detected in experiment versus computation. 
Overall, both bodies of work are in good complementary agreement and support an 
allosteric mechanism whereby the binding of an effector pre-pays the entropic cost for 
binding a complementary peptide in the secondary site. 
If a change in the structural stability (or dynamics) is what drives the allosteric 
mechanism, one could explore alternative ways to modulate the stability of KIX in order 
to affect binding affinity.  It was previously proposed that stabilizing the C-terminus of α3 
through MLL binding would result in favorable side chain electrostatic interactions 
between residues Glu665 and Glu666 of α3 and Arg294 and Lys291 of c-Myb.28 Not 
surprisingly, these electrostatically complementary residues are essentially conserved in 
all known c-Myb and CBP/p300 sequences.28 Table 2 reports the top six point mutant 
candidates that were predicted from AGADIR 67-71 to increase the helical propensity of 
the α3 helix and therefore can potentially affect cooperative binding. Out of all the C-
terminal residues located in the α3 helix which make no intermolecular native contacts 
with either c-Myb or MLL, only six point mutations at either Lys667 or Ser670 caused a 
significant increase in the predicted helicity of α3 (ca. 3.5-12.7%) relative to the wild type 
sequence. Thus, we predict that, even in the absence of MLL, one or more of these 
strategically selected point mutations could mimic the effects of MLL binding to KIX 
and result in an increased c-Myb binding affinity. These predictions can be verified 
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experimentally and could inform the design of small molecules that could stabilize KIX 
and allow for further structural characterization. For instance, Mapp and coworkers 
recently solved the first crystal structure of KIX complexed to a small molecule referred 
to as fragment 1-10.19 It was found that the L12-G2 loop had large temperature factors (or 
B factors), the C-terminal residues of the helix α3 were unresolved, and the size of the 
hydrophobic core was reduced in comparison to the NMR ternary structure. This suggests 
that the entropy of KIX would not be reduced upon binding fragment 1-10 and, in light of 
the observations made in the current study, we would predict that this would not lead to 
an increase in affinity of KIX for c-Myb. This strategy of complementing experiment 
with computation can be applied generally to other conformationally dynamic proteins 
and potentially lead to a faster discovery of effective small molecule modulators. 
In conclusion, we have carried out a set of simulations of KIX-free, MLL-KIX, 
KIX-c-Myb, and MLL-KIX-c-Myb in order to better understand how cooperative binding 
is regulated in this particular transcriptional activation system. Remarkably, our 
simplified model was able to capture relevant changes in thermodynamics, binding 
kinetics, and structural dynamics, all of which were in good agreement with experiment. 
Specifically, we discovered that the intermolecular native contact formation between c-
Myb and KIX is unaffected by MLL binding, and vice versa, and that the folding-and-
binding mechanism is well preserved. Furthermore, our results confirm that KIX 
occupation by a single transactivation domain was found to stabilize the L12-G2 loop and 
increase the helicity of the α3 helix. This lowered the entropic cost for binding a 
complementary peptide at the allosteric site and was accompanied a narrowing of the pre-
existing KIX ensemble towards a ternary-like KIX conformation. We also proposed that 
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a well-chosen mutation(s) or small molecule(s) targeted towards stabilizing the α3 helix 
and/or the L12-G2 loop would be effective in controlling cooperative binding. As a whole, 
our study directly links the effects of the microscopic changes in structural dynamics to 
the macroscopic binding affinities and provides a thermodynamic description of the 
allosteric mechanism involved in KIX cooperative binding. 
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5.4 Methods 
Simulation model and set up 
An initial Cα-based Gō-like model constructed from the NMR coordinates of the 
MLL-KIX-c-Myb ternary complex (PDBID: 2AGH) 28 was generated using the 
Multiscale Modeling Tools for Structural Biology (MMTSB) Gō-Model Builder 
(http://www.mmtsb.org) 72. MLL (19 residues ranging from 839-857), KIX (87 residues 
ranging 586-672), and c-Myb (25 residues ranging from 291-315) contained 22, 198, and 
40 intramolecular native contacts, respectively, while the total number of intermolecular 
native contacts between MLL-KIX and KIX-c-Myb were 28 and 29, respectively. 
Structural models of the individual monomers and binary complexes were derived 
directly from the ternary complex model. The coarse-grained Gō-like model was then 
calibrated to match the helical content and binary dissociation constants reported in 
previous experiments (Figure 10). Each of the four simulation models (i.e. free KIX, 
MLL-KIX, KIX-c-Myb, and MLL-KIX-c-Myb) was simulated for 15 µs using 
CHARMM 73,74 and repeated 60 times in order to sample multiple c-Myb/MLL binding 
events in the presence and absence of MLL.  
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Analysis 
2-D free energy surfaces were computed at 300 K by constructing 2-D histograms 
along two reaction coordinates of interest. Qintra and Qinter corresponding to the fraction of 
native intra- and intermolecular contacts, respectively. The root-mean-square deviation 
(RMSD) of the L12-G2 loop (residues 614-621) was calculated after fitting parts of helices 
α1, α2, and α3 (residues 600-613, 622-662) of KIX from each simulation snapshot to the 
native NMR structure 31. Similarly, the RMSD of helix α3 (residues 646-669) was 
calculated by pre-fitting the rigid N-terminal portion of helix α3 (residues 646-657) to the 
native NMR structure. The size of the hydrophobic core (residues 607-612, 650-661) 29, 
Figure 5.10:  Calibration of (A-B) the helical content (α increases from left-to-
right)and (C-D) the binding affinities (Kd). The final simulated scaling factors are 
indicated by red arrows and the target ranges are shown as blue bars (c-Myb: ~25-30% 
helicity; MLL: ~1-5% helicity; KIX-c-Myb: Kd = 10 ± 2 µM; MLL-KIX: Kd = 2.8 ± 
0.4 µM). 
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whose shape can be approximated by an ellipsoid 31, was calculated from the square root 
of the second eigenvalue of the gyration tensor 75. 
 We estimated the configurational entropy, S, using:  
S = −kB p L,A,H( ) ln p L,A,H( )
L,A,H
∑        (1) 
where kB is the Boltzmann constant and p(L,A,H) is the probability of occupying a 
particular state along the three collective variables L, A, and H (corresponding to the L12-
G2 loop RMSD, helix α3 RMSD, and KIX hydrophobic core size, respectively) in a given 
simulation. All ΔS were calculated with respect to free KIX at 300 K. 
Principal component analysis (PCA) was carried out to study the dynamics of 
KIX for each system. Each simulation snapshot was superimposed onto the three helices 
of KIX (residues 600-613, 622-662) in the native NMR structure and the eigenvalues and 
eigenvectors were obtained by diagonalizing the covariance matrix constructed from the 
fluctuations of residues 600-669. 
 
Simulation model and details 
To study the allosteric binding involved in the MLL-KIX-c-Myb ternary complex, 
we used the sequence-flavored Gō-like model developed by Karanicolas and Brooks.34,35 
In this model, each protein residue is represented as a single bead with a mass equal to its 
corresponding amino acid, centered at its Cα atom, and connected to neighboring 
residues along the protein backbone via virtual bonds. The potential energy function, V, 
consists of both bonded and non-bonded terms: 
V =Vbond +Vangle +Vdihedral +Vnon−bondednon−native +Vnon−bondednative   (2) 
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where Vbond and Vangle are harmonic potentials with equilibrium values set to those found 
in the NMR structure.28 Vdihedral is a statistical potential based on probability distributions 
obtained from Ramachandran plots for each of the 20 x 20 amino acid pairs and, thus, 
provides additional sequence-specific information while remaining independent of the 
protein topology and avoiding locally driven folding that results from directly 
incorporating native dihedral angles into Vdihedral. Native non-bonded terms mediating the 
interaction between residue pairs, i and j, are modeled using a 12-10-6 Lennard-Jones-
type potential whose interaction strength is proportional to the statistical potential 
reported for the residue types of i and j by Miyazawa and Jernigan.76 All non-native 
interactions, defined by residue pairs with all side chain heavy-atoms separated by more 
than 4.5 Å and that do not form backbone hydrogen bonds, were subject to repulsive 
interactions. We can also separate Vnon−bondednative  into its intra- and intermolecular 
components: 
Vnon−bondednative =αVintramolecuarnative + βVintermolecularnative  (3) 
 
where α and β are scaling factors used for renormalizing the intra- and intermolecular 
interaction energies, respectively (see below).  
The cumulative production simulation time for each simulation model is 900 µs 
(i.e., each set consists of 60 independent x 15 µs-long simulations) and with at least 70 c-
Myb binding events and 150 MLL binding events being observed in total. With the 
exception of KIX-free, which was simulated in a 60 Å per edge cubic volume, each 
system was simulated with a 120 Å per edge cubic volume using a periodic volume to 
account for the finite concentration of species in the simulation, e.g., MLL + KIX, etc. 
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All simulations were performed at 300 K using Langevin dynamics with a 0.1 ps-1 
friction coefficient along with a 15 fs simulation time step. The cutoff for non-bonded 
interactions was set to 25 Å and virtual bonds were constrained using SHAKE.77 
 
Calibrating the Gō-like model 
In accordance with the calibration protocol described in ref. 37, the intramolecular 
interaction energies of c-Myb and MLL were rescaled by systematically altering α in Eq. 
(3) above so as to match the experimentally reported helical content. The intermolecular 
interaction energies between KIX-c-Myb and MLL-KIX were also recalibrated by tuning 
β so as to match the experimentally reported binary dissociation constants. The 
intramolecular interaction energies for KIX were unaltered (i.e. αKIX = 1.0). All 
simulations of the MLL-KIX-c-Myb ternary complex use only the tuned α and β 
parameters from the monomer and binary systems, respectively. No further adjustments 
are made. 1.5 µs-long simulations were initially used to calibrate α. The percent helicity, 
measured as the fraction of the native intramolecular contacts formed, was found to be 
identical even with ten times more sampling. Simulations for calibrating β (eventually 
used in the production simulations) were 15 µs in length and repeated 30 times in order to 
provide an accurate estimate of the experimentally reported dissociation constants. 
 When the native Gō-like model was used (α = 1.0), the fraction of helical content 
was ~70% and ~80% for c-Myb and MLL, respectively.78-80 Therefore, the 
intramolecular interaction energies were reduced by rescaling α in order to match the 
helical content reported in the literature (~25-30% for c-Myb) 62,78,80 and as predicted 
empirically by AGADIR (~1-5% for MLL).67-70 In order to achieve this, the final 
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intramolecular interaction energies were scaled down to αc-Myb = 0.45 and αMLL = 0.05 for 
c-Myb and MLL, respectively. In contrast, the intermolecular interaction energies for the 
KIX-c-Myb and MLL-KIX binary complexes were increased to βKIX-c-Myb = 1.2 and βMLL-
KIX = 1.55, respectively, to match the reported binary dissociation constants.12  
 While all of the intramolecular and intermolecular native contacts were derived 
from the NMR ternary complex, it is important to reiterate that our recalibration process 
only targets experimental observables from the monomeric and binary systems. In other 
words, no additional tuning was made to influence cooperative binding (αc-Myb = 0.45 and 
αMLL = 0.05 were used when scaling  but none of the scaling parameters were tuned to 
match the ternary dissociation constants). Thus, one would not expect changes in the 
binding affinities for the ternary complex unless allostery was at play and could be 
adequately captured by our coarse-grained model. Additionally, unlike traditional all-
atom simulations where only a single binding/unbinding event is often observed, we 
recorded multiple binding/unbinding events from long, continuous trajectories and so any 
biases caused by the starting structure are minimized as a result of increased statistics. 
 
Fraction of bound and unbound states 
If the Cα-Cα distance between any given native interaction (or, equivalently, 
native contact) was within 1 Å of its native contact distance (found in the NMR structure), 
then the native contact was considered formed. We defined a bound state as having at 
least one native intermolecular contact being formed or a configuration that had last 
visited a bound state (without first visiting an unbound state) and with at least one native 
intermolecular contact within 25 Å (corresponding to the cutoff distance for non-bonded 
β
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interactions). This helps to remove any bias in rebinding coming from long-range 
interactions and ensures that binding events are uncorrelated. Conversely, an unbound 
state was defined as having all native intermolecular contact distances greater than 25 Å 
or a configuration that had last visited an unbound state and had no native intermolecular 
contacts. Together, these definitions provide a clear delineation between the bound and 
unbound states. 
The dissociation constants, , were calculated from: 
 (4) 
 
where V0 is the box volume in units of Å3, 1660 converts the concentration from units of 
molecules/Å3 to units of mol/L, and Punbound is the fraction of unbound states. 
 
Contact appearance order 
To assess whether or not the binding of one peptide changes the order in which 
the native intermolecular contacts are formed between a second peptide and KIX, we 
adopted the contact appearance order metric originally developed to study protein folding 
81. Here, we record the order in which each native intermolecular contact is formed 
during N independent c-Myb or MLL binding events. Then, we calculate the probability 
of each native intermolecular contact being formed at a given order in time. 
 
 
 
 
Kd
Kd =
1660
V0
⋅ Punbound
2
1− Punbound
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Kinetic rates 
By treating the ligand binding process as a simple two-state process with either 
bound or unbound states, we estimated the kinetic rate constants, koff and kon, by 
calculating the mean first passage time (MFPT) for the off and on reactions: 
;
      
 
(5) 
 
where koff has units of s-1 and kon is dependent on the concentration (or fraction of 
unbound states) and so has units of M-1s-1. 
 
Principal component analysis 
The overall translational and rotational motion was removed by fitting each 
simulation snapshot to the average KIX structure. Then, a symmetric covariance matrix, 
C, of the positional deviations was constructed: 
C = r t( )− r( ) r t( )− r( )T  (6) 
 
where < > denotes an ensemble average and r(t) is a 3N-dimensional vector of x, y, and z 
coordinates for all N atoms at some simulation time, . C can then be diagonalized by an 
orthogonal coordinate transformation to obtain the mean square fluctuations 
(eigenvalues) along each principal component/mode (eigenvectors) of the system. When 
the eigenvectors are sorted by their corresponding eigenvalues in decreasing order, the 
total fluctuations of the system can often be described by the first few lowest frequency 
modes. 
koff =
1
MFPToff
kon =
1
MFPTon ⋅
1660
V0
⋅Punbound
⎛
⎝⎜
⎞
⎠⎟
t
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In silico mutations 
Six C-terminal residues (Glu663, Glu666, Lys667, Ser670, Arg671, and Leu672) 
of the α3 helix, which make no intermolecular native contacts with either c-Myb or MLL, 
were chosen for mutational studies to increase the helicity in this region. The KIX 
sequence was mutated (to either Ala, Leu, Arg, Met, Lys, Asn, Glu, Ile, Trp, or Ser) at 
each of the six target positions and the increase in the percent helicity was predicted 
using AGADIR 67-70 (see Table 2). 
 
 
 
 
 
 
 
 
 
 
 0
 1
 2
 3
 4
 5
 6
 7
 0
 1
 2
 3
 4
 5
 6
 7
 0
 1
 2
 3
 4
 5
 6
 7
α3 RMSD (Å)
H
yd
ro
ph
ob
ic 
Co
re
 S
ize
 (Å
)
 0
 1
 2
 3
 4
 5
 6
 7 KIX-free
KIX-c-Myb
MLL-KIX
MLL-KIX-c-Myb
0 5 10 15 20 25
-8
-7
-6
-5
-4
-3
-2
-1
0
kcal/mol
B
C
D
A
0 5 10 15 20 25
L 1
2-
G
2 
Lo
op
 R
M
SD
 (Å
)
F
G
H
eerf-XIKE
KIX-c-Myb
MLL-KIX
MLL-KIX-c-Myb
 0
 5
 10
 15
 20
 25
 0
 5
 10
 15
 20
 25
 30
 0
 5
 10
 15
 20
 25
 0
 5
 10
 15
 20
 25
α3 RMSD (Å)
 = 0.8 kcal/mol
 = 1.2 kcal/mol
 = 1.4 kcal/mol
 = 0.0 kcal/mol
 = 0.8 kcal/mol
 = 1.2 kcal/mol
 = 1.4 kcal/mol
 = 0.0 kcal/mol
Fig. S6. Two-dimensional free-energy surfaces as a function of the α3 rmsd and (A–D) the hydrophobic core size or (E–H) the L12-G2 loop rmsd. All rmsd values
were calculated relative to the NMR structure, w ich had a hydroph bic core size of ∼3.6 Å. All ΔS were calculated with r spect to KIX-free at 300 K (Methods
in the main text).
Table S1. KIX point mutations predicted to increase the helicity
of α3
Point mutation Percent helicity increase*
K667L 4.4 (1.5)
K667R 9.2 (3.1)
S670L 3.5 (1.2)
S670R 9.5 (3.2)
S670K 7.5 (2.5)
S670N 12.7 (4.2)
*Calculated from α3 (residues 646–672) and, in parentheses, from the full
length of KIX (residues 586–672).
Law et al. www.pnas.org/cgi/content/short/1405831111 6 of 6
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Chapter 6 
Conclusions and future outlook 
 
6.1 Summary of chapters  
Previously, structure-based docking approximated the receptor as a rigid entity.1,2 
This is a reasonable approximation for receptors that follow a lock and key mechanism of 
binding their ligands. However, as more biophysical and structural data has become 
available the importance of flexibility has become extremely apparent.2-5 This importance 
of flexibility was really highlighted in Chapter 4 and 5, when considering receptors that 
are highly dynamic and promiscuous like the GACKIX domain of CBP.6-8 
Targeting protein-protein interactions with small molecules is important from 
both a biochemical and drug design point of view. Being able to selectively inhibit a 
protein-protein interaction would be invaluable for biochemical assays towards 
understanding of intricate cellular regulatory processes, such as transcription regulation 
as described in Chapters 4 and 5. Also, from a drug discovery standpoint, having more 
tools is important for targeting these challenging receptors involved in protein-protein 
interactions, as they are integral in so many cellular processes.  
Towards providing such tools we developed a flexible receptor docking 
methodology within the CHARMM simulation package. The docking tool was 
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implemented as an MMTSB style script to interface user input with CHARMM as 
outlined in Chapter 2.9,10 This method uses the grid based docking methodology as 
previously outlined by Wu et al, and achieved receptor flexibility by incorporating 
explicit side-chains from the receptor.11-14 While the backbone atoms are held fixed the 
rest of the residue samples conformational space simultaneously as the small molecule 
ligand. Addionally, we implemented a new sampling method within CDOCKER that 
includes advanced sampling techinque of self-guided Langevin dyanmics (SGLD).15,16 
This should account for local rearrangement of side-chain rotamers as frequently seen 
across receptor structures when bound to different ligands.17-20 However, this method of 
incorporating receptor flexibility cannot account for large-scale structural changes that 
may occur upon ligand binding, and these would have to address in some other 
manner.3,21,22  
The new flexible receptor CDOCKER outperforms its rigid counterpart in both 
redocking and cross docking trials. This was exciting, as by adding receptor degrees of 
freedom could have reduced the docking accuracy in redocking trials, since the receptor 
is in the experimental conformation that it would be bound to the ligand. Furthermore, 
Flexible CDOCKER is competitive with other commonly used docking methodology, 
Autodock and Glide, in redocking trials.23,24  
As an application for the CDOCKER methodology I worked on several 
collaboration projects. One project I worked on with the Raghavan research group at the 
University of Michigan where we identified a putative ATP binding site on calreticulin 
(CRT). CRT is a chaperone protein that is involved in MHC Class I assembly, which is 
responsible for displaying peptide fragments on the cell surface as part of the immune 
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response.25-29 We used a consensus docking approach to predict a binding site for ATP on 
the surface of CRT (Chapter 3).30,31 These predictions were confirmed by experiment and 
showed for the first time that the chaperone CRT both binds and catalyzes ATP.  
As outlined in Chapter 4, we further developed Flexible CDOCKER to include a 
tethering technique that is used in experiment to screen a large library of small-molecule 
fragments.8,32,33 We modified Flexible CDOCKER to include a physical disulfide bond in 
an automated fashion between the small-molecule fragments and cysteine on a receptor. 
Using this Flexible CDOCKER methodology we were able to identify a docked 
conformation of a small molecule fragment (Frag 1-10) that was very similar to the 
crystallographic conformer in a cross docking trial that included a large rotameric shift of 
a tyrosine residue. Encouraged by these results we docked a larger fragment (Frag 2-64) 
that was identified by experiment but were unable to achieve crystals of high enough 
quality to use for structure determination. In the docking trials, Frag 2-64 proved to be 
too large to interact with GACKIX in the same manner as Frag 1-10 had in the 
experimental structure. Frag 2-64 was predicted to interact in a way that could disrupt 
key crystal-contacts, suggesting a hypothesis for the lack of high quality crystals of this 
complex.  
In Chapter 5, I moved away from docking, but not from protein-protein 
interaction systems.6 Using Gō-like models, we were able to capture an allosteric signal 
of a ternary complex using simulations parameterized using binary systems.34,35 We were 
able to recapitulate both KD and kinetic rate constants for two peptides, MLL and c-Myb, 
binding to GACKIX. We were able to show the binding and folding mechanisms of the 
two peptides that were expected based on previous experimental results, and these 
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mechanisms were unchanged with the allosteric signal.36 Most interestingly, we showed 
that the allostery arises from a slowing of the koff, which was consistent with work done 
by the Clarke research group published in parallel with our own.37 This slowing was due 
to a shrinking of the conformational ensemble after the first peptide binds. This suggests 
an allosteric signal that is being driven by entropy, the first peptide essentially paying the 
entropic cost for the second.  
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6.2 Future outlook 
This series of successful studies are encouraging front runners for future studies, 
which I believe have excellent prospects of being a multi-scale approach. For example, 
Frag 1-10 binding to GACKIX shows interesting behavior that varies depending where 
on the protein it is tethered. This small-molecule inhibits a peptide binding at the pKID 
site when it is tethered to residue 664 (as seen in the crystallographic structure 4i9o.)8 
However, when Frag 1-10 is tethered to residue 627 there is a positive allosteric signal, 
leading to enhanced affinity for the peptide interacting at the pKID site.38 To investigate 
the origin of this allostery a multi-scale computational approach could be undertaken.  
Firstly, docking studies would have to be undertaken, as a structure for Frag 1-10 
bound to residue 627 has not been solved experimentally. The resulting docking trials and 
the Frag 1-10//GACKIX (L664C) experimental structure could be subjected to some sort 
of advanced sampling technique. One such approach could be WExplore, which has been 
developed by the Brooks Research group.39,40 This approach allows for rapid sampling of 
conformational space through tecillating the space as new conformations are sampled, 
pushing the trajectory away from the starting structure. 
This sampling would yield an ensemble of conformations that can give a variety 
of needed information for subsequent steps. This sampling could confirm that the ligand 
conformation identified by the docking trials is indeed the native-like low energy 
conformation. Additionally, these MD studies would identify key residues that interact 
with the small-molecules and their preferred distances to the small molecule. These 
residues and distances can be used to develop a Gō-like model potential for the Frag 1-
10/GACKIX complex. Simulations similar to those outlined in Chapter 5 could be 
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performed to investigate the origin of the allosteric signal. Does it stabilize the flexible 
loop when it binds at residue 627, as the MLL peptide did in the previous studies? 
Perhaps the advanced sampling will show a structural, or enthalpically driven origin for 
an allosteric signal. These interesting investigations would lay the groundwork for other 
multi-scale approaches for similar purposes and improve our understanding of different 
types of allostery.  
With the improvements of computer hardware and computational software, it is 
an exciting time to be a computational chemist. The ability to work hand-in-hand with 
experimental groups is rewarding and mutually beneficial. For example, in Chapter 3, the 
computational predictions were confirmed by experiment, and the resulting experiments 
fed back into the computational model. Together we were able to make progress in 
understanding the ATP dependence of CRT, a chaperone involved in the immune 
response. The advancements in the CHARMM docking methodology is a necessary step 
towards properly modeling receptors that do not follow the lock and key mechanism of 
binding, like GACKIX domain of CBP in Chapter 4 and 5. This dynamic receptor is just 
one example in the mountains of biophysical and structural data that demonstrate just 
how fluid bio-macromolecules can be. I am positive that the field will continue to 
develop so that it may continue to make important contributions, both towards 
understanding fundamental biological mechanisms and in structure-based drug design.    
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Appendix A 
The datasets that were the test sets for Flexible CDOCKER in Chapter 2. This includes, 
PDBIDs, lowest found RMSDs and the RMSD of the lowest scored ligand conformation.  
Table A.1: 
The PDBIDs and CDOCKER results for CCDC/Astex subset. Included are lowest RMSD 
conformation found and the RMSD for the lowest energy conformation for the two 
simulated annealing implementations and the MD+Minimization protocols.  
Rigid CDOCKER results 
 
SA- 1 Grid 
 
SA- 2 Grids 
 
MD+Minimization 
PDBID 
Lowest 
RMSD 
Lowest 
Energy 
Lowest 
RMSD 
Lowest 
Energy 
Lowest 
RMSD  
Lowest 
Energy 
1a28 0.2 0.3 0.4 0.4 0.2 0.2 
1a6w 1.8 2.2 1.5 2.9 1.8 2.1 
1abe 1.2 2.9 1.7 2.6 1.1 2.9 
1abf 0.9 3.2 2.2 3.4 1.2 3.2 
1acj 0.6 0.7 0.3 0.6 0.4 0.5 
1acl 2.3 4.2 2.3 5.5 2.5 2.7 
1acm 1.1 2.0 1.5 2.3 0.9 1.2 
1aco 0.9 3.7 1.7 2.9 0.8 1.4 
1aec 1.4 2.5 1.4 1.4 1.6 1.6 
1ai5 0.6 1.1 1.0 1.3 0.6 0.6 
1aoe 1.9 2.2 1.8 1.9 1.8 2.0 
1aqw 0.8 2.5 1.6 2.7 0.7 1.3 
1ase 1.6 3.1 1.7 2.9 1.1 3.1 
1azm 1.6 5.8 1.7 2.0 1.6 2.0 
1b59 0.4 5.3 0.5 6.9 0.5 5.6 
1b9v 1.8 2.1 1.9 2.5 1.7 2.0 
1baf 1.0 6.1 1.9 4.4 1.1 2.4 
1bbp 1.1 8.3 1.2 2.3 1.1 2.7 
1bgo 1.8 1.8 1.6 2.1 2.0 2.1 
1blh 1.8 1.8 1.4 2.5 1.7 1.8 
1bmq 1.6 2.3 1.6 2.0 1.9 1.9 
1byg 0.6 2.6 0.5 1.6 0.5 1.7 
1c12 1.6 2.3 1.8 2.5 1.7 2.3 
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1c1e 0.6 4.4 0.7 0.8 0.5 0.6 
1c5c 1.7 2.3 1.4 3.4 1.5 2.3 
1c5x 1.2 1.3 0.5 0.9 1.2 1.3 
1c83 0.6 0.6 1.0 1.0 0.6 0.9 
1cbs 0.9 1.1 0.8 1.1 1.0 1.1 
1cbx 0.7 1.1 0.9 1.3 0.6 1.1 
1cdg 1.8 4.0 1.8 2.9 2.0 2.9 
1ckp 0.6 2.9 0.6 2.9 0.6 2.9 
1cle 2.1 3.1 1.4 1.9 2.3 2.3 
1com 1.7 4.3 0.6 4.3 1.0 1.7 
1coy 0.8 0.9 0.7 1.2 0.8 0.9 
1cqp 1.1 1.1 1.0 2.0 1.1 1.2 
1cvu 1.1 1.7 1.2 2.3 1.1 2.3 
1cx2 1.5 1.8 1.5 1.8 1.5 1.7 
1d0l 1.2 1.4 1.2 1.8 1.2 3.0 
1d3h 1.5 7.3 0.9 1.1 1.4 7.3 
1d4p 1.1 1.6 1.3 2.2 1.1 8.5 
1dbb 1.8 5.3 1.4 5.2 1.3 4.6 
1dbj 0.7 0.8 0.6 0.7 0.7 0.8 
1dd7 3.0 3.9 3.1 6.0 1.1 4.6 
1dg5 1.5 5.8 1.5 6.0 1.5 2.5 
1did 1.2 5.5 1.9 2.6 1.2 5.4 
1dmp 3.4 3.4 3.5 4.9 3.5 3.9 
1dog 0.4 4.1 1.0 3.1 0.3 3.7 
1dr1 0.5 2.5 1.0 2.4 0.6 2.4 
1dwb 2.0 2.2 0.9 2.1 0.6 2.2 
1dwc 0.9 1.3 2.6 5.6 1.0 1.0 
1dwd 2.3 6.1 2.5 5.7 1.2 1.3 
1dy9 1.4 1.4 1.8 3.1 1.3 1.4 
1eap 2.2 4.3 2.3 3.6 2.3 3.8 
1ebg 0.6 3.0 0.9 2.6 0.6 3.0 
1ei1 0.6 0.6 1.9 1.9 0.6 0.6 
1ejn 1.8 5.5 1.7 4.1 1.6 5.7 
1eoc 1.5 1.7 1.3 2.5 1.5 1.5 
1epb 1.1 2.8 1.1 1.8 1.1 1.2 
1etr 0.9 0.9 0.9 0.9 1.0 1.0 
1ets 3.5 4.5 3.2 4.2 3.6 4.6 
1f0r 2.0 4.1 1.8 3.8 2.5 3.9 
1f0s 1.4 3.9 1.8 4.2 2.4 3.9 
1fen 0.6 0.8 0.6 0.6 0.5 0.6 
1fgi 0.6 5.7 0.5 0.6 0.7 1.1 
1fkg 1.4 2.3 1.0 1.8 1.0 2.0 
1fl3 0.6 1.2 0.7 0.7 0.7 0.8 
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1flr 2.3 4.5 2.3 4.5 2.3 4.5 
1frp 1.0 1.0 1.2 2.3 0.7 1.0 
1glp 0.9 0.9 1.0 3.0 1.6 1.8 
1glq 3.1 4.8 2.7 5.4 3.0 4.5 
1hak 1.9 4.0 1.5 7.8 1.8 4.3 
1hdc 0.8 1.2 0.8 1.2 0.8 0.9 
1hfc 2.3 3.8 2.2 3.5 1.9 3.4 
1hiv 1.2 1.7 1.8 1.9 1.9 3.1 
1hpv 1.0 1.2 1.1 1.4 1.0 1.1 
1hri 0.9 2.0 1.0 1.2 0.9 1.1 
1htf 1.8 1.9 1.5 7.4 1.7 3.5 
1hyt 2.4 3.2 2.4 2.9 2.5 2.8 
1ibg 0.7 0.8 0.6 1.5 0.7 0.7 
1imb 2.7 6.7 3.2 6.6 2.6 7.1 
1ivb 2.0 3.5 2.4 3.3 2.0 4.5 
1kel 1.1 1.4 1.4 1.8 1.2 1.4 
1lah 0.5 1.1 1.1 2.7 0.5 1.1 
1lcp 0.6 1.0 0.9 1.0 0.5 0.8 
1lic 1.3 3.9 1.4 2.2 1.5 2.7 
1lpm 0.9 4.8 0.5 0.5 0.6 0.6 
1lst 1.1 1.2 1.1 2.2 1.0 2.0 
1mcq 0.7 1.1 0.7 1.9 0.7 1.1 
1mdr 1.3 2.5 1.5 2.6 1.3 2.5 
1mld 1.3 1.5 1.6 2.6 1.4 1.5 
1mrg 1.2 4.8 1.0 3.4 1.2 4.8 
1mrk 1.4 1.7 1.4 1.5 1.4 1.5 
1mts 0.9 2.1 1.1 2.1 1.1 2.0 
1mup 1.2 1.4 1.1 4.3 1.1 1.3 
1nco 1.1 3.5 1.1 2.6 1.4 3.5 
1ngp 1.8 4.1 0.9 4.4 1.2 4.0 
1okl 1.7 2.4 1.0 3.0 1.3 2.0 
1pdz 1.7 2.2 1.7 4.4 1.4 2.2 
1phd 1.8 3.0 2.1 7.0 1.6 3.6 
1phg 2.1 4.9 1.3 6.4 1.9 4.9 
1poc 1.0 1.0 1.5 1.5 1.0 1.0 
1ppc 1.6 3.1 2.3 7.5 1.2 1.2 
1pph 4.9 6.2 4.4 6.1 4.9 5.6 
1ptv 4.3 7.3 3.9 7.2 4.3 8.6 
1qcf 1.3 1.4 0.8 0.8 1.3 1.4 
1qpe 1.7 2.2 0.7 0.7 1.4 1.5 
1qpq 0.7 3.0 1.1 2.4 0.7 3.0 
1rnt 0.6 0.6 0.8 1.1 0.5 0.5 
1rob 0.9 1.1 0.7 3.3 0.9 1.1 
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1rt2 0.6 0.6 0.6 0.7 0.5 0.6 
1slt 2.2 3.0 2.1 2.8 1.4 4.8 
1snc 1.2 5.3 2.6 5.3 0.7 1.4 
1srj 0.9 3.6 0.9 1.2 0.9 2.8 
1tdb 1.6 1.8 1.4 3.5 1.4 2.1 
1tmn 1.5 1.8 2.3 2.8 1.7 2.4 
1tng 0.4 0.4 4.4 4.4 0.3 0.4 
1tnh 1.4 1.5 1.4 1.5 1.4 1.6 
1tni 1.3 3.0 1.5 2.1 1.6 1.6 
1tpp 5.7 7.1 4.8 6.5 5.7 5.9 
1tyl 0.8 0.8 0.6 2.1 0.9 0.9 
1ukz 0.6 6.3 0.8 4.5 0.6 0.9 
1ulb 0.9 0.9 0.6 3.5 0.7 0.9 
1uvs 1.8 2.2 1.7 3.9 1.5 1.7 
1uvt 3.2 3.8 3.3 3.4 3.1 3.9 
1vgc 1.3 2.0 1.3 5.3 1.3 5.3 
1xid 1.3 2.1 1.2 2.6 1.2 1.8 
1xie 1.6 1.9 3.9 6.5 1.5 1.9 
1ydr 0.9 4.0 0.8 3.5 0.9 0.9 
1yee 0.9 1.0 1.1 3.2 0.9 1.1 
25c8 1.8 2.6 1.6 1.9 1.7 2.0 
2aad 0.8 0.9 0.5 1.0 0.8 0.8 
2ada 0.8 1.1 0.7 0.8 0.7 1.0 
2cht 1.1 3.9 1.3 4.1 1.0 3.4 
2cmd 1.1 1.5 1.6 3.4 1.2 1.8 
2cpp 0.3 2.7 1.5 2.8 0.3 2.6 
2ctc 2.1 2.5 2.1 2.7 1.1 1.6 
2fox 1.4 1.4 1.1 1.3 1.2 1.6 
2gbp 0.3 0.7 0.7 3.5 0.3 0.7 
2h4n 2.0 5.6 1.7 5.8 1.4 5.6 
2ifb 1.0 1.3 0.9 1.6 1.0 1.5 
2mcp 1.0 3.0 4.5 4.6 0.9 1.0 
2pk4 1.2 2.3 1.0 2.8 1.1 2.2 
2r07 0.7 0.7 0.7 0.7 0.7 0.7 
2yhx 0.8 2.8 1.6 5.4 1.0 1.4 
2ypi 1.1 1.5 1.1 1.3 0.7 1.4 
3ert 0.6 1.1 1.1 1.5 0.7 1.1 
3gpb 1.3 5.5 0.8 2.3 1.2 5.5 
3hvt 0.9 0.9 0.8 0.8 0.9 0.9 
4aah 0.7 1.0 1.2 5.9 0.6 5.8 
4cox 0.6 0.7 0.4 0.7 0.6 0.7 
4cts 1.8 2.1 1.7 2.1 1.3 2.2 
4dfr 2.9 4.7 1.7 5.6 2.3 3.8 
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4est 2.3 2.9 2.2 3.8 2.2 3.4 
4fbp 0.6 5.7 1.7 2.2 0.4 1.7 
4lbd 1.0 1.0 1.0 1.2 1.0 1.0 
4phv 3.2 4.8 2.9 5.4 3.2 5.0 
5abp 0.8 0.8 0.8 1.4 0.8 0.8 
5cpp 2.0 3.0 1.9 2.2 2.0 3.0 
6rnt 1.8 2.4 3.0 4.0 1.3 4.1 
6rsa 0.8 1.1 0.9 2.1 0.8 0.8 
7tim 0.9 1.6 1.3 1.8 0.8 1.6 
Averages 1.4 2.7 1.5 2.9 1.3 2.4 
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Flexible CDOCKER results 
 
SA- 1 Grid 
 
SA- 2 Grids 
 
MD+Minimization 
PDBID 
Lowest 
RMSD 
Lowest 
Energy 
Lowest 
RMSD 
Lowest 
Energy 
Lowest 
RMSD  
Lowest 
Energy 
1a28 0.2 0.2 0.2 0.3 0.2 0.3 
1a6w 1.8 3.0 1.8 2.8 1.7 2.2 
1abe 1.1 2.9 2.3 2.9 1.3 2.8 
1abf 0.8 3.0 3.3 10.6 1.1 3.0 
1acj 0.4 0.7 0.6 1.2 0.3 0.4 
1acl 2.1 4.3 2.1 4.2 2.1 3.3 
1acm 1.4 2.1 3.3 10.0 0.4 2.4 
1aco 0.4 2.9 6.2 7.2 0.6 1.1 
1aec 1.7 3.2 4.5 6.9 1.5 1.7 
1ai5 0.5 1.0 0.6 8.0 0.6 0.9 
1aoe 0.9 1.7 2.6 8.0 1.7 1.8 
1aqw 1.1 2.5 1.3 6.5 0.7 2.0 
1ase 2.4 4.9 3.1 4.7 1.4 2.7 
1azm 1.6 2.2 2.5 4.4 1.5 2.0 
1b59 0.4 2.7 2.9 4.0 0.4 2.2 
1b9v 1.8 1.9 2.6 8.5 1.6 1.9 
1baf 2.3 2.5 3.9 7.3 3.3 3.9 
1bbp 1.3 8.1 2.2 3.9 1.4 1.8 
1bgo 1.9 2.1 2.4 3.8 1.5 2.2 
1blh 1.9 1.9 3.8 4.8 1.8 2.0 
1bmq 2.0 2.3 5.0 5.0 1.6 1.9 
1byg 0.4 1.8 0.4 0.9 0.3 0.3 
1c12 1.5 2.3 1.3 2.8 1.3 2.3 
1c1e 0.3 0.3 0.4 0.4 0.3 0.4 
1c5c 1.6 4.7 2.6 5.2 1.4 3.9 
1c5x 0.9 0.9 0.9 0.9 0.9 0.9 
1c83 0.6 1.0 5.5 11.1 0.8 1.0 
1cbs 0.8 1.1 1.0 3.5 1.1 1.4 
1cbx 0.6 1.1 3.7 5.6 0.7 1.3 
1cdg 2.0 2.0 2.0 2.5 2.0 2.6 
1ckp 0.9 1.2 3.2 5.2 0.5 1.0 
1cle 3.6 5.1 4.2 4.7 3.0 3.1 
1com 1.6 3.9 4.8 8.3 0.9 1.9 
1coy 0.7 0.8 0.5 0.9 0.6 0.8 
1cqp 0.7 1.0 1.1 1.6 1.0 1.5 
1cvu 0.9 1.1 1.2 1.7 1.3 1.4 
1cx2 1.5 1.7 1.6 1.7 1.5 1.6 
1d0l 1.3 1.7 3.3 5.4 1.1 1.5 
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1d3h 1.5 1.9 1.3 7.6 1.5 1.9 
1d4p 1.0 1.3 1.9 7.9 1.0 1.4 
1dbb 0.7 4.4 3.0 5.0 0.8 3.5 
1dbj 0.4 0.8 0.9 1.3 0.4 0.5 
1dd7 2.3 5.1 3.8 6.3 1.8 4.0 
1dg5 1.4 2.9 2.5 4.6 0.7 0.9 
1did 1.0 5.7 4.9 7.7 1.0 5.7 
1dmp 3.5 5.0 3.4 4.5 3.5 4.2 
1dog 1.6 2.2 1.9 8.4 0.2 0.3 
1dr1 0.4 2.4 3.6 3.6 0.3 2.3 
1dwb 0.5 0.5 0.4 2.0 0.4 0.4 
1dwc 0.9 0.9 3.3 5.1 0.9 0.9 
1dwd 2.2 3.7 3.6 7.5 1.3 1.9 
1dy9 1.6 1.6 3.5 5.6 1.4 1.5 
1eap 2.0 4.1 2.5 3.7 2.3 4.1 
1ebg 0.5 2.0 8.7 9.9 0.4 1.6 
1ei1 0.4 0.5 8.2 9.7 0.5 0.5 
1ejn 1.5 7.0 1.2 4.7 1.7 3.9 
1eoc 2.0 4.5 5.4 7.2 1.8 2.4 
1epb 1.0 1.3 0.9 1.2 1.0 1.2 
1etr 0.7 0.7 6.1 6.8 0.8 0.9 
1ets 3.7 3.7 3.7 4.1 4.0 4.2 
1f0r 2.2 4.6 2.2 4.0 2.4 3.3 
1f0s 2.5 4.9 1.6 3.4 1.9 5.0 
1fen 0.6 0.7 0.5 0.6 0.6 0.7 
1fgi 0.4 0.6 2.9 4.7 0.5 0.5 
1fkg 1.5 1.6 1.7 2.4 1.3 1.3 
1fl3 0.5 1.0 0.8 1.4 0.8 1.2 
1flr 2.2 4.5 2.8 4.9 2.2 4.5 
1frp 0.4 1.1 5.8 9.8 0.4 0.5 
1glp 1.0 5.0 5.3 5.8 1.1 1.4 
1glq 2.5 6.7 5.1 6.8 2.0 2.1 
1hak 2.2 3.8 2.3 6.2 1.9 3.7 
1hdc 0.9 1.2 0.9 1.3 0.8 1.0 
1hfc 2.6 3.4 2.4 4.7 2.2 2.4 
1hiv 2.2 3.5 1.3 1.3 2.5 2.5 
1hpv 1.0 1.4 1.1 1.2 1.3 1.3 
1hri 0.9 2.5 0.8 3.8 0.7 0.9 
1htf 1.9 3.9 1.8 3.0 1.5 2.2 
1hyt 2.5 2.8 2.4 2.9 2.4 3.2 
1ibg 0.8 1.8 1.8 2.2 0.7 0.7 
1imb 2.8 6.5 5.4 11.8 2.6 4.2 
1ivb 1.7 3.8 2.4 4.3 1.8 1.8 
! 141!
1kel 1.0 1.3 1.8 1.8 1.4 1.4 
1lah 0.4 1.1 1.5 2.5 0.5 1.1 
1lcp 0.8 0.9 1.2 8.2 0.6 0.9 
1lic 1.7 2.7 2.7 3.9 1.2 2.6 
1lpm 1.9 2.4 1.6 4.2 1.2 2.3 
1lst 1.1 1.4 0.9 1.8 1.0 1.6 
1mcq 0.7 1.7 0.7 1.2 0.7 2.5 
1mdr 1.1 3.0 2.4 4.1 1.2 2.0 
1mld 1.5 1.7 3.6 4.1 1.4 1.8 
1mrg 1.2 2.5 5.3 10.5 1.1 1.3 
1mrk 0.8 1.1 5.7 10.5 0.8 1.2 
1mts 0.9 1.3 1.4 2.2 1.1 1.2 
1mup 0.9 1.4 1.2 1.5 0.9 1.2 
1nco 1.3 2.2 3.6 3.8 0.9 2.1 
1ngp 1.1 3.6 2.9 5.0 1.0 3.7 
1okl 0.5 2.2 3.4 5.5 1.5 2.2 
1pdz 1.4 3.7 2.7 3.2 1.4 2.0 
1phd 1.6 4.2 1.5 6.7 1.5 2.6 
1phg 2.5 4.2 2.8 6.4 2.4 2.7 
1poc 0.8 1.0 1.3 2.1 0.9 0.9 
1ppc 2.0 3.3 3.5 7.2 1.2 2.0 
1pph 4.9 5.6 5.2 6.1 4.8 5.7 
1ptv 4.4 8.0 4.1 9.8 4.1 8.5 
1qcf 0.8 1.3 3.8 9.5 1.3 1.3 
1qpe 0.7 1.2 1.7 1.7 1.1 1.3 
1qpq 1.2 1.5 2.6 12.1 0.8 1.2 
1rnt 0.8 1.3 3.9 7.0 0.8 0.8 
1rob 0.9 0.9 4.6 8.8 0.7 1.1 
1rt2 0.6 0.7 0.5 0.6 0.5 1.1 
1slt 1.3 4.7 2.1 6.3 1.0 1.8 
1snc 0.9 1.9 4.7 5.8 0.8 4.6 
1srj 0.8 1.9 3.4 3.4 0.7 1.0 
1tdb 1.6 3.4 3.8 8.7 1.1 1.6 
1tmn 1.8 2.1 2.4 2.7 1.4 3.0 
1tng 0.1 0.1 3.5 3.7 0.1 0.2 
1tnh 1.4 1.8 1.3 1.6 1.4 1.7 
1tni 1.4 2.8 1.4 2.0 1.6 2.6 
1tpp 5.6 6.0 6.3 11.2 5.5 5.8 
1tyl 0.9 1.5 1.5 3.0 0.7 0.8 
1ukz 0.5 2.4 5.1 7.7 0.5 0.7 
1ulb 0.5 1.3 2.7 7.8 0.4 1.3 
1uvs 1.5 1.9 3.8 6.0 1.7 2.4 
1uvt 2.9 3.2 3.1 3.5 3.5 4.7 
! 142!
1vgc 1.1 2.0 1.1 1.5 1.1 1.5 
1xid 1.4 2.3 1.3 1.6 1.3 1.4 
1xie 1.9 4.3 8.2 12.2 1.1 2.2 
1ydr 0.5 0.6 1.0 1.6 0.5 0.6 
1yee 1.2 1.2 2.3 3.7 1.0 1.2 
25c8 1.7 2.1 2.4 4.3 1.5 1.7 
2aad 0.6 0.8 3.8 6.9 0.6 0.8 
2ada 0.4 0.5 2.9 11.1 0.5 0.5 
2cht 1.4 3.1 2.4 8.7 1.1 1.6 
2cmd 1.3 1.8 2.8 4.1 1.3 2.1 
2cpp 0.5 2.1 1.9 5.5 0.2 0.3 
2ctc 2.3 2.6 2.2 2.7 2.3 2.8 
2fox 1.1 1.5 6.1 7.9 0.6 1.5 
2gbp 0.5 0.7 2.1 14.6 0.3 0.4 
2h4n 1.6 1.7 1.8 3.9 1.6 1.8 
2ifb 1.0 1.7 1.8 2.6 1.0 1.8 
2mcp 0.9 1.6 4.2 6.5 0.8 1.2 
2pk4 1.1 2.1 1.2 2.3 1.3 2.5 
2r07 0.6 0.9 0.6 1.3 0.6 0.8 
2yhx 0.8 2.9 1.8 6.2 0.7 0.8 
2ypi 1.0 1.5 3.0 10.3 0.9 1.5 
3ert 1.0 1.2 0.9 1.2 0.9 1.4 
3gpb 1.1 2.1 3.0 13.0 1.1 2.0 
3hvt 0.5 0.7 0.4 0.8 0.7 0.9 
4aah 0.5 0.8 4.0 5.6 0.5 3.8 
4cox 0.4 0.6 0.7 0.9 0.5 0.5 
4cts 2.1 3.7 3.9 8.2 1.5 1.6 
4dfr 2.9 8.4 3.5 5.3 2.4 3.5 
4est 2.1 2.9 2.3 2.9 2.3 3.5 
4fbp 0.3 0.5 5.7 10.8 0.3 0.4 
4lbd 1.0 1.0 1.0 1.1 1.0 1.0 
4phv 3.7 5.2 3.4 4.9 3.5 4.2 
5abp 0.5 0.5 2.1 11.5 0.4 0.5 
5cpp 1.9 1.9 1.9 5.4 1.9 1.9 
6rnt 1.5 2.1 6.7 10.8 1.0 1.1 
6rsa 0.4 0.8 2.6 10.1 0.4 0.9 
7tim 1.1 1.7 3.6 4.0 0.8 1.7 
Averages 1.3 2.4 2.8 5.2 1.3 1.9 
 
 
 
! 143!
Table A.2: 
Results for HIV Reverse Transcriptase cross-docking trial, totaling 173 unique protein-
ligand complexes. The MD+Minimization protocol was the only one used in this trial as 
it was the most successful docking protocol in the redocking trials. Reported are the 
lowest RMSD structure sampled and the lowest energy RMSD conformation.  
  
Rigid CDOCKER Flexible CDOCKER 
Receptor 
PDBID 
Ligand 
PDBID 
Lowest 
RMSD 
Lowest 
Energy 
Lowest 
RMSD 
Lowest 
Energy 
1c1b 1c1c 0.9 6.0 1.0 1.6 
1c1b 1ep4 1.7 7.2 1.5 5.5 
1c1b 1rth 0.9 6.2 0.9 6.2 
1c1b 1vru 1.1 2.2 0.9 5.6 
1c1b 2be2 1.3 1.8 1.4 1.5 
1c1b 2rf2 2.6 3.4 2.6 2.9 
1c1b 2rki 1.9 2.2 1.9 5.7 
1c1b 3dlg 1.2 1.3 2.4 8.9 
1c1b 3dol 2.5 10.8 3.8 10.6 
1c1b 3dya 2.9 3.0 2.9 3.7 
1c1c 1c1b 0.8 2.0 0.8 2.1 
1c1c 1ep4 2.0 7.0 1.7 6.1 
1c1c 1rt2 0.7 0.7 0.8 1.6 
1c1c 1rth 1.2 14.6 1.1 6.3 
1c1c 1vru 1.5 5.2 1.5 5.5 
1c1c 2be2 1.0 2.2 1.0 1.3 
1c1c 2rf2 2.2 6.3 2.1 6.1 
1c1c 2rki 1.8 2.5 1.7 7.8 
1ep4 1c1b 0.9 1.3 1.4 2.8 
1ep4 1rt2 1.3 2.0 1.4 5.1 
1ep4 1rth 1.2 12.4 1.7 4.6 
1ep4 1vru 1.6 5.1 2.1 4.9 
1ep4 2be2 1.5 1.6 1.3 2.0 
1ep4 2rf2 3.2 5.8 3.3 5.8 
1ep4 2rki 2.8 5.0 3.0 5.7 
1ikw 1c1b 4.1 5.7 4.3 7.2 
1ikw 1c1c 4.2 5.9 4.7 7.0 
1ikw 1ep4 3.7 6.6 3.9 6.5 
1ikw 1vru 4.9 5.5 4.8 6.5 
1ikw 2be2 7.1 10.4 6.7 10.8 
1ikw 2rf2 4.4 7.3 4.4 6.7 
1ikw 2rki 5.2 8.8 5.2 8.8 
1ikw 3dol 7.9 10.0 7.9 10.6 
! 144!
1rt2 1ep4 2.2 13.6 2.1 2.8 
1rt2 1rth 1.5 14.9 4.2 14.7 
1rt2 1vru 1.8 14.9 1.6 5.1 
1rt2 2be2 1.4 13.1 1.3 2.4 
1rt2 2rf2 2.1 15.4 2.1 2.2 
1rt2 2rki 1.7 13.2 1.8 2.8 
1rt2 3dlg 1.0 12.8 0.8 1.6 
1rth 1c1b 0.9 4.1 0.9 2.1 
1rth 1c1c 1.3 5.4 1.2 1.7 
1rth 1rt2 2.4 7.8 2.8 7.3 
1rth 1vru 1.3 4.6 0.8 5.3 
1rth 2be2 3.1 6.6 2.6 6.3 
1rth 2rki 2.8 7.7 2.8 7.9 
1s1t 1c1b 0.8 1.2 1.1 1.5 
1s1t 1c1c 1.0 6.2 1.1 5.5 
1s1t 1rt2 2.6 7.8 2.5 7.0 
1s1t 1rth 1.0 13.8 1.1 6.1 
1s1t 1vru 1.2 2.3 0.9 5.2 
1s1t 2be2 2.3 6.3 2.2 6.8 
1s1t 2rf2 1.7 1.9 1.4 4.7 
1s1t 2rki 1.7 7.6 2.4 7.4 
1s1t 3dlg 3.8 11.4 4.4 8.5 
1vrt 1c1b 1.0 5.1 1.0 5.8 
1vrt 1c1c 1.1 3.2 1.1 2.9 
1vrt 1rt2 2.7 7.3 3.0 7.3 
1vrt 1rth 0.7 14.5 0.6 6.1 
1vrt 2be2 2.6 6.5 2.4 6.5 
1vrt 2rf2 1.2 4.5 1.5 4.5 
1vrt 2rki 2.5 8.2 2.8 6.2 
1vru 1c1b 1.0 5.0 1.0 1.9 
1vru 1c1c 1.2 3.1 1.2 5.0 
1vru 1rt2 3.3 7.9 2.9 7.1 
1vru 1rth 0.8 13.0 0.7 1.3 
1vru 2be2 3.2 6.3 2.9 6.5 
1vru 2rf2 1.5 4.5 1.4 5.8 
2be2 1c1b 1.3 1.4 1.2 5.0 
2be2 1c1c 1.2 1.2 1.2 1.4 
2be2 1rt2 1.2 13.1 1.1 1.6 
2be2 1rth 1.9 13.4 2.3 5.9 
2be2 2rf2 2.2 5.8 2.3 6.8 
2hnd 1c1b 1.3 5.7 1.3 1.3 
2hnd 1c1c 1.3 5.5 1.1 5.5 
2hnd 1rth 1.3 13.9 0.8 1.7 
! 145!
2hnd 2rf2 1.0 4.4 1.0 4.5 
2hny 1c1b 1.3 5.8 1.2 5.5 
2hny 1c1c 1.2 3.3 1.2 3.1 
2hny 1rth 1.2 4.4 1.0 1.3 
2hny 2rf2 0.9 4.3 0.9 4.5 
2hny 3dlg 4.6 9.5 4.8 7.8 
2hny 3dol 6.9 11.4 6.5 11.2 
2ops 1c1c 1.3 5.4 1.1 1.6 
2ops 1rt2 2.2 6.2 2.7 6.3 
2ops 1rth 1.1 14.3 0.7 6.0 
2ops 2be2 2.7 6.5 3.1 6.8 
2ops 2rf2 1.6 4.6 1.5 4.5 
2ops 3dlg 3.9 8.5 4.1 9.4 
2rf2 1c1b 1.5 13.9 1.3 5.4 
2rf2 1c1c 1.1 5.5 1.3 5.5 
2rf2 1ep4 3.4 9.3 3.2 7.3 
2rf2 1rt2 2.8 7.6 3.0 7.9 
2rf2 1rth 1.4 16.0 1.6 6.0 
2rf2 1vru 1.8 1.8 1.6 5.0 
2rf2 2be2 3.8 13.7 3.5 7.2 
2rf2 2rki 2.7 14.9 2.6 4.2 
2rf2 3dlg 4.2 13.1 4.3 10.2 
2rf2 3dol 6.9 13.7 6.2 12.3 
2rf2 3dya 3.6 14.2 3.6 7.1 
2rki 1c1b 1.6 12.2 1.6 2.5 
2rki 1c1c 1.6 5.7 1.3 5.5 
2rki 1ep4 2.4 10.9 2.3 7.5 
2rki 1rt2 1.5 13.3 1.2 1.6 
2rki 1rth 2.3 13.7 2.6 6.0 
2rki 1vru 2.1 6.6 3.1 4.3 
2rki 2be2 1.7 12.2 2.0 2.1 
2rki 2rf2 1.5 12.8 1.2 4.7 
2rki 3dlg 1.5 4.8 1.5 1.5 
2rki 3dol 2.5 10.8 2.3 2.3 
2rki 3dya 1.6 11.6 1.5 8.7 
2zd1 1c1b 1.5 2.7 1.5 1.6 
2zd1 1c1c 1.8 6.7 1.9 6.6 
2zd1 1ep4 3.3 6.8 3.3 6.4 
2zd1 1rt2 3.0 7.7 3.0 7.9 
2zd1 1rth 1.1 5.4 0.9 6.2 
2zd1 1vru 1.6 2.3 1.8 2.4 
2zd1 2be2 3.1 7.6 2.4 6.0 
2zd1 2rf2 2.5 5.0 2.4 5.1 
! 146!
2zd1 2rki 3.0 8.2 3.0 8.1 
2zd1 3dlg 4.6 9.8 4.3 9.2 
2zd1 3dol 6.5 11.7 6.6 11.4 
2zd1 3dya 3.4 6.7 3.4 6.5 
3bgr 1c1b 1.4 3.1 1.4 6.1 
3bgr 1c1c 1.9 7.0 1.9 6.7 
3bgr 1ep4 2.8 8.7 2.8 6.2 
3bgr 1rt2 2.5 9.0 3.0 7.8 
3bgr 1rth 1.1 6.1 1.0 1.5 
3bgr 1vru 1.5 3.3 1.7 4.0 
3bgr 2be2 2.2 5.6 2.0 5.6 
3bgr 2rf2 3.0 5.2 2.9 5.1 
3bgr 2rki 2.8 10.3 3.1 8.2 
3bgr 3dol 6.5 13.0 6.2 9.4 
3bgr 3dya 2.3 6.4 2.9 6.4 
3dle 1c1b 1.2 14.3 1.3 6.0 
3dle 1c1c 1.5 6.0 1.3 4.8 
3dle 1ep4 2.3 13.2 2.2 2.7 
3dle 1rt2 0.7 12.4 0.5 0.8 
3dle 1rth 3.7 14.6 4.8 5.0 
3dle 1vru 3.2 5.3 3.8 5.2 
3dle 2be2 1.4 1.7 1.3 2.5 
3dle 2rf2 2.3 5.0 2.7 7.4 
3dle 2rki 2.4 15.4 2.0 2.8 
3dle 3dol 1.1 4.4 1.7 2.2 
3dle 3dya 2.5 11.9 2.4 2.5 
3dlg 1c1b 1.3 13.9 1.7 5.2 
3dlg 1c1c 1.2 14.6 1.6 6.3 
3dlg 1ep4 2.2 13.7 2.1 5.6 
3dlg 1rt2 1.0 13.4 1.0 2.1 
3dlg 1rth 1.9 12.4 6.0 12.5 
3dlg 1vru 2.7 14.8 3.5 4.5 
3dlg 2be2 1.2 1.5 1.0 1.5 
3dlg 2rf2 2.3 5.0 3.7 5.6 
3dlg 2rki 2.2 11.9 2.2 6.8 
3dlg 3dol 1.4 2.4 1.7 2.5 
3dlg 3dya 2.5 3.6 2.3 2.5 
3dol 1c1b 4.7 13.5 2.6 2.6 
3dol 1c1c 4.4 5.5 4.8 5.7 
3dol 1ep4 3.0 12.8 4.0 8.4 
3dol 1rt2 1.9 11.8 2.2 2.6 
3dol 1vru 5.4 15.8 4.8 6.8 
3dol 2be2 2.4 2.4 2.3 2.9 
! 147!
3dol 2rki 3.4 13.3 3.2 4.3 
3dol 3dlg 1.6 2.7 1.4 1.4 
3dol 3dya 3.2 4.1 1.5 1.5 
3dya 1c1b 2.3 2.5 2.2 2.2 
3dya 1c1c 2.1 6.6 1.9 6.5 
3dya 1ep4 2.1 3.0 2.0 2.8 
3dya 1rt2 2.3 2.9 2.1 2.4 
3dya 1rth 3.0 13.6 3.2 6.7 
3dya 1vru 3.3 6.0 3.9 5.8 
3dya 2be2 1.3 2.3 1.4 2.3 
3dya 2rf2 1.9 2.7 1.9 6.4 
3dya 2rki 2.2 2.7 2.0 2.3 
Averages      2.3    7.7     2.3    5.2 
 
